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Infectious diseases are a significant threat to public health. Though society enacts 
practices to prevent the spread of these dangerous diseases, challenges remain. Therefore, 
continual advancements in treatment and prevention are required. Wastewater treatment 
and viral clearance in pharmaceutical applications are two key health measures that 
prevent the spread of infections.  
A low-cost, low-technology biosolids treatment process was developed to 
improve wastewater treatment by collecting key information on storage temperature, 
ammonia, volatile solids, moisture content, pH, and pathogen inactivation in biosolids 
over long-term storage at two wastewater treatment plants located in northern climates of 
the United States. Inactivation of pathogens in the biosolids was enhanced by freeze-thaw 
cycles, intermediate moisture contents (16% total solids), and time. Biosolids required 
over a year of long-term storage to reach standard pathogen limits for treatment in 
northern climates.  
To improve viral clearance in therapeutic protein manufacturing, the use of 
arginine and buffers was studied at pH ≥ 4 to retain the stability of the final protein 
product. A stabilized virus membrane structure, resulting from lipid packing density or 
membrane proteins, hindered the inactivation efficacy of arginine and buffers. The 
influence of membrane properties on arginine and buffer interactions supports the 
inactivation mechanisms of viral membrane deformation. Increased hydrophobicity and 
clustering enhanced the inactivation of enveloped viruses by arginine at pH 4 and 7. 
xxiii 
Electrostatic interactions increased the inactivation of enveloped viruses by buffers at pH 
4.  
Overall, the mechanisms for pathogen inactivation were further understood for the 
improvement of biosolids treatment and therapeutic protein manufacturing to facilitate 
the prevention of infectious diseases. 
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1 Introduction and Chapter Summaries 
1.1 Introduction  
 Infectious diseases affect billions of people annually, significantly impacting 
world health1. Infectious diseases are caused by microorganisms and are spread from one 
person to another2. These highly dangerous diseases resulted in 3 million mortalities in 
2016 through lower respiratory infections alone, ranking as the fourth top cause of death1.  
Recent coronavirus outbreaks that produce severe respiratory infections include the 
Middle East Respiratory coronavirus (MERS-CoV), severe acute respiratory syndrome 
coronavirus (SARS-CoV), and the novel coronavirus (SARS-CoV-2)3. Additional 
infections including diarrheal diseases (1.4 million deaths) and tuberculosis (1.3 million 
deaths) were also classified in the top ten causes of death worldwide1. For this reason, 
considerable safety measures must be taken to minimize the threat of infectious diseases.  
 In order to prevent infectious diseases, society has enacted practices to protect 
itself through immunization, health measures, surveillance, and treatment4 . Though 
many barriers exist that impede infectious diseases from causing harm to public health, 
humans still remain vulnerable to these microorganisms. For this reason, advancements 
need to continually be implemented to fight current obstacles in treatment and prevention 
of infectious diseases4. 
 Wastewater treatment and viral clearance during pharmaceutical applications are 
two examples of health measures that society enacts to minimize the spread of infectious 
diseases. Wastewater is liquid or water-transported wastes originating from residential, 
business, industry, or natural sources5. Wastewater processes remove and treat infectious 
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materials from residential areas to prevent the spread of disease. Viral clearance in 
pharmaceutical applications prevents infections by removing or inactivating viruses from 
biological medical products6. Examples of biological medical products include 
recombinant therapeutic proteins, monoclonal antibodies, glycoproteins, and tissue/ blood 
products6. This dissertation investigates various processes that improve wastewater 
treatment and viral clearance in therapeutic protein manufacturing to protect the public 
from infectious diseases.  
1.2 Chapter Summaries 
The chapters of this dissertation describe different projects focused around the 
removal of infectious pathogens that can cause human disease. 
Chapter 2 focuses on the improvement of wastewater treatment through a low-
cost, low-technology biosolids treatment method. Many wastewater treatment plants are 
looking to upgrade their biosolids treatment systems to open additional avenues for land 
application and distribution of biosolids7. However, a large majority of wastewater 
treatment plants lack the resources to implement the high-tech and high-costs processes 
required to upgrade their biosolids treatment. Therefore, there is a growing need for low-
cost, low-tech treatment options. One example of low-cost, low-tech treatment is the 
inactivation of pathogens in biosolids through long-term storage. However, long-term 
storage is not widely used since universal conditions required to meet treatment standards 
are not known. To further understand the conditions required to meet pathogen 
inactivation standards during long-term storage, a year-long pilot-scale study was 
undertaken at Gogebic Iron Wastewater Authority (GIWA) and Portage Lake Water and 
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Sewer Authority (PLWSA). Fundamental information was collected on the impact of key 
parameters including storage temperature, organic matter content, ammonia, pH, and 
moisture on the rate of inactivation of pathogens. The data collected provided insight into 
the conditions required for low-cost, low-technology biosolids treatment processes. 
Chapter 3 is a literature review on the mechanisms of enveloped virus inactivation 
by the amino acid arginine. Arginine inactivates enveloped viruses at conditions that 
retain protein stability, making it a desired viral clearance process during therapeutic 
protein manufacturing. Conditions for optimal inactivation include arginine 
concentrations of 0.7-1 M, an incubation time of 60 minutes, and a synergistic factor of 
either ≥ 40°C, ≤ pH 4, or Tris buffer 8-16. However, not all enveloped viruses are fully 
inactivated by arginine at these optimal conditions. Viruses that are resistant to arginine 
have increased protein stability or increased membrane stability17. Arginine interacts with 
both proteins and lipids, and therefore, either interaction may be key to understanding the 
mechanisms of inactivation. Three hypotheses are drawn to explain the mechanisms of 
inactivation by arginine. Hypothesis 1 describes inactivation through inhibition of viral 
protein function. Hypothesis 2 describes inactivation through membrane destabilization. 
Hypothesis 3 describes inactivation by membrane pore formation. Understanding the 
mechanisms of arginine may elucidate the use of functional groups, charges, or additives 
to enhance inactivation.  
 Chapter 4 dives into the mechanisms and improvement of enveloped virus 
inactivation by arginine. First, the effect of virus structure on inactivation by arginine was 
explored. Enveloped viruses with highly stable membranes were less affected by arginine 
than enveloped viruses with less stable membranes. Additionally, the sensitivity of 
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viruses to membrane cholesterol depletion correlated to arginine sensitivity. The 
influence of membrane properties on inactivation supported the mechanism of membrane 
deformation by arginine. To enhance the inactivation of viruses with stabilized 
membranes, arginine-derivatives, arginine clustering, hydrophobicity, and buffer type 
were examined. Overall, higher hydrophobicity and arginine-clustering increased 
inactivation by arginine. Dynamic light scattering (DLS) and transmission electron 
microscopy (TEM) were used to determine structural changes to viruses after arginine 
exposure. Increasing virus size after arginine exposure was observed, supporting lipid 
expansion or arginine binding as the mechanism for inactivation. Overall, the data 
supports membrane deformation as the mechanisms of arginine inactivation. Inactivation 
can be enhanced through added hydrophobicity or increased arginine clustering.  
 Chapter 5 explores the influence of virus properties, buffer properties, and time on 
the inactivation of viruses at pH 4. Enveloped viruses including pseudorabies virus 
(SuHV-1), herpes simplex virus 1 (HSV-1), and equine arteritis virus (EAV), and the 
non-enveloped porcine parvovirus (PPV) were tested with glycine, acetate, and citrate 
buffers at concentrations ranging from 20-500 mM. Inactivation levels were dependent 
on all properties tested. The stabilized membrane of small EAV protected the virus 
against inactivation at pH 4. Similarly, the non-enveloped PPV was also unaffected by 
pH 4, likely resulting from the absence of a lipid bilayer. EAV and PPV may require 
harsher conditions for inactivation, such as lower pH or higher temperatures. Larger 
viruses with less stabilized membranes (HSV-1 and SuHV-1) were inactivated to the 
highest levels by citrate and the lowest levels by glycine. Higher buffer concentrations 
either increased or had no effect on inactivation. Buffers with opposite charges to the 
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virus produced higher inactivation. It is hypothesized that electrostatic interactions 
between the virus and the buffer promote inactivation. Overall, inactivation by buffers at 




2 Low-Cost, Low-Tech Biosolids Treatment 
2.1 Introduction  
Clean water and sanitation are essential for life. Wastewater processes support life 
by treating and removing contaminated water from populated areas to prevent the 
accumulation of infectious materials. Wastewater contains liquid or water-transported 
wastes originating from residential, business, industry, or natural sources (groundwater, 
surface water, or stormwater)18.  In the absence of wastewater treatment, infectious waste 
would accumulate in populated areas, leading to poor sanitation and disease.  
Treatment of wastewater in the United States commonly includes preliminary, 
primary, secondary, and tertiary processes, illustrated in Figure 2-118. Treatment 
processes remove solids, nutrients, pathogens, organic compounds, and odors to convert 
wastewater into an effluent that is safe for human and environmental health18. 
Preliminary treatment applies bar screens and grit chambers to separate large materials 
such as rags or grit. A portion of suspended solids and organic matter are removed via 
primary sedimentation. Secondary treatment uses biological treatment to remove 
additional suspended solids and biodegradable organics. Tertiary treatment employs final 
disinfection for safe discharge. Examples of final disinfection practices include chemicals 
or ultraviolet light (UV). After treatment is completed, the final effluent is discharged 






Figure 2-1. Wastewater originates from residential industry/business or stormwater 
sources. Treatment includes preliminary, primary, secondary, and tertiary processes. 
Solids can be disposed of by incineration, landfill, or land application. 
 
Wastewater solids contain pathogens and use an oxygen demand, and therefore, 
solids must be removed before safe discharge. Solids are typically removed from 
wastewater during primary and secondary treatment through clarifiers. Though termed 
solids, this wastewater constituent is a semisolid liquid between 0.25-12% solids18. Solids 
disposal options include incineration, surface landfills, or reuse by land application after 
treatment18. Treated wastewater solids contain high nutrient and organic matter content, 
and, therefore reuse through land application is a sustainable and cost-effective means of 
disposal.  
Because of the presence of pathogens and the potential to attract vectors (e.g. 
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rodents, insects, and birds), treatment of wastewater solids is required to protect human 
and environmental health before reuse. Treated residual wastewater solids are termed 
biosolids (Figure 2-2). The United States Environmental Protection Agency (U.S. EPA) 
regulates biosolids treatment, quality, use, and disposal under the Code of Federal 
Regulations, Title 40, Part 503 rule19. Under the EPA regulations, biosolids products are 
classified into two distinct levels: Class A and Class B. Class A biosolids undergo an 
advanced sludge process train, reducing pathogens below detectable limits, while Class B 
biosolids receive a less aggressive treatment and contain low but detectable levels of 
pathogens. As a consequence of advanced treatment, Class A biosolids can be re-used 
with limited regulations.  
Figure 2-2. Treated sewage solids are termed biosolids. Biosolids 
can be land applied as a fertilizer or soil amendment. 
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Wastewater Treatment Plants (WWTPs) throughout the U.S. are pursuing Class A 
biosolids treatment systems to open additional avenues for land application and 
distribution of biosolids7. Public scrutiny, lack of resources and high energy costs are 
only a fraction of challenges that WWTPs face20. To adequately treat wastewater, plants 
utilize 2-4% of the total energy generated in the U.S. in a given year, producing high 
operation costs21. Rural WWTPs pay ~$0.16 per cubic meter of wastewater treated or 
about $700,000 per year22. By producing Class A biosolids, WWTPs can land apply 
biosolids without the extra costs associated with lower quality biosolids, while gaining 
revenue for the final product to supplement energy costs. However, the majority of Class 
A biosolids treatment processes are high-tech and high-cost, leaving many WWTPs 
without the resources to implement the design. Consequently, there is an increasing 
demand for low-cost, low-tech (LCLT) treatment options to produce Class A biosolids.  
2.2 Literature Review 
2.2.1 Pathogens in Biosolids  
Numerous pathogenic organisms exist in wastewater solids including bacteria, 
viruses, protozoa, helminths, and fungi (Table 2-1)23, and therefore, solids must be 
treated to reduce pathogens before reuse. If solids are improperly treated, pathogens can 
spread to agricultural soil during land application. Therefore, it is important to understand 
the quantity and type of microorganism present in the solid waste for effective treatment 
and safe re-use.   
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High concentrations of bacteria exist in wastewater treatment solids. The most 
prevalent bacteria include species that infect the human gut. Typical conditions for gut 
bacteria survival are high organic content in mesophilic temperatures of around 37 °C23.  
Over 140 different types of viruses have been found in biosolids23. These viruses 
commonly cause respiratory illness, acute gastroenteritis, conjunctivas, and diarrhea. 
Feces of infected individuals contain very high levels of virus. The infectious dose of 
enteric viruses, ranging from 10-100 infectious units, is very low, making proper 
treatment necessary for human safety23.  
The majority of parasites found in biosolids are classified under helminth ova, 
which include Ascaris ova, or protozoa. These parasites are prevalent around the world 
causing many illnesses. Parasite infectivity can range from 1-10 cysts egg per person24. 
With low infectivity dose, it is crucial to properly treat for parasites. Parasites are the 
most resilient pathogen in biosolids due to their protective outer shell, and therefore, are 
Pathogen Size Range Common in Biosolids 





Virus ~20-200 nm 
Adenovirus 
Enterovirus 
Hepatitis A virus 
Rotavirus 






commonly used as indicator organisms. Indicator organisms are organisms whose 
abundance suggests the presence of various pathogenic species. Whether it be bacteria, 
viruses, or parasites, it is important to properly treat sewage solids to reduce pathogens.  
2.2.2 Biosolids Treatment  
In 1984, the U.S. EPA created a policy that endorsed the beneficial reuse of 
biosolids as a fertilizer or soil amendment. The EPA defines biosolids as “a primarily 
organic solid product produced by wastewater treatment processes that can be 
beneficially recycled19.” For this reason, biosolids are seen as an item for re-use.  
Biosolids refer to sewage solids that have undergone treatment to reduce pathogens and 
the potential for vector attractions. Class A biosolids can be applied to agricultural land, 
disturbed areas, forests, recreation areas, cemeteries, and residential gardens19. The U.S. 
EPA regulates biosolids monitoring, testing, treatment, and pathogen levels.  
Class A and Class B biosolids are two distinct levels of treated sewage solids. 
Class A biosolids undergo an advanced process train to reduce pathogens below 
detectable limits. Class A biosolids can be disposed of with limited EPA regulations due 
to undetectable pathogen levels. Class B biosolids receive less aggressive treatment and 
contain detectable, but low, levels of pathogens. Class B biosolids are more restricted 
than Class A when it comes to reuse as a result of pathogen levels as well as metals 
content and vector attraction criteria. Required pathogen limits for Class A and B 





Table 2-2. Class A and B Pathogen Limits. Class A has stricter pathogen limits but a 
wider range of land application options compared to Class B Biosolids. 
 
Pathogen Class A Limit Class B Limit 
Fecal 
coliforms 
< 1000 MPN/g dry solids < 2 million 
MPN/g dry solids 
Enteric 
viruses 





< 1 viable ovum/4 g dry solids 
with a 2-log10 reduction shown 
N/A 
2.2.2.1 Alternatives to Meet Class A Pathogen Requirements  
Both Class A and B biosolids have several treatment options to meet EPA standards. 
As discussed further below, six alternatives exist for producing Class A biosolids under 
the EPA part 503 regulations19: 
Alternative 1: Thermally Treated Biosolids  
Specific time and temperature regimes must be met.  
Alternative 2: Sewage Sludge Treated in a High pH-High Temperature Process 
Specific pH, temperature, time and air-drying methods must be met. 
Alternative 3: Sewage Sludge Treated in Other Processes 
Fecal coliform or Salmonella, the density of enteric viruses, and the density of 
helminth ova are all at or below the EPA pathogen limits through a specific 
treatment process. Once this has been met, the plant may maintain operating 
conditions for pathogen reduction. 
Alternative 4: Sewage Sludge Treated in Unknown Processes 
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EPA regulatory limits for Salmonella or fecal coliform bacteria, enteric viruses, 
and viable helminth ova at the time of biosolids disposal are met. Monitoring for 
pathogens must occur before all biosolids disposal applications.  
Alternative 5: Biosolids Treated in a Process to Further Reduce Pathogens (PFRP) 
Solids must be treated in one of the PFRPs listed in Appendix B of the EPA 503 
regulations. The PFRP’s include: 
 Composting: aerobic decomposition of solids using a within-vessel or 
static aerated pile method.  Temperatures must remain at 55°C (131°F) or 
higher for 3 consecutive days. 
 Heat Drying: sewage solids are dried to 10% total solids or lower by hot 
gases. Temperatures of the solids must exceed 80°C (176°F) or the wet 
bulb temperature exposed to the solids must exceed 80°C (176°F). 
 Heat Treatment: solids reach a temperature of ≥180°C (356°F) over 30 
minutes. 
 Thermophilic Aerobic Digestion: solids maintain aerobic conditions for 10 
consecutive days at 55°C to 60°C (131°F to 140°F). 
 Beta Ray and Gamma Ray Radiation: solids are treated with beta rays or 
gamma rays at doses of at least 1.0 megarad at room temperature. 
 Pasteurization: solids temperature is maintained at 70°C (158°F) or higher 
for 30 minutes or longer. 
Alternative 6: Use of a Process Equivalent to PFRP 
14 
Solids are treated with a process equivalent to a PFRP that meets EPA pathogen 
regulations. The permitting authority determines the equivalency of the process. 
2.2.2.2 Vector Attraction Reduction 
Vectors are organisms that are attracted to biosolids and could contribute to the 
spread of pathogens19. Insects, birds, and rodents are examples of vectors. To prevent the 
spread of pathogens, vector attraction is reduced through the breakdown of volatile 
solids, inhibition of microbial activity, or enacting a physical barrier. The 503 regulations 
state that pathogen and vector attraction reduction (VAR) can occur simultaneously with 
other biosolids treatments. A total of 12 options exist to satisfy vector attraction reduction 
requirements: 
VAR Option 1: 38% volatile suspended solids reduction. 
VAR Option 2: anaerobic digestion.  
VAR Option 3: aerobic digestion.  
VAR Option 4: anaerobic digestion system meets specific oxygen uptake rates. 
VAR Option 5: aerobic processes greater than 40°C. 
VAR Option 6: pH raised to 12 and maintained at pH 11.5 for 24 hours.  
VAR Option 7: solids content exceeds 75% and the product contains stabilized 
solids. 
VAR Option 8: unstabilized solids must be over 90% total solids before it can be 
added and mixed with other materials. 
VAR Option 9: injected into the earth’s surface to create a barrier between the 
vectors and biosolids. 
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VAR Option 10: incorporated into the soil within eight hours from discharge.  
VAR Option 11: covered on-site with soil or other material. 
VAR Option 12: pH of domestic septage must be raised to 12 and held for 30 
minutes. 
2.2.3 Low-Cost, Low-Tech Treatment  
From the above alternatives and VAR options, it is clear that there are several 
ways to treat biosolids. However, what alternatives can be used to meet low-cost, low-
tech demands for producing Class A biosolids? Alternative 6 for Class A biosolids 
treatment can be used to produce an equivalent process to a PFRP, allowing for the 
creation of a low-cost, low-tech certified process. Under Alternative 6, a Pathogen 
Equivalency Committee (PEC) provides guidance and expertise to create an equivalent 
process to a PFRP. The guidance includes a three-log10 reduction of enterovirus and a 
two-log10 reduction of helminth ova. Though a specific log-reduction must be met, 
pathogen limits must also be satisfied (Table 2-2).  
Sustainable LCLT treatment alternatives for producing Class A biosolids do exist 
and have been successfully implemented. Options for LCLT treatment include long term 
storage, air drying, and cake storage25. Many large WWTPs currently implement LCLT 
treatments, including Chicago, Illinois and San Jose, California25,26. The Stickney Water 
Reclamation Plant (Metropolitan Water Reclamation District of Greater Chicago) 
combines long-term storage, air drying, and cake storage to treat their biosolids to a Class 
A level27. Biosolids are first treated in Chicago with the use of anaerobic digestion (35° C 
for 20 days), followed by two solid process trains to obtain a final product that is Class A 
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certified and yields 60% total solids. The two sludge process trains include a high solids 
sludge process train (HSSPT) and a low solids sludge process train (LSSPT). The HSSPT 
and LSSPT produce equal amounts of treated biosolids throughout the year. During the 
HSSPT, solids are conditioned with a cationic polymer followed by dewatering with 
centrifuges to 25% total solids. This material is transported to a storage lagoon 
throughout the year, except when the temperature is below -4°C. In the LSSPT, solids are 
pumped straight from the anaerobic digesters into a separate set of lagoons. Both the 
LSSPT and HSSPT lagoons are filled for a period of 1 to 3 years. Solids settle to the 
bottom, while supernatant is recycled back to the WWTP. Lastly, the solids are air-dried 
to achieve a final product of 60% total solids. 
Though many WWTPs are beginning to enact LCLT practices, widespread adoption 
and regulatory approval of these methods have been hindered by a lack of information on 
the impacts of environmental factors and biosolids properties on pathogen inactivation. 
Most determinations of equivalency for LCLT treatment are based on environmental 
conditions at each individual site. However, if similar conditions exist and pathogens 
requirements are met across various sites, the process could qualify for national 
equivalency. Reduced testing, increased public confidence, and a sustainable and safe 
process are benefits for national equivalency. However, the application for equivalency 
can be time-consuming and expensive. The best way to obtain this certification is to 
provide the EPA with a full record of pathogen inactivation related to environmental 
conditions at various sites. If mechanisms for pathogen reduction are well enough 
understood, new low-cost, low-tech processes could be realized on a national basis.  
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2.2.3.1 Long-Term Storage  
One of the most effective LCLT treatment options is long-term storage. Long-
term storage (lagoon storage) is defined as a process where biosolids are stored and left 
unfed for a specific period of time, allowing for pathogen inactivation and organic matter 
decomposition25. To initiate long-term storage, lagoons are filled with biosolids 
continuously or intermittently, which can take several months to a year to accomplish. 
Biosolids are typically aerobically or anaerobically digested prior to this process.  During 
the filling of the lagoon, solids settle and the supernatant is collected and returned to the 
beginning of the wastewater treatment process. This system is then left unfed to allow for 
pathogen destruction and organic matter breakdown. Once pathogens in the lagoon have 
dropped to levels certified by the EPA, biosolids can be used as a fertilizer or soil 
amendment. Figure 2-3 shows a schematic of the lagoon storage process. Inactivation of 
pathogens during long-term storage occurs through a variety of mechanisms including 
chemical action, storage time, temperature, and freeze-thaw cycles.  
 
Figure 2-3. Long-Term Lagoon Storage/Treatment18. During long-term storage, lagoons 




Chemical Action  
Chemical action refers to any process of inactivation that involves the 
composition or structure of active chemical substances. Specific properties of the solids 
that aid in pathogen die-off during chemical action include unionized ammonia (NH3) 
content, pH, total solids, volatile solids, and volatile fatty acid content.  
Biosolids that undergo anaerobic digestion contain large amounts of ammonia28. The 
fraction of toxic ammonia, NH3, is minor at normal operating conditions (pH 5.0-7.0), 
because the dominant species is NH4+, ammonium ion. Even at low levels,  NH3 produces 
toxic effects against pathogens, including enteric viruses29-31, pathogenic bacteria32,33, and 
Ascaris ova32,34,35. Ammonia in urea concentrations of 0.4% inactivates Ascaris eggs and 
Salmonella to Class A limits after short treatment times at 28°C32. Poliovirus and F2 
bacteriophage are undetectable after treatment with 800 mg of NH3/L within hours at 
20°C29.  Overall, the levels of toxic ammonia in biosolids can inactivate pathogens.  
Total solids (TS) and volatile solids (VS) are principle factors affecting pathogen 
reduction in lagoon storage. It is widely accepted that increasing total solids reduces 
pathogens through desiccation and autolysis of cells27,36-41. For example, fecal coliforms 
were reduced to Class A levels at 90% total solids at 38°C in less than 10 days37. 
Inversely, high moisture content increases the decay rate for pathogenic bacteria as a 
result of the increased non-pathogenic bacterial competition42.  Volatile solids also affect 
pathogen growth and decay in biosolids. Volatile solids are organic matter that act as a 
food source for bacteria in biosolids. At low ratios of volatile solids, the food source is 
low, decreasing bacteria growth43. However, at a high ratio of volatile solids, increased 
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growth of non-pathogenic bacteria can occur, inhibiting pathogenic bacterial growth.  
Both total solids and volatile solids affect pathogen inactivation at high and low levels.  
Volatile fatty acids (VFAs) are fatty acids containing two to six carbon atoms and 
are naturally occurring in wastewater solids44. VFAs reduce bacteria growth45-53 and 
produce toxic effects on Ascaris ova54,55. Inactivation of Salmonella occurs within 12 
days during anaerobic digestion at a VFA concentration of 5000 mg/L at pH 6.0 46. VFAs 
have been more effective in pathogen inactivation at lower pH values where the acids 
exist primarily in the uncharged form. Because of the hydrophobic nature of the 
uncharged form, the acid can readily cross the lipid bilayer to distress the pathogen and 
cause inactivation54. Overall, unionized ammonia (NH3) content, pH, total solids, volatile 
solids, and volatile fatty acid content all affect pathogenic growth and decay in biosolids 
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Storage Time and Temperature   
Information exists at different temperature ranges (elevated and ambient) about 
the time of exposure in inactivating pathogens during long-term storage34. Microbial 
activity in biosolids can produce high temperatures of up to 60C that aid in the reduction 
of pathogens56. In biosolids at 55C, E. coli and Salmonella were reduced by 8-log10 in 
60 min and 10 min, respectively57. At 49.5C in anaerobically digested, vacuum filtered, 
and air-dried biosolids, an 8-log10 reduction in Salmonella, poliovirus, and Ascaris suum 
eggs occurred in 7, 10, and 40 days, respectively58. Natural ambient temperatures can 
also inactivate pathogens in biosolids to Class A levels. In the southern hemisphere, 
where ambient temperatures remain around 13.3C with little variability, Class A 
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pathogen inactivation in biosolids occurs within 1-3 years59-64. In northern climates that 
have greater temperature variability and can reach below freezing, pathogen inactivation 
can take longer62,65,66; however, Class A biosolids can still be produced in these climates. 
The amount of time needed to meet EPA standards is primarily based on the degradation 
of Ascaris ova, which are the most resilient pathogen because of their protective outer 
shell. Time and temperature can be varied in diverse climates to meet Class A regulations 
for biosolids (Table 2-4).  
 
Table 2-4. Literature Review on the Inactivation of Pathogens by Storage Time and 
Temperature. 
 
Temperature Time Pathogen Inactivation  
55C 





7 days Salmonella58  
10 days Poliovirus58 
40 days Ascaris Ova58 
Southern Hemisphere-
temps around 13.3C with 
little variability 
1-3 years Class A Levels59-61,64  
Norther Hemispheres-
greater temp variability 





Freeze-Thaw Cycles  
Freeze-thaw cycles are widely known to increase dewaterability (or ability to lose 
water) in biosolids through structure modifications67-70. Recent investigations have 
demonstrated that freeze-thaw cycles can inactivate bacterial pathogens71-73 in dewatered 
sanitary wastewater (blackwater)74, stabilization ponds75, activated sludge76,77, reed 
beds66, untreated wastewater treatment solids77 and biosolids slurries treated via aerobic 
or anaerobic digestion78.  
The ideal conditions (i.e. temperature, freezing rate, # of cycles, and moisture 
content) for freeze-thaw cycles to reduce pathogens are not well understood. The rate of 
freezing and thawing is thought to be the key component of inactivation77. At slow rates 
of freezing (~1C/min), liquid water molecules diffuse out of cells through the membrane 
in response to the chemical potential gradient and contribute to the formation of 
extracellular ice crystals79,80. Cellular damage under these conditions may result from cell 
desiccation and/or the stress exerted by extracellular ice crystals as they grow and 
squeeze cells in diminishing unfrozen channels containing high concentrations of rejected 
solutes71,79. In contrast, at high rates of freezing (~100C/min), ice crystals form at rates 
faster than liquid water molecules can diffuse through the cell membrane. If sufficiently 
large, the resulting intracellular ice crystals disrupt the cell membrane and inactivate 
cells. For example, freezing to -65C in yeast cells at a cooling rate of 1C/min leaves a 
cell density of 30% of the initial concentration, while a cooling rate of 200C/min leaves 
a cell density of 21% the original concentration80.  Cellular damage and/or inactivation 
can also occur during thawing, e.g., resulting from osmotic shock.  
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Summary  
From the literature, it is apparent that chemical action, temperature, storage time, and 
freeze-thaw cycles have a large impact on pathogen reduction during long-term storage. 
The mechanisms needed to inactivate pathogens are known to change across differing 
climates, operating parameters, and biosolids properties. However, the correlation 
between these essential mechanisms in pathogen die-off is not well understood. 
Fundamental information on how key environmental parameters affect pathogen 
inactivation is needed so that conditions necessary to achieve Class A pathogen 
inactivation requirements in LCLT biosolids treatment systems can be accurately and 
reliably predicted.  
2.3 Objectives 
The overall goal of this multi-phase project is to develop a universal approach for a 
long-term storage process to serve as a Class A treatment alternative. First, a preliminary 
study was performed to determine the relationship between total solid content and 
pathogen reduction in biosolids subjected to freeze-thaw cycles. After the preliminary 
study was completed, a broad research effort was initiated to determine the impact of key 
process parameters on the inactivation of pathogens during long-term storage. Pilot-scale 
studies for long-term storage were performed in conjunction with two collaborating 
WWTPs; the Portage Lake Water and Sewage Authority (PLWSA) in Houghton, MI, and 
the Gogebic-Iron Wastewater Authority (GIWA) in Ironwood, MI.  
This overall goal was investigated through the following specific research objectives:  
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Objective 1: Determine the relationship between total solids and pathogen reduction 
in biosolids subjected to freeze-thaw cycles.  
We hypothesize the total solids content of the biosolids sample will affect the rate 
of biosolids freezing, which affects pathogen inactivation. 
Pathogen inactivation may occur during biosolids storage under ambient 
conditions; however, the mechanisms and rates of pathogen inactivation under these 
conditions are not well understood. Objective 1 used a combination of field and 
laboratory experiments to quantify the effects of freeze-thaw cycles on the inactivation of 
fecal coliforms in biosolids with varying moisture levels. This information is needed 
because WWTPs can use natural freeze-thaw cycles in cold regions to predict and 
optimize pathogen inactivation in biosolids.  
 
Objective 2: Evaluate the pathogen inactivation under long-term storage as a 
function of environmental conditions.  
We hypothesize that the mechanisms inactivating pathogens during lagoon 
storage can be understood by ambient environmental conditions, storage temperature, 
moisture, organic matter, ammonia (NH3), volatile fatty acids (VFAs), alkalinity, and pH.  
To further understand the mechanisms of pathogen inactivation during long-term 
storage, a year-long pilot-scale study was conducted at GIWA and PLWSA to meet 
objective 2. Fundamental information was collected on the impact of key parameters, 
e.g., storage temperature, organic matter content (measured as volatile solids (VS)), NH3 
content, pH, and TS on the rate of pathogen inactivation. This data can be used to 
25 
develop a rational and universal approach for the design of a LCLT Class A biosolids 
treatment process. 
Completing the above research objectives will improve our understanding of 
pathogen inactivation under a broad range of conditions, enabling rational design of 
LCLT treatment systems for high-quality biosolids production. This will contribute to the 
greater implementation and EPA approval of LCLT treatment processes under alternative 
6 for Class A biosolids treatment, thus allowing more wastewater treatment plants to 
sustainably and economically produce high-quality biosolids.  
2.4 Materials and Methods 
2.4.1 Study Sites 
Study sites for objectives 1 and 2 included Gogebic Iron Wastewater Authority 
(GIWA, Ironwood, Michigan, USA) and Portage Lake Water and Sewage Authority 
(PLWSA, Houghton, Michigan, USA) (Figure 2-4). The two WWTPs are similar in size 
and have comparable treatment processes. GIWA treats an average wastewater flow of 
3.4 million gallons per day (mgd) and PLWSA treats an average flow of 3.1 mgd. Table 
2-5 provides information for wastewater treatment schemes. The key differences in 
biosolids treatments are seen during secondary treatment where GIWA undergoes 






Treatment Process GIWA PLWSA 
Pretreatment Screening and grit removal 
Screening and grit 
removal 
Primary Treatment Primary clarification Primary clarification 
Secondary Treatment 





Phosphorus removal via 
chemical addition, 
chlorination, 
dechlorination and effluent 
aeration 
Phosphorus removal via 




Table 2-5. Comparison of GIWA and PLWSA Wastewater Treatment Processes. 
Differences in biosolids treatments are seen during secondary treatment where GIWA 
undergoes oxidation ditch activated sludge, while PLWSA uses a conventional activated 
sludge process. 
 
Figure 2-4. Location of GIWA and PLWSA Study Sites. GIWA is located in Ironwood, 
Michigan while PLWSA is located in Houghton, MI. 
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 GIWA and PLWSA perform mesophilic anaerobic digestion for vector attraction 
reduction, followed by dewatering via belt-filter press during the solids process train. 
Both plants produce materials that are classified as Class B biosolids. Large uninsulated 
storage sheds are currently used for winter biosolids storage at PLWSA and GIWA.  
2.4.2 Objective 1: Effect of Freeze-Thaw Cycles on Biosolids 
2.4.2.1 Field Study 
 A 3 ft high biosolids pile was constructed with freshly dewatered biosolids in the un-
insulated biosolids storage shed at PLWSA in May of 2013. Temperature profiles were 
monitored at 3 locations within the pile. For each temperature profile, four Thermochron 
iButton temperature data loggers (Embedded Data Systems; Lawrenceburg, KY), with 
temperature ranges of -5 to 26 ˚C, were waterproofed with a silicone sealant, secured to a 
wooden stake at 0, 5, 10, 20, and 50 cm depths (measured from the top of the pile) and 
programmed to record the temperature at 4 h intervals for one year. When the biosolids 
were not frozen, samples were collected monthly at each depth for analysis of total solids 
and fecal coliforms. Total solids and fecal coliform levels were quantified in each sample 
using the EPA Method 168481, and the Most Probable Number Method EPA Method 
168182, respectively.  
2.4.2.2 Freeze-Thaw Cycle Pathogen Inactivation  
 A 200 g biosolids sample, collected from GIWA or PLWSA, was diluted with sterile 
deionized water to achieve desired total solids concentrations, which ranged from 5 to 
25% total solids. Initial total solids and fecal coliform levels were quantified in each 
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sample using the EPA Method 168481, and the Most Probable Number Method EPA 
Method 168182, respectively. The sample was then divided into 100 g subsamples, placed 
in Erlenmeyer flasks, and covered tightly with Parafilm. One subsample served as the 
control and was incubated at 4 °C for 48 hr. The other subsample was incubated at -20 °C 
for 48 hr and then thawed for 24 hr at 4 °C. After 72 hr, the subsample subjected to the 
freeze-thaw cycle and control were analyzed for fecal coliforms.  
2.4.2.3 Freezing Rate 
 Tests were performed to relate percent total solids to the freezing rate of biosolids. 
Figure 2-5 illustrates the basic approach of the freezing rate experiments. Insulated 
biosolids were placed on top of a water bath at 5 ˚C and in a freezer at -5 ˚C. A below-
freezing temperature on top and an above-freezing temperature on the bottom of the 
biosolids created a temperature gradient. The temperature gradient caused the cooling 
front in the biosolids to move from top to bottom to simulate conditions in natural lagoon 
storage freezing83. The system was operated in this manner for 24 hr. Temperature 














2.4.2.4 Scanning Electron Microscopy  
Prior to analysis with a FEI Philips XL 40 Environmental Scanning Electron 
Microscope, biosolids were oven-dried at 40°C for 1.5 days, directly mounted onto a 
sample button using carbon tape, and coated with a 10 µm-thick platinum-palladium 
alloy.  Images of biosolids were taken from 10-100 µm in diameter at a resolution of 15.0 
kV. 
Figure 2-5. Schematic of the biosolids freezing rate experiments. Biosolids were placed 
between insulation with a water bath at 5°C beneath, and air at -5°C to ensure the cooling 
front moved top to bottom. 
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2.4.3 Objective 2: Pilot-Scale Studies 
2.4.3.1 Pilot-Scale Test Boxes  
 Whether biosolids are stored indoors or outdoors affects solar radiation, temperature, 
and moisture content. Therefore, two pilot-scale tests were assembled in triplicate at each 
site, with pilot test boxes located inside and outside the storage shed. The pilot-scale 
boxes were designed to meet four main specifications. First, the boxes had to maintain 
structural integrity while holding ~two tons of solids, plus precipitation throughout the 
year, and undergoing freeze/thaw cycles of the biosolids. Next, the boxes had to remain 
watertight for up to two years, not allowing leachate to leak from the structure. Thirdly, 
the boxes had to allow drainage water from the biosolids to be collected and disposed of 
properly. Lastly, the boxes had to withstand ambient temperatures (~20°F to 95°F). To 
simulate average dimensions of a biosolids pile, boxes were built 4' high, 4' wide, and 8' 























Liners, a drainage system, and temperature sensor stacks were installed in the 
pilot boxes to meet design criteria. First, a sand layer was added to the bottom of the 
boxes to protect the liner from the wood (Figure 2-7A). Custom-made, potable water 
grade vinyl liners (Tri-City Vinyl, Saginaw, MI) were placed inside the interior of the 
box and attached to the outside by wood cleats (Figure 2-7B). Next, a hole was cut in the 
liner and the box to fit a polyvinyl chloride (PVC) drainage pipe (ASTM No. D2729 
specifications) at the bottom of the box (Figure 2-7C). Small gravel was added to the box 
below the drainage pipe (Figure 2-7D) followed by size 6A gravel to a depth of ~ 2” to 
ensure proper drainage and prevent clogging (Figure 2-7E). Over the gravel, filter fabric 
was laid down to allow leachate to drain while holding solids in place (Figure 2-7F). 
     
A B 
Figure 2-6. Wooden box construction A) during assembly and B) after completing 

















To begin filling the boxes, biosolids were carefully placed around the filter paper 
to prevent exposure to any of the sand or gravel. Boxes were filled by shoveling biosolids 
from a front-end loader to attain even packing consistency across all boxes to a level of 3 
feet (Figure 2-8).   
A B C
D E F
Figure 2-7. Boxes showing A) 1.5-2’’ base sand layer, B) vinyl liner, C) drainage pipe, 
D) small gravel layer, E) 6A gravel to a level of ~2” and, F) cross braces, sensor stacks, 
and filter fabric on bottom. 
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2.4.3.2 Enumeration of Microorganisms  
To meet the requirements for alternative 6 of Class A biosolids production, or a 
“Process Equivalent to a PFRP", pathogen limits of  ≥ 3-log10 reduction of total enteric 
viruses, ≥ 2-log10 reduction of viable Ascaris ova, and ≥ 1-log10 reduction of fecal 
coliforms had to be met19. However, biosolids in the U.S. do not contain high enough 
Figure 2-8. Final construction of pilot scale boxes. A front-end loader was used to evenly 
fill boxes with biosolids. 
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levels of Ascaris ova or enteric viruses to demonstrate adequate pathogen reduction. For 
this reason, Ascaris ova and enteric viruses were seeded into the pilot-scale boxes to 
levels of 104 Ascaris ova/g total solids and 105-106 plaque-forming units (PFU) enteric 
virus/g total solids. The vaccine-grade type 1 human poliovirus (ATCC) was used as the 
enteric virus and is an attenuated virus that is noninfectious.  
Sentinel Chamber Design 
Chambers were designed for spiking pathogens into the biosolids. Separate 
chamber designs for Ascaris ova (~35 to 50 µm diameter)84 and poliovirus (~28 nm 
diameter)85 were created based on pathogen size.  Chambers included a membrane 
system that prevented the release of pathogens while allowing for an exchange of gas and 
liquid with the biosolids. Therefore, conditions inside and outside the chambers in the 
biosolids boxes were essentially the same.  
The ova chambers followed the design from Gould et al86. ANKOM F57 filter 
bags (ANKOM Technology, Macedon NY) were used because their pore size (25 µm) 
was small enough to contain the ova. Additionally, the filter bags were chemically 
resistant and capable of being heat-sealed. A complete ova sentinel bag is shown in 




Figure 2-9. Complete Ascaris ova chamber with a pore size of 25 µm to contain the ova. 
 
Sentinel chambers for poliovirus followed the design of Sidhu and Toze87.  The 
sentinel chambers were composed of a Teflon tube that was open on both ends. The tube 
was secured at each end by a membrane (25 mm-diameter, 0.025-µm pore size, 
Millipore). The membrane was protected by a marine-grade stainless steel mesh (0.5 
mm). An O-ring secured the membrane and mesh within a groove at the end of the 
chamber. Brass pressure plates, screws, and nuts held the full assembly together.   
The Teflon chambers were fabricated by the Michigan Tech College of Engineering 
Machine Shop. Figure 2-10A illustrates the brass pressure plates that are on the top and 
bottom of the Teflon chamber. Figure 2-10B shows the side view of the chamber. The 
screws and nuts were made from stainless steel to prevent corrosion and rust. Figure 2-
10C illustrates the top view of the chamber.  The area between the first and second 
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circles were notched so that an O-ring and membrane could sit on the grove in the 
chamber. Figure 2-10D shows the final view of a complete sentinel chamber.  
Sentinel Chamber Seeding and Safety  
Sentinel chambers were seeded through the use of biological safety procedures to 
prevent environmental release or worker exposure. Before the release of sentinel 
chambers into the environment, precautions were taken to ensure accurate quantity and 
safety of pathogens. 
The Ascaris eggs sentinel chambers were filled in a designated biosafety area. 
Three grams of biosolids were placed at the bottom of each bag, ensuring the top of the 
A B 
C D 
Figure 2-10. Sentinel chamber design for poliovirus. A) pressure plate, B) side view of 
sentinel chamber, C) top view of Teflon chamber, D) complete poliovirus sentinel 
chamber. 
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bags were free of biosolids. After, ova were added and mixed into the biosolids to a final 
concentration of 104 ova/gram. The bags were sealed three times with a heat sealer 
(ANKOM HS). Any bags that could not be sealed properly (biosolids inhibiting sealing 
of bags) were properly disposed of by autoclaving for 60 min at 121°C. The integrity of 
all ova bags was tested before use by placing two ova spiked bags into a biosolids pile for 
seven days. The bags were then stirred in a beaker of deionized water for 24 
hours.  Double centrifugation was used with water and then magnesium chloride to 
retrieve any helminth ova that could have escaped from the bag into the water. Looking 
under the microscope, no eggs were found from this test, ensuring the safety of the sealed 
bags.  
A biological safety cabinet (BSC) was used to assemble and spike the poliovirus 
sentinel chambers. The Teflon chamber, bottom membrane, mesh, O-ring, and two brass 
plates were assembled. Five grams of biosolids were then weighed and added to the semi-
completed chamber. The chamber was placed inside the BSC, and the virus was added 
and mixed into the biosolids to a concentration of 105 MTT50/ gram. The top membrane, 
mesh, O-ring, and two brass plates were assembled to the structure. The top and bottom 
brass plates were fastened tightly to secure the O-rings in place. To ensure that the virus 
would not escape the chamber, ample time and attention were taken to guarantee the 
membranes and mesh were correctly positioned in the Teflon chamber. The complete 
chambers were wiped down with 10% bleach followed by deionized water. To test the 
structural integrity and safety of the chambers, one chamber underwent 5 freeze/thaw 
cycles over the course of a week. The chamber was disassembled to check the membrane 
and mesh for any damage. No damage was observed.   
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Sentinel Chamber Installation and Retrieval   
Ascaris ova chambers were placed in a nylon monofilament drawstring bag with a 
25-µm mesh size (filterbag.com) and hung from a pipe for biosolids installation. The 
drawstring bag hung in a "low" position, a "middle" position, and a "high" position to 
represent different heights within the biosolids. Each pipe was placed inside an outer 
PVC pipe that was placed in the bulk biosolids and packed with biosolids to surround the 
chambers. To sample the ova, the inner pipe was lifted out, and a chamber was randomly 
chosen for analysis.  
The poliovirus sentinel chambers were installed in the pilot-scale test boxes using a 
similar design as the Ascaris ova chambers. (Figure 2-11). The chambers were inserted 
through holes on each side of a square pipe and secured with a zip tie (Figure 2-11B). 
The square pipe was then inserted in an outer PVC pipe (Figure 2-11A) placed in the 
bulk biosolids and packed with biosolids to surround the chambers. As a control, 
chambers with pathogen-spiked biosolids were stored in plastic bags at 4°C. Controls 
were measured at each sampling event.  
 
Figure 2-11. Installation of poliovirus sentinel chambers in pilot-scale boxes. A) Pipe in 
pipe design and B) poliovirus sentinel chamber installation. 
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2.4.3.3 Sample Characterization  
Environmental Conditions 
Biosolids temperature was measured in triplicate at 0.5', 1.5' and 2.5' from the top 
of the 3’ high bulk biosolids using Thermochron iButton sensors (Embedded Data 
Systems). The iButton sensors have an accuracy of ± 1°C and an operating range of -40 
to + 85°C. These devices measure and store temperature data every 2 hours for up to 2 
years. The first two stacks, made from PVC, had iButton cables running from the 
iButtons to the top of the biosolids. These cables were connected to a computer with the 
use of an iButton Adaptor (Embedded Data Systems) to download the temperature data. 
The third iButton stack was not connected to cables, therefore, data could not be 
downloaded unless the iButtons were taken out of the test box and connected to an 
iButton probe cable reader (Embedded Data Systems, Cat. No. DS1402-RP3+). The third 
stack was a safety measure in case the main iButtons failed. All iButtons were 
waterproofed with Marine Adhesive Goop (Eclectic Products, Inc.) and mounted with the 
use of a clip holder (Embedded Data Systems) 
Physical/Chemical Parameters 
Pilot-scale test boxes were sampled monthly at each WWTP while the biosolids 
were unfrozen. Samples were analyzed for total solids, volatile solids, pH, VFAs, and 
ammonia. Sampling was performed based on the guidance for sampling dewatered sludge 
drying beds under the USEPA (1989)88. Sampling practices included compositing four 
samples from separate quarters of each box, and preserving samples for analysis.  
Total and volatile solids were measured by the EPA method 168489. EPA Method 
9045D90 was used to measure the pH of the biosolids. Volatile fatty acids, bicarbonate 
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alkalinity, and total alkalinity were determined through the use of the Anderson and Yang 
titration method91. The HACH company TNTplus 832 (range 2 to 47 mg/L NH3-N) 
Ammonia Method 10205 colorimetry procedure, equivalent to the USEPA Method 
350.192, was used to measure the content of ammonia-nitrogen in the biosolids.  
Microbial Assays 
Levels of fecal coliforms, infectious enteric viruses, and Ascaris ova were 
monitored throughout the study for compliance with Class A pathogen requirements19. 
Coliphage levels were measured for comparison to enteric viruses.  
Fecal coliforms were measured by the most probable number (MPN) EPA Method 
168193. Briefly, a sample of 30 grams of collected biosolids was homogenized in a 
blender with 270 mL of water. After, the sample was diluted several times in phosphate-
buffered water. Samples from four separate serial dilutions were then placed in glass 
tubes with 2 mL of sterile A-1 Media and an inverted gas collection tube. There were 5 
tubes per dilution, with 4 dilutions tested, making a total of 20 tubes per sample. These 
tubes were incubated at 35°C ± 5°C for 2 hours, and then at 44.5°C ± 5°C for 22 hours.  
A most probable number program was used to calculate the fecal coliform concentration 
based on the number of positive gas bubbles found in the inverted collection tubes. 
Quality control included on-going precision and recovery samples, spiked samples, and 
duplicated analyses. 
Enteric virus levels were measured based on a two-step process. First, poliovirus 
was recovered from the biosolids using the methods of ASTM D4994-8994. After, the 
virus was quantified using either the 1) plaque assay from Appendix H in Control of 
Pathogens and Vector Attraction in Sewage Sludge95 or the 2) quantal assay from 
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Chapter 15 of the USEPA Manual of Methods for Virology96. The plaque assay was used 
at the beginning of the study to measure high levels of poliovirus, whereas the quantal 
assay was used at the end of the study to measure low levels of poliovirus.  
Ascaris ova were measured following the method of Bowman et al.97. First, biosolids 
were collected from the sentinel bags, broken up, homogenized and sieved (20, 60, 80, 
and 100 mesh) to remove large particles. The remaining particles were allowed to settle 
overnight in a solution containing an anionic detergent (7x) to release eggs adhered to 
particles. Eggs were then separated from particles with the use of settlement, flotation, 
and sieving. After, eggs were suspended in formalin and incubated at 22-28°C for a 
minimum of 28 days. Eggs were centrifuged after the incubation period, treated with 10% 
sodium hypochlorite (bleach) to decolorize the outer shell of the eggs, centrifuged, and 
suspended in water. A 100 µL of the sample was placed on a slide, and 1st stage, 2nd 
stage, and 3rd stage viable ova were counted. The sub-sample results were multiplied for a 
representative sample. 
Levels of coliphage reduction are not required to meet PFRP equivalency. However, 
coliphages were measured because of their similar size, morphology, and structure to 
enteric viruses. Coliphages are abundant in wastewater and measured with a simple and 
rapid culture-based assay. The single agar layer EPA Method 160298 was used to measure 
coliphages. Both the male-specific coliphage (MS2, ATCC #15597-B1) and host (E. coli 
HS (pFamp) R, ATCC #700891), and the somatic coliphage (phi-X 174, ATCC #13706-
B1) and host (E. coli CN-13, ATCC #700609) were used for the study. Coliphages were 
propagated in their host, filtered through a 0.22 µm syringe filter, and mixed with 40% 
glycerol to allow for frozen storage. These phages were used as a positive control for the 
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study. To begin the single agar layer procedure, 12 grams of biosolids were mixed with 
100 mL of water in a sterile container.  Dilutions were made using phosphate-buffered 
dilution water. The log-phase host was added to each dilution and mixed with tryptic soy 
agar, warmed to 49°C ± 5°C, and appropriate antibiotics were added. Agar at 11 mL and 
the phage solution were poured into five 150-mm Petri dishes. After the agar hardened, 
the Petri dishes were sealed with parafilm to hold in moisture and placed in an incubator 
for 16-24 hours at 36°C ± 5°C. After, the plate was counted in plaque-forming units to 
determine a coliphage quantity.  
2.5 Results and Discussion 
2.5.1 Objective 1: Effects of Freeze-Thaw Cycles on Biosolids  
Freeze-thaw cycles naturally occur in biosolids over winter storage in northern 
climates. Freeze-thaw cycles increase dewaterability (or ability to lose water) of 
biosolids67-70 and can inactivate pathogens in biosolids. However, little is known about 
the effect of pathogen inactivation in anaerobically digested biosolids. Here we study the 
influence of freeze-thaw cycles on pathogen inactivation in anaerobically digested 
biosolids as a function of moisture content. Understanding the correlation of freeze-thaw 
cycles to pathogen inactivation in sewage solids will allow WWTPs to utilize a natural 
process to treat biosolids.  
2.5.1.1 Visual Analysis of Physical Changes  
Biosolids properties after winter storage were evaluated. Based on a visual 
assessment of the biosolids, it was obvious that the physical characteristics of the 
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biosolids had changed after over-winter storage. Figure 2-12A shows the biosolids pile 
in the GIWA storage shed after winter storage. Figure 2-12B shows a close-up of the top 
layer of biosolids that experienced freeze-thaw cycles over the winter. Biosolids were 
very dry with a light texture. This is quite different from the physical appearance of the 
fresh biosolids as demonstrated in Figure 2-13B. Figure 2-13 provides a comparison of 
the freeze-dried and non-frozen biosolids. The biosolids that experienced freeze-thaw 
cycles have a smaller particle diameter, and reduced pore size between particles, while 
the non-frozen biosolids particles clump together, and contain large pore spaces between 
the flocs. The nature of the biosolids subjected to freeze-thaw cycles at the particle scale 
is illustrated in Figure 2-14 by the environmental scanning electron microscopy images 
of biosolids particles from GIWA. A biosolids particle is comprised of a complex array 
of structures of various shapes and sizes. Overall, biosolids properties change after 
exposure to freeze-thaw cycles to a lighter and drier texture.  
 
 
Figure 2-12. Freeze-dried biosolids A) in the GIWA storage shed after winter storage, 
and B) in a close-up view. 
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Figure 2-13. Comparison of A) freeze-dried biosolids to B) non-frozen biosolids from 
GIWA. Structural changes occur after freezing which includes a less dense texture. 
 
Figure 2-14. SEM Images of freeze-dried biosolids from GIWA. A biosolids particle 
clearly is comprised of a complex array of structures of various shapes and sizes. 
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2.5.1.2 Field Study  
During the field study, fecal coliforms and total solids were measured at five depths 
in a pile located in the enclosed biosolids storage shed at PLWSA from May 2013 to June 
2014. Similar patterns were observed at all depths for temperature, total solids, and fecal 
coliforms (Figure 2-15). The temperature in the biosolids followed an overall trend of 
increasing from May through August, decreasing from August through November, and 
increasing again from March through June. It is important to note that the iButtons had a 
lower temperature limit of -5°C. Ambient temperatures below this level occurred 
frequently between November 2013 and March 201499, thus it is likely that temperatures 
below -5°C occurred in the pile. Overall, biosolids temperature followed temporal 
patterns and variation in temperature decreased with increasing depth. 
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Figure 2-15. Temperature, total solids (TS), and fecal coliforms (FC) measured at depths 
of A) 0 cm, B) 5 cm, C) 10 cm, D) 20 cm, and E) 50 cm, as measured from the surface of 
biosolids stored in an enclosed storage shed at PLWSA. Note that the minimum 
temperature that could be measured was -5˚C, but lower ambient temperatures were 
frequently observed between November 2013 and March 2014. 
47 
From May through October, when temperatures remained above 5°C and below 
27°C, regrowth of fecal coliforms occurred at all depths except 50 cm (Figure 2-15). 
However, after October when freeze-thaw cycles occurred in the biosolids, fecal coliform 
numbers decreased to non-detectable levels at all depths. At the 50 cm depth, regrowth 
was never observed and fecal coliforms decreased to non-detectable levels by September.  
Total solids steadily increased for all depths (other than 50 cm), presumably resulting 
from a combination of evaporation and freeze-drying (Figure 2-15). The largest increase 
in total solids occurred at the 0 and 5 cm depths after September 2013, suggesting that 
freeze-drying was especially important at the top of piles. Total solids were highest at the 
0 cm depth and eventually reached 79%. At the 50 cm depth, a small decrease in total 
solids was initially observed, presumably resulting from the input of drainage from the 
upper layers. Thus, the 50 cm depth behaved differently than the above layers. The total 
solids increased at the 50 cm depth from 17% in November 2013 to 30% in June 2014. 
2.5.1.3 Freeze-Thaw Cycles Pathogen Inactivation  
The relationship between freeze-thaw cycles, total solids, and fecal coliform 
reduction are presented in Figure 2-16 with samples from both GIWA and PLWSA. 
Despite the different biosolids sources, the data suggest a similar trend in fecal coliform 
reduction as a function of total solids for samples frozen at -20C.  Lower percent fecal 
coliform reductions were observed at low total solids (< 10% TS), and high total solids (≈ 
25% TS).  At intermediate solids contents (10-20% TS), the percent reduction in fecal 
coliforms plateaued with reductions ranging from 60-95% with many data points around 
80-90%. The maximum reduction (93.5%) in fecal coliforms was observed at 16% total 
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solids. These results suggest that there may be an optimum range of total solids for 
maximizing fecal coliform inactivation during freeze-thaw cycles; however, additional 
data points at the upper and lower total solids regions are required to confirm these 
trends.  
 
Figure 2-16. Percent fecal coliform (FC) reduction after one freeze-thaw cycle in relation 
to total solids (TS). There is an ideal total solids content that produces the highest 
reduction of fecal coliforms. 
2.5.1.4 Freezing Rate 
Implicit in the analysis of the field- and laboratory-scale data is the assumption 
that the biosolids freezing rate increases with increasing total solids content. To evaluate 
the effect of total solids content on the biosolids freezing rate, the rate at which a one-
dimensional freezing front migrated through biosolids was determined with 
thermocouples at various depths within biosolids samples. Total solids values of 8, 13, 































The initial rates of temperature changes were compared for each total solid 
condition and thermocouple location. As expected, the initial rate of temperature change 
was slowest in the 8% total solids sample and fastest in the 18% total solids sample 
(Figure 2-17). The initial rates of temperature change in the 13% and 16% total solids 
samples were similar and in between those measured in the 8 and 18% total solids. These 
results are consistent with our hypothesis that the freezing rate for biosolids decreases 
with increasing moisture content. In addition, the similar freezing rates (between 5-
10ºF/hour) measured at the intermediate total solids levels (13 and 16%) are consistent 
with the similar levels of fecal coliform reduction at those total solids levels.  
 
 
Figure 2-17. Initial cooling rate at various depths in biosolids. The largest rate of cooling 
occurred at the highest total solids content. 
2.5.1.5 Discussion  
The field study provided anecdotal evidence that freeze-thaw cycles contribute to 

























was observed at all depths during storage, the greatest reduction in fecal coliform levels 
occurred in the top and driest layers (Figure 2-15). These observations suggest that the 
biosolids moisture content affects the degree of fecal coliform inactivation during freeze-
thaw cycles. Therefore, a laboratory study designed specifically to quantify the fecal 
coliform reduction in biosolids during freezing at different total solids was undertaken 
using samples collected at PLWSA and GIWA. 
This laboratory evaluation was needed because little is known about the effects of 
freeze-thaw on pathogen inactivation in wastewater solids. Sanin et al. (1994) studied the 
correlation between temperature, freezing rate, and freezing time on pathogen reduction 
in activated sludge (rather than digested and dewatered biosolids), and observed pathogen 
inactivation after freezing and thawing77. Likewise, freezing and thawing have been used 
as a pretreatment technique to improve the dewaterability of sludge through the formation 
of compact aggregates that enhance sludge thickening and filtration100. However, the 
effects of several important variables, such as moisture content, on the efficacy of freeze-
thaw cycles for pathogen reduction in stored biosolids has not been studied. 
The laboratory data showed that inactivation of fecal coliforms appears to be less 
effective at lower (below 10% total solids) and higher total solids concentrations (above 
20% total solids) compared to intermediate total solids concentrations (between 12% and 
20%). To understand these results, it is important to understand that freezing 
temperatures alone do not cause cell death. In fact, cells have several strategies for 
preserving viability in freezing temperatures, including increasing cell membrane 
fluidity, producing polyols (i.e., alcohols with multiple hydroxyl groups) and antifreeze 
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proteins, and creating cold-shock proteins and cold-active enzymes101. The interactions 
between ice crystals and cells produce inactivation during freeze-thaw cycles. 
The rate at which freezing occurs determines the size and location (intra- or 
extracellular) of ice crystals inside/outside the pathogenic microorganism79. At the lowest 
total solids, pathogens cool slowly enough that water can move across the membrane via 
exostosis before freezing79. Thus, the ice crystals that form are primarily outside the 
pathogenic membrane, where they cause less damage than intramembrane ice crystals, 
which can disturb coat proteins and nucleic acids74 and rupture pathogens if sufficiently 
large. The formation of ice crystals outside of the membrane at slow freezing rates could 
explain why fecal coliform inactivation is lower at the lower total solids levels. Note that 
some inactivation is still expected because ice formation causes differences in the 
extramembrane and intramembrane solute concentrations that can cause dehydration and 
other cell damage during freezing and thawing102. When cells cool more rapidly (i.e., 
higher total solids), water may freeze (crystallize) before passing through the membrane. 
The size of these intramembrane ice crystals also depends on the rate of freezing79,103. 
When the rate of cooling is very fast, the rate of ice nucleation (initiation of ice crystal 
structures) is faster than the rate of ice crystal growth, resulting in large numbers of small 
crystals, which are less damaging than the large crystals that are expected to form at 
somewhat lower cooling rates. Figure 2-18 shows a schematic of the freezing concepts.  
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2.5.2 Objective 2: Pilot-Scale Studies  
Pilot-scale studies were initiated at PLWSA in July and GIWA in August of 2016. 
Environmental conditions and key physical/chemical properties were monitored 
throughout the study. Though poliovirus sentinel chambers were set up during this study, 
the data had not yet been collected for these enteric viruses and are not included in this 
dissertation. Data collection occurred from August 2016- August 2017 to demonstrate 
emerging trends, though the long-term storage study continued for up to a year after 2017 
and was followed by air drying.  
Figure 2-18. Conceptual model for inactivation of fecal coliforms (FC) at different total 
solids (TS). At low total solids and high total solids, the fecal coliform reduction is low. 
At intermediate total solids, the fecal coliform reduction is high. 
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2.5.2.1 Environmental Conditions  
Biosolids temperatures in the test boxes at PLWSA and GIWA are presented in 
Figure 2-19. As expected based on ambient temperatures, biosolids temperature 
decreases from August through December and increases from March through August. 





2.5.2.2 Physical/Chemical Parameters  
Total and volatile solids at GIWA and PLWSA contain some similarities and 
differences (Figure 2-20). The total solids at both plants stayed relatively constant until 
December and increased after the winter thaw. At both plants, biosolids stored indoors 
dried out to a greater extent than those stored outdoors. The volatile solids at PLWSA and 
 
Figure 2-19. Ambient and Biosolids Temperatures during long-term storage at A) 
PLWSA and B) GIWA. Biosolids temperatures closely followed the trends for ambient 
temperatures. 
54 
GIWA decreased indoors and outdoors. However, the volatile solids at PLWSA 
experienced a large decrease (60% to 20%) between day 28 and 59 followed by an 













The pH levels observed in the test boxes are shown in Figure 2-21. Initial pH levels 
at both plants started above pH 8 and dropped throughout the study. The pH at PLWSA 
steadily dropped to 6.5 while the pH at GIWA drastically dropped to below 5. The pH 
differences in the indoor and outdoor boxes at GIWA started to increase after winter thaw 
where pH levels in the indoor boxes dropped to 6.0 while pH levels in the outdoor boxes 
dropped to 4.5.  






































Figure 2-20. Total Solids at A) PLWSA and B) GIWA, and Volatile Solids at C) 
PLWSA and D) GIWA. 
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There were no distinct trends in the bicarbonate and volatile fatty acid levels (Figure 
2-22). At both WWTPs, the volatile fatty acid levels remained below 40,000 mg/kg.  At 










Figure 2-21. pH at A) PLWSA and B) GIWA. pH decreased at both plants, but decreased 
more drastically at GIWA. 
A B 
Figure 2-22. Volatile Fatty Acid (VFA) concentrations at A) PLWSA and B) GIWA. 
VFAs decreased in both plants. 
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The ammonia concentrations at PLWSA increased before winter and decreased after 
winter (data not shown). There is no clear trend in ammonia at GIWA. However, after 
winter, ammonia concentration increased in the indoor boxes and decreased in the 
outdoor boxes at GIWA. The main trends for physical/chemical parameters included an 
increase in total solids and a decrease in pH.  
2.5.2.3 Pathogen Inactivation  
The data from both plants followed similar trends, providing evidence into the 
reproducibility of long-term storage treatment. Comparable pathogen inactivation was 
observed at GIWA and PLWSA. Pathogen indicator organisms including fecal coliforms, 
Ascaris ova, and coliphages were measured. Though the enteric poliovirus was spiked 
into the biosolids, inactivation data for this specific pathogen is not included. Enteric 
virus inactivation was measured after the completion of this report. Fecal coliforms 
decreased steadily at both locations, and after winter reached Class A levels as shown in 




Figure 2-23. Fecal Coliforms at A) PLWSA and B) GIWA. Fecal coliform reduction at 
both plants follows similar trends with pathogens decreasing after winter storage. 
 
Similar trends for Ascaris ova were observed at both plants. 2nd stage viable Ascaris 
ova remained constant at both plants and did not reach the Class A requirement of a 2-
log10 reduction (Figure 2-24). Variability in all Ascaris ova samples is large, likely 
associated with the wide error and variability associated with the Bowman method. 
Ascaris ova have been shown to be inactivated to Class A levels through warmer 





















No clear trends were observed with the coliphage inactivation data, and therefore it 
was not added to this report. Pathogens in the biosolids were affected by all of the 
physical/chemical parameters measured during the study. High temperatures and 
freeze/thaw cycles are known to inactivate microorganisms. Drying of biosolids can 
dehydrate microorganisms and inactivate pathogens. Volatile solids act as an organic 
food source for microorganisms, and low levels can cause inactivation. High pH levels 
can increase the toxic form of ammonia, while low pH levels increase the toxic form of 
volatile fatty acids.  
2.6 Conclusions  
Objective 1 combined field- and laboratory-scale experiments to determine the 
relationship between total solids and pathogen reduction in biosolids subjected to freeze-
thaw cycles. During the field study, fecal coliforms reduced after winter freeze-thaw 
B A 
Figure 2-24. Viable 2nd Stage Ascaris Ova at A) PLWSA and B) GIWA. Levels 
remained steady and did not decrease to Class A levels. 
59 
cycles to undetectable levels. The lab-scale study found that intermediate total solids 
levels (~16% TS) reduced fecal coliforms to the greatest extent. Observations of 
significant reductions in fecal coliforms as a result of freeze-thaw cycles in both the field- 
and laboratory-studies are meaningful for WWTPs that store their biosolids indoors over 
winter with below-freezing temperatures. Nevertheless, additional testing will be required 
to confirm the ideal range of the rate of freeze/thaw and the moisture content for 
pathogen inactivation. Additionally, the impact of multiple freeze-thaw cycles should be 
evaluated. Supplementary tests should also be performed to examine the effects of freeze-
thaw cycles on other indicator organisms besides fecal coliforms. 
Objective 2 evaluated pathogen inactivation under long-term storage as a function 
of environmental conditions. The initial results from the long-term storage pilot-scale 
study demonstrated changes in environmental conditions, physical-chemical parameters, 
and microbial populations (August 2016-August 2017). Temperature profiles confirmed 
that biosolids stored over winter at both GIWA and PLSA underwent multiple freeze-
thaw cycles. The main trends observed in physical/chemical parameters over the year 
were an increase in total solids and a decrease in pH. Fecal coliforms quickly reduced to 
Class A levels after winter storage, however, Ascaris ova did not reach Class A levels 
after one year of storage. Since Class A requirements were not met, monitoring will 
continue for several years to verify that pathogen reduction complies with the EPA 
methods for alternative 6 of Class A biosolids production. Longer storage time, more 
drastic levels of pH, or higher temperatures would be able to decrease pathogens in the 
biosolids to a Class A limit. Ultimately, the results of this study should contribute to the 
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implementation and approval of LCLT treatment processes to allow for the economical 
production of Class A biosolids. 
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3 Arginine Enveloped Virus Inactivation and Potential 
Mechanisms  
3.1 Abstract  
Arginine synergistically inactivates enveloped viruses at a pH or temperature that 
does little harm to proteins, making it a desired process for therapeutic protein 
manufacturing.  However, the mechanisms and optimal conditions for inactivation are not 
fully understood, and therefore, arginine viral inactivation is not used industrially.  
Optimal solution conditions for arginine viral inactivation found in the literature are high 
arginine concentrations (0.7-1 M), a time of 60 minutes, and a synergistic factor of high 
temperature (≥ 40°C), low pH (≤ pH 4), or Tris buffer (5 mM). However, at optimal 
conditions, full inactivation does not occur over all enveloped viruses. Enveloped viruses 
that are resistant to arginine often have increased protein stability or membrane 
stabilizing matrix proteins.  Since arginine can interact with both proteins and lipids, 
interaction with either entity may be key to understanding the inactivation mechanism. 
Here, we propose three hypotheses for the mechanisms of arginine induced inactivation. 
Hypothesis 1 describes arginine-induced viral inactivation through inhibition of vital 
protein function. Hypothesis 2 describes how arginine destabilizes the viral membrane. 
Hypothesis 3 describes arginine forming pores in the virus membrane, accompanied by 
further viral damage from the synergistic factor.  Once the mechanisms of arginine viral 
inactivation are understood, further enhancement by the addition of functional groups, 




3.2 Introduction  
Therapeutic proteins have improved the treatment of diseases including cancers, 
autoimmunity/inflammation, infections, and genetic disorders104. As a result, there has 
been continued growth in therapeutic protein sales with over 200 therapeutic protein 
products currently approved105. With the growing demand for therapeutic proteins, 
advancements in the manufacturing process are desired so that large quantities of 
effective and safe protein products can be produced.  
The Food and Drug Administration (FDA) requires two orthogonal virus 
clearance steps for enveloped and non-enveloped viruses in any biotherapeutic process. 
This creates a robust system that greatly reduces the chance of non-desired infectious 
agents from entering the final product. Conventionally, non-enveloped viruses are 
removed by nanofiltration or chromatographic separation8,9,11,106-111, while enveloped 
viruses are inactivated by low pH (~3.5)112, solvent/detergent treatment113 or heat 
treatment8,114. However, conventional processes for enveloped virus inactivation can 
harm the desired protein product and reduce final yields. Specifically, pH values less than 
4.0114,115, high detergent concentrations114,116 or temperatures above 37°C117-122 produce 
conformational changes, aggregation, or precipitation that destroy the activity of 
therapeutic proteins. To maintain the stability and structure of proteins during viral 
clearance, more favorable solution conditions are desired.  
One solution to inactivate enveloped viruses without causing aggregation or 
fragmentation of the therapeutic protein product lies in the addition of the amino acid 
arginine. Arginine synergistically inactivates enveloped viruses at a less acidic pH (≥ 4)8-
15 or lower temperature (30-40°C)16 than conventional inactivation methods, increasing 
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therapeutic protein stability and yield. However, synergistic arginine inactivation is not 
currently used in industry since the conditions and phenomena for viral inactivation are 
not clear. Understanding the physical phenomena of arginine viral inactivation could give 
greater insight into a safe, effective and sustainable way of meeting therapeutic protein 
viral clearance requirements while maintaining protein stability. 
 Arginine is a naturally occurring, highly hydrophilic and polar amino acid that is 
required for protein structure and function123,124. Arginine contains a protonated 
guanidinium group (Figure 3-1) that is able to form ionic and hydrogen bonds with 
proteins and lipids124-126. Some common uses of arginine are to prevent protein 
aggregation13,127-129 and to translocate through the lipid bilayer130. Arginine is used in the 
biotechnology field for protein refolding129, protein aggregation suppression127,131,132, and 
protein solubilization133. Arginine also increases column chromatography elution 
efficiency134, is present in high frequency in antimicrobial (AMP) or cell penetrating 
peptides (CPP)124, and inactivates enveloped viruses135.  
 
Figure 3-1. Arginine structure at physiological pH. The guanidinium group has a +1 
charge while the peptide backbone is amphiphilic. 
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While there is evidence that arginine interacts with proteins and lipids, there is 
little theoretical understanding of the interaction with virus. Here, virus inactivation data 
for arginine and some of its derivatives is summarized. Then, potential hypotheses for the 
mechanism of virus inactivation is compared to current knowledge of protein and lipid 
interactions with arginine to elucidate a better understanding of the mechanism of virus 
inactivation by arginine. Presented are three likely mechanisms. The goal of this paper is 
to lay out directions of future study on virus inactivation by arginine. Once the 
mechanism of arginine viral inactivation is better understood, the method has potential to 
become a commercially viable virus inactivation processes for protein therapeutics. 
3.3 Virus Biochemistry  
Arginine exclusively inactivates enveloped viruses while having no effect on non-
enveloped viruses, signifying that specific virus or host structures are susceptible to 
arginine15. Enveloped and non-enveloped viruses contain a structural array of proteins 
that form a capsid to protect the nucleic acid cargo. However, the capsid of an enveloped 
virus is enclosed by a lipid bilayer while non-enveloped viruses expose the viral capsid to 
the environment without the presence of the lipid bilayer136.  
 Enveloped viruses gain their membrane from the host cell. After viral infection, 
enveloped viruses typically undergo a budding process that results in a portion of the host 
cell membrane becoming the outer viral envelope137,138, although the viral lipid bilayer 
can also originate from the Golgi apparatus139 or the endoplasmic reticulum140 in certain 
cases. Though the lipid bilayer is derived from the host cell in enveloped viruses, proteins 
incorporated into the viral membrane originate from the viral genetic code141.  
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 Non-enveloped viruses release from the host cell through membrane disruption 
without forming an outer envelope137,138. Due to the absence of a lipid bilayer, non-
enveloped viruses only contain outer proteins that compose the viral capsid. Non-
enveloped viruses are generally smaller and more stable than enveloped viruses. 
Considering the variation in structure and stability, non-enveloped viruses are 
conventionally removed through filtration or chromatography8,9,11,106-111, while enveloped 
viruses are inactivated through chemical or physical processes8,112-114 in therapeutic 
protein manufacturing.  
3.4 Traditional Enveloped Virus Inactivation  
Physical and chemical processes that are licensed to inactivate enveloped viruses in 
therapeutic protein solutions include heat8,114, low pH112 and solvent detergent 
treatment113. Bonds that maintain virus integrity and protein structure are similar, and 
therefore, conventional methods for virus removal inherently harm the final protein 
product142. To combat negative protein interactions, stabilizers, such as sugars, are 
commonly added to solution143. Sugars stabilize proteins by increasing preferential 
protein hydration to minimize binding of additional solvent components that may disrupt 
native protein structure144. However, stabilizers must be removed prior to final 
processing, increasing yield losses, overall cost, and production time145. 
 The FDA and EPA require a minimum of a 4 log removal value (LRV), defined in 
Eq. 3-1, for a method to be considered as a virus removal step146,147. A 4 LRV results in 
99.99% removal of virus, depending on the method of detection, which is typically either 
by infectious titer or polymerase chain reaction (PCR). In many cases, this requires high 
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titers of virus to be tested so that the required LRV can be measured within the detection 





                                         (Eq. 3-1) 
Certified heat treatments in therapeutic protein manufacturing inactivate 
enveloped viruses by destroying the structural integrity of the virus148 and altering key 
viral properties required for infection149,150. The temperature necessary for inactivation 
depends on many factors, including viral structure, time of exposure, and environment119. 
For example, hepatitis C virus is inactivated at 37°C in 2 days and at 56°C in 40 min117. 
Heat inactivation for immunoglobulin, the most common class of protein therapeutics, is 
60°C for 10 hours at pH 5.5142. Though heat treatments are certified for pathogen 
inactivation in therapeutic protein manufacturing, mechanisms for viral heat inactivation 
can mutually harm protein products and therefore are not regularly used in production.  
Low pH treatments are commonly used in therapeutic protein manufacturing to 
inactivate enveloped viruses through lipid hydrolysis151-153 and protein structural 
changes115,154-163. Values of pH between 3.4 and 4.2 can fully inactivate enveloped 
viruses given the ideal time frame for the specific virus112,142. For example, xenotropic 
murine leukemia virus is inactivated in 30 min at pH 3.8164.  Though low pH treatments 
are very effective at inactivating enveloped viruses, inactivation mechanisms may harm 
proteins. Added stabilizers are used to increase protein yields during inactivation, 
however, this adds additional downstream costs for removal.  
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Solvent detergent treatments inactivate enveloped viruses by solubilizing the lipid 
bilayer142 through the addition of non-volatile organic solvents or detergents. Viruses 
including HIV (human immunodeficiency virus), BVDV (bovine viral diarrhea virus) and 
SuHV-1 (pseudorabies) have been successfully inactivated through solvent detergent 
treatment145. Though solvent detergent treatment produces little to no protein loss, a 
downstream step is required to remove added chemicals which increases production 
costs145. Currently all conventional enveloped virus inactivation treatments either harm 
proteins or add downstream costs, creating a need for improved processing.  
3.5 Virus Inactivation with Arginine  
Compared to conventional methods, arginine inactivates enveloped viruses under 
conditions that do less harm to therapeutic proteins. Additionally, downstream removal of 
arginine is not required since it is often found in formulations165, lowering processing and 
analytical costs. Low pH treatments of pH 3.5 or less often cause protein degradation or 
fragmentation10,11,13. However, when low pH is paired with arginine, viral inactivation 
occurs at a more protein friendly pH of 4.0 or greater. Heat treatments without arginine 
for hepatitis virus require 10 hours at pH 5.5 and 60°C142. When arginine is paired with 
heat, a less elevated temperature is necessary (30-40°C) for enveloped viral inactivation 
in a shorter period of time (60 min), generating fewer adverse effects on the therapeutic 
proteins16. Arginine itself has been shown to cause minimal fragmentation of proteins at 
high temperatures and oxygen content, likely due to the production of NOx166. However, 
arginine largely interacts positively with proteins by suppressing aggregation, increasing 
solubility, and preventing protein binding167. The use of arginine in protein solutions 
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leads to enhanced recovery of proteins166. Though arginine improves protein yields 
during virus inactivation11, optimal conditions for full inactivation of all enveloped 
viruses is not known, hindering its use in manufacturing.    
A range of enveloped and non-enveloped viruses have been tested for inactivation 
by arginine and many are shown in Table 3-111,168-175.  These viruses are models for a 
variety of human viruses that contain different structures. Key viral differences include 
the occurrence of an outer envelope, genome, and size.  
Table 3-1. Properties of Tested Viruses 
Virus Acronym Envelope Genome Size (nm) 
Minute virus of mice MMV No DNA 18-24 
Poliovirus Polio No RNA 22-30 
Herpes simplex virus 1 HSV-1 Yes DNA 110-200 
Herpes simplex virus 2 HSV-2 Yes DNA 110-200 
Pseudorabies SuHV-1 Yes DNA 120-200 
Xenotropic murine leukemia 
virus 
XMuLV Yes RNA 100-120 
Influenza virus - Yes RNA 100-300 
Sendai virus - Yes RNA 150-200 
Newcastle disease virus NDV Yes RNA 150-350 
 
 Compounds tested for viral inactivation at pH 4 include arginine, butyroyl-
arginine, citrate and NaCl (Figure 3-2). Molecular structures can be found in Table 3-
274,75. Virus inactivation by arginine and butyroyl-arginine was first compared to survey 
molecules with a guanidinium group but different charges. Butyroyl-arginine is a 
derivative of arginine that contains a guanidium group, a net charge of zero at 
physiological pH, and a capped amine. Butyroyl-arginine produced similar or higher 
virus inactivation in comparison to arginine for all viruses (Fig. 2)10. The charge 
distribution on butyroyl-arginine allows for dense, self-aggregated clusters to form, 
which likely explains the enhanced virus inactivation10. Neither arginine nor butyroyl-
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arginine inactivated poliovirus, a non-enveloped virus. Arginine and its derivatives do not 
affect non-enveloped viruses, suggesting that inactivation occurs through lipid bilayer 
interactions. 
 
Figure 3-2. Viral inactivation at pH 4.0 on ice for 60 min with enveloped and non-
enveloped viruses. Different enveloped viruses showed various levels of inactivation by 
arginine, while non-enveloped viruses were unaffected. Duplicates or triplicates were 












Table 3-2. Properties of Solutes and Buffers 
*Partial average charges exist at pH values close to the pKa 
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NaCl and citrate produced lower viral inactivation than arginine and its derivates at 
pH 4. The consistently lower inactivation over all viruses by NaCl (Figure 3-2) 
demonstrates that ionic strength is not the only mechanism contributing to virus 
inactivation with arginine. Citrate also inactivated viruses to low levels at pH 4. 
Interestingly, citrate is commonly used to inactivate enveloped viruses during low pH 
treatment at pH 3.515. Either the increased acidity or the charge difference on citrate must 
enhance inactivation at pH 3.5 over pH 4. At a pH of 3.5, most of the citrate molecules 
have a -1 charge, which may strengthen inactivation. As the pH increases to 4, nearing 
the pKa of 4.65, some of the citrate molecules will gain an additional negative 
charge176,177. 
 Although arginine and its derivatives produce high inactivation for some 
enveloped viruses, not all enveloped viruses are fully inactivated. The clear difference in 
inactivation levels suggests that arginine preferentially interacts with certain viral 
properties. Specifically, arginine must favor properties of HSV-1 due to its high 
inactivation. HSV-1 is a large enveloped DNA virus with a diameter of 110 to 200 
nm168,175. HSV-1 has a highly ordered structure (Figure 3-3) where the envelope encloses 
a tegument protein layer, containing over 20 identified proteins168. Tegument proteins 
participate in a range of viral functions from viral assembly to host cell entry178. Complex 
formation between HSV-1 glycoproteins and cell receptors initiates the fusion between 
the host cell and viral membranes, leading to viral capsid uptake179.  
  Influenza virus has proteins and an infection process that differ from HSV-1, 
likely explaining the lesser inactivation. Influenza virus is an enveloped RNA virus with 
a diameter of 100-300 nm169,180. Three proteins are imbedded in the lipid bilayer, 
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including the hemagglutinin (HA), neuraminidase (NA)181, and matrix-2 (M2)180.  The 
hemagglutinin protein must undergo proteolytic cleavage by host cell proteases prior to 
membrane fusion182. Surrounding the nucleocapsid, a matrix protein called matrix-1 (M1) 
connects the lipid bilayer to the viral core169, shown in Figure 3-3. The integration of M1 
into the lipid bilayer stabilizes the virus structure more than the free-floating tegument 
proteins in HSV-1. Influenza virus infection is also different than HSV-1. Infection 
begins through attachment of the cleaved HA protein to sialic acid receptors on the host 
cell membrane, followed by uptake through the low pH endosomal pathway183. The low 
pH prompts the virus and endosomal membrane to fuse, causing the release of the 
nucleocapsid into the cytoplasm180.  
 
Figure 3-3. Comparison of HSV-1 and influenza virus structure. HSV-1 contains a 
tegument of proteins between the nucelocapsid and the lipid bilayer. Influenza virus 
contains a M1 matrix protein that stabilizes the lipid bilayer by connecting the viral core 




Sendai virus and NDV belong to the paramyxovirus family, and undergo a similar 
infection process to influenza virus184. Sendai virus and NDV are RNA viruses with 
diameters of 150-350 nm171. Two spike-like glycoproteins, including a fusion protein (F) 
and a hemagglutinin-neuraminidase protein (HN), are imbedded in the lipid bilayer. 
Similar to influenza virus, the lipid bilayer of Sendai virus and NDV overlays the matrix 
protein, M1, that encloses the nucleocapsid185.  Proteolytic cleavage of the F and HN 
protein, either intracellularly or extracellularly, is required for virulence186,187. Distinct 
from influenza virus, infection of Sendai and NDV are independent of the low-pH 
endosomal pathway.  
 A clear difference between viruses that are highly inactivated by arginine (HSV-
1), compared to viruses that show lower inactivation (influenza A virus, Sendai virus, and 
NDV), is the presence of the M1 matrix protein, and the requirement of proteolytic 
cleavage prior to infection. The M1 matrix protein tightly associates the lipid bilayer to 
the viral core, aiding in membrane stabilization188. A highly stabilized bilayer may hinder 
the direct penetration of arginine into the lipid bilayer. On the other hand, increased 
protein stability prior to proteolytic cleavage may suppress arginine from denaturing that 
protein. Prior to proteolytic cleavage, the influenza virus uncleaved HA is highly acid-
stable189. Increased stability of the uncleaved HA proteins would prohibit detrimental 
arginine-protein interactions. It is hypothesized that the presence of a M1 matrix protein 
or the increased protein stability prior to proteolytic cleavage prevents arginine from fully 
inactivating some viruses.  
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3.5.1 Charge and pH  
While virus properties may affect the levels of arginine inactivation, what is 
special about the arginine molecule to cause virus inactivation? Arginine contains a 
guanidinium moiety that is able to form ionic and hydrogen bonds with proteins and 
lipids124-126, likely aiding in virus inactivation. Various guanidine-based solutes with 
different charge patterns can inactivate enveloped viruses. Guanidine-based solutes that 
have been tested for enveloped virus inactivation are shown in Table 3-2. Guanidine 
hydrochloride at a pH of 5 completely inactivates HSV-1 in 10 min177, but this required a 
concentration of 6 M. Concentrations of guanidine hydrochloride below 2 M are not 
effective in virus inactivation118. The next potent solute is arginine, which inactivates 
HSV-1 completely at pH 4 at a concentration of 0.7-1 M in 60 min13-15.  The most potent 
arginine derivative is butyroyl-arginine, which can highly inactivate viruses where 
arginine fails, including influenza virus, at pH 4 and a concentration of 0.7 M in 60 min10. 
At a pH between 4 and 5, guanidine hydrochloride has a +1 charge, arginine has a +1 
charge and is zwitterionic, and butyroyl-arginine has a neutral charge and is zwitterionic. 
Since guanidine hydrochloride requires the highest concentration to inactivate virus, 
charge or the multiple binding sites on guanidine are not the dominating factors in the 
antiviral properties of arginine.  
 The zwitterionic properties of arginine and butyroyl arginine likely enhance viral 
inactivation through strong lipid binding and self-interactions. Alone, guanidinium is able 
to form multiple hydrogen bonds with lipids190. However, in combination with the strong 
charge distribution of arginine, the hydrogen binding of guanidinium to lipids is 
strengthened190. Additionally, the opposite charge distribution on arginine and butyroyl-
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arginine can cause the formation of clusters due to self-aggregation191. Clusters can also 
form through like-charge pairing of guanidinium moieties192,193.  
Clusters magnify localized concentrations, strengthening protein127 and lipid 
interactions194-198. Specifically, arginine clusters crowd out hydrophobic protein-protein 
interactions to prevent aggregation199-201. Preventing aggregation is one mechanism to 
stabilize proteins. Stabilized proteins may not undergo the conformational changes 
needed to initiate the virus infection cycle202. Arginine clusters can also weaken lipid 
bilayers, resulting in translocation through the lipid bilayer124,130,203. It is hypothesized 
that viral inactivation by arginine is due to protein or lipids interactions, and therefore, 
strengthening these interactions would increase inactivation.  
Butyroyl-arginine is the most effective arginine-derivative, conceivably due to its 
cluster forming structure. Butyroyl-arginine contains one positive and one negative 
charge that occupy different ends of the molecule to enhance self-interactions. Arginine 
contains an additional positive charge, which would reduce the density of clusters due to 
charge repulsion. The lesser viral inactivation of arginine as compared to butyroyl-
arginine is presumably explained by the efficacy to form clusters.   
 The buffer used to control the pH during inactivation experiments may combine 
with arginine to enhance viral inactivation. Buffers that have been used in arginine 
inactivation experiments are found in Table 3-2. Tris buffer added to arginine at neutral 
pH inactivates XMuLV and SuHV-111. Several experiments at pH 4 with acetate buffer 
have been shown to inactivate a variety of viruses9,12-15. The charge on added buffers can 
interact with proteins, lipids, or DNA to aid in viral inactivation. In addition to charge, 
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functional groups, such as the amine group on Tris, are hypothesized to interact with viral 
proteins and lipids204,205, aiding in inactivation.  
3.5.2 Concentration and Time  
Synergistic inactivation by arginine is amplified at higher concentrations. The 
LRV of HSV-1 increases with solute concentration, shown in Figure 3-4A. Arginine has 
a solubility of ~1 M, limiting the concentrations that can be tested. The need for high 
concentrations of arginine suggest that the interactions of arginine with the lipid bilayer 
structure are weak15. Furthermore, high arginine concentrations imply that dense arginine 
clusters are required for viral inactivation194-198.  
 When arginine synergizes with low pH, inactivation occurs in less than 60 
minutes for HSV-115. HSV-1 was reduced by 5 LRV in under 20 min at pH 4 (Figure 3-
4B). In comparison, a gradual increase with 0.1 M citrate resulted in only 1.3 LRV over 
60 min. The fast rate of arginine-induced viral inactivation indicates that the mechanism 




Figure 3-4. A) Viral inactivation of HSV-1 as a function of arginine and butyroyl-
arginine concentration. Increasing the concentration of arginine derivatives leads to 
higher virus inactivation.  Inactivation occurred at pH 4.0 on ice for 60 min with 20 mM 
acetate buffer. (B) Viral inactivation of HSV-1 as a function of time at pH 4 on ice. PBS 
control at pH 7. Low pH arginine inactivation occurs under 60 min. Duplicates or 
triplicates were performed for all data points. (Reformatted15) 
3.5.3 Synergistic Factors: pH, Temperature, Buffers  
Arginine synergizes with acidic pH to inactivate enveloped viruses. At pH 4, 
HSV-1 is equally inactivated by arginine and butyroyl-arginine to ~6 LRV, shown in 
Figure 3-5A. However, as pH continues to increase, viral inactivation decreases across 
all solutions. A pH of at least 4.0 is required to synergize with arginine for enveloped 
viral inactivation.  
 The viral inactivation of influenza virus with cleaved hemagglutinin (CHA) spike 
proteins and uncleaved hemagglutinin (UCHA) spike proteins (Figure 3-5B & C), was 
found to differ. CHA was inactivated to much higher levels than UCHA at pH 4 with 
arginine. On the other hand, butyroyl-arginine produced high inactivation in both CHA 
and UCHA at pH 4. Even up to pH 4.5, butyroyl-arginine highly inactivated CHA 
influenza virus.  
78 
 
Figure 3-5. Viral Inactivation of HSV-1, CHA influenza virus and UCHA influenza virus 
as a function of pH on ice for 60 min. As pH increases, arginine induced viral 





The difference of arginine inactivation for CHA and UCHA indicates a 
dependence on protein structure. CHA spike proteins are required for uptake of influenza 
virus into the host cell, while UCHA must experience proteolytic cleavage to form CHA 
prior to cell uptake10,180. CHA proteins undergo essential conformational changes during 
the low pH endosomal pathway required for cell fusion189. UCHA proteins do not 
undergo low pH conformational changes as a result of increased acid stability, hindering 
viral infection202. It is speculated that arginine and low pH can denature the CHA protein, 
while having no effect on the acid-stable UCHA protein. It may also be true that arginine 
further stabilizes the CHA protein, inhibiting the required conformational change during 
the low pH endosomal pathway to undergo infection. Considering that the magnitude of 
viral inactivation is contingent on protein structure, the synergistic effects of arginine 
may interact with proteins.  
 There are multiple cases where a difference in membrane proteins, such as with 
UCHA and CHA influenza virus, could influence arginine interactions with the lipid 
bilayer. For example, protein structure can modify packing density of the surrounding 
lipids206. With a looser lipid packing, arginine-lipid interactions would be enhanced to 
increase inactivation206.  Furthermore, negative charges on proteins may attract arginine, 
preventing arginine from interacting with the lipid bilayer to induce viral inactivation. 
Considering the data as a whole, as pH increases, the effectiveness of arginine decreases, 
leaving open the hypothesis that arginine interacts with envelope proteins or the lipid 
bilayer.  
High temperature, like low pH, can synergize with arginine to inactivate 
enveloped viruses. The temperature dependence on viral inactivation of HSV-2 is shown 
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in Figure 3-6. For reference, HSV-2 and HSV-1 are very similar in structure and 
function. Classification of these virus types is based on antigenic differences, or how 
viral proteins are modified to avoid an immune response207. Temperatures higher than 
35°C initiated the synergistic effect of arginine at a pH of 4.4. Increasing the temperature 
to 40°C improved arginine synergistic viral reduction by 2.3 LRV. Citrate followed a 
similar trend to arginine but with a consistently lower inactivation. On the contrary, 0.1 
M citrate/0.6 M NaCl produced insignificant inactivation up to a temperature of 40°C. 
This data suggests that an increase in ionic strength decreases the effect of temperature 
and pH on HSV-2 inactivation in contact with citrate. Again, it appears that ionic strength 
is not the dominating force responsible for virus inactivation at higher temperatures. The 
addition of salt ions to intermediate concentrations is largely known to increase protein 
stability208. At intermediate salt concentrations, the added charges from salt can decrease 
unfavorable interactions in solutions that could denature a protein209,210. Salts can also 
shield the charge on citrate, and that charge may be an important factor in the antiviral 
mechanism of citrate. Conclusively, arginine produced the highest viral inactivation 
compared to citrate and NaCl with increasing temperature.  
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Figure 3-6. Viral inactivation of HSV-2 as a function of temperature at pH 4.4. At 35°C, 
arginine begins to synergize with temperature to inactivate HSV-2. (Reformatted14) 
 
Similar to temperature and pH, Tris buffer seems to synergize with arginine to 
inactivate enveloped viruses. The inactivation of SuHV-1, X-MLV, and MMV at neutral 
pH for 60 min at 4°C with 5mM Tris buffer is shown in Figure 3-7. SuHV-1 and X-
MLV are both enveloped viruses that were inactivated to near 4 LRV. The following data 
is the only example in literature where neutral pH and arginine inactivated enveloped 
viruses, and therefore, it is assumed that Tris buffer is the synergistic factor. MMV is a 
non-enveloped virus and was negligibly inactivated when exposed to arginine and Tris, 
consistent with results that arginine has little effect on non-enveloped viruses10. 
Compared to conventional inactivation methods, Tris buffer paired with arginine at 
neutral pH and 4°C maintains the full activity of proteins11, making it a desired process in 
therapeutic protein manufacturing. 
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Figure 3-7. Viral inactivation with 1M arginine and 5 mM Tris buffer at pH 7.0 for 60 
min at 4°C. At a neutral pH, arginine can synergize with Tris buffer to inactivate 
enveloped viruses. (Reformatted11) 
 
It is curious as to how Tris synergizes with arginine at neutral pH to inactivate 
viruses. Tris undergoes multiple interactions that may disrupt biological processes to aid 
in inactivation211. For example, Tris is toxic to rat nerve cells at concentrations as low as 
10 mM212.  Interactions of Tris with lipid bilayers may explain the observed toxicity. 
When exposed to a phospholipid bilayer at room temperature, Tris buffer increased lipid 
disorder213. Similarly, in strains of Escherichia coli, Tris buffer increased membrane 
permeability, leading to a loss of cell membrane components214. On the contrary to the 
above studies, in supported lipid bilayers, atomic force microscopy measurements 
demonstrated that Tris buffer reduced membrane stress, while other ions, such as Ca2+, 
increased membrane stress215. Though there are mixed results on the effects to lipid 
bilayers, Tris buffer does interact with membranes.   
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Aside from lipid bilayers, Tris undergoes additional interactions in biological 
solutions. Tris can stabilize proteins through electrostatic and hydrogen bonding216,217 and 
can associate with DNA218.  The positive charge and primary aliphatic amine group of 
Tris, shown in Table 3-2, are thought to be the root cause of multiple 
interactions204,216,218,219. Charges on molecules interact with proteins and lipids215,220-224, 
while primary aliphatic amines interact with several compounds including 
DNA204,216,218,219.  Either through lipid bilayer, protein or DNA interactions, Tris is 
thought to synergize with arginine to inactivate enveloped viruses.  
 At optimal solution conditions and synergistic abilities, arginine is an effective 
means of inactivating some enveloped viruses. High concentrations (0.7-1M) and a time 
of 60 minutes combined with the synergistic factor of high temperature, low pH, or Tris 
buffer is needed for maximum virus inactivation.  After gaining a comprehensive 
understanding of arginine interactions with proteins and viruses, we list three hypotheses 
for the mechanisms of synergistic arginine viral inactivation.  
3.6 Hypotheses for Synergistic Arginine Viral Inactivation  
We propose three mechanisms for arginine induced enveloped viral inactivation and 
go into greater detail on the potential phenomenon involved (Figure 3-8). Hypothesis 1 
describes arginine-protein interactions leading to the loss of viral infectivity. Hypothesis 
2 describes the destabilization of the viral membrane by arginine. Hypothesis 3 describes 
pore formation by arginine, followed by further viral damage from the synergistic factor.  
84 
 
Figure 3-8. Hypotheses on the virus inactivation mechanism of arginine. It is 
hypothesized that viral inactivation occurs by either the 1) disruption of protein activity, 
2) destabilization of the lipid bilayer, or 3) pore formation in the lipid bilayer. Arginine is 
shown as its molecular structure and the synergistic factor is represented as a blue sphere. 
Examples of synergistic factors are low pH, temperature or buffer molecules. 
3.6.1 Hypothesis 1: Arginine with Synergistic Factor Interacts with Viral Proteins  
Hypothesis 1 states that arginine synergizes with Tris, low pH or temperature to 
directly inhibit protein function. There are two ways in which proteins are speculated to 
lose their function by arginine. First, the synergy of arginine is thought to denature or 
fracture viral proteins. Second, arginine may bind to or crowd out proteins to prevent 
required conformational changes or attachment to host cell receptors225. Regardless of the 
process, the loss or inability of viral proteins to undergo necessary functions induced by 
arginine will hinder viral infection.  
 The combination of arginine with the synergistic factor may disrupt protein 
structure. Low pH and high temp are common protein denaturants, though, the levels 
used with arginine have little effect on proteins10,11,13,16.  Combined with arginine, the 
effects of low pH or high temp to destabilize proteins may be enhanced. Arginine 
contains multiple binding opportunities that possibly disrupt protein structure. The 
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cationic guanidinium group of arginine has the capacity to form up to six hydrogen bonds 
with anionic species226. The binding of the guanidinium group to the carbonyl oxygen on 
the protein backbone can structurally stabilize a protein’s secondary and tertiary 
structure227. But when arginine is external to the protein, the bonds holding the secondary 
and tertiary structure may favor binding to the external arginine rather than internal 
bonds, leading to protein fracturing or denaturation. In solution, water surrounds proteins 
to create a hydration shell that maintains protein structure228. When arginine binds to 
proteins through hydrogen and cation-π bonds129,191,201,229, the protein hydration shell is 
likely disrupted, leading to protein destabilization. Arginine is also highly common in salt 
bridges230; the presence of arginine in solution could disrupt or create new salt bridges in 
proteins, altering protein structure.  
Though it seems plausible that arginine and the synergistic factor denatures 
proteins, other evidence suggests that this is the weakest of the hypotheses. Tris buffer 
was shown to synergize with arginine to inactivate virus at neutral pH11 (Figure 3-7). 
Tris is known to stabilize proteins216,217, suggesting that there are no harmful effects on 
protein conformation.  Arginine is also largely known to prevent protein aggregation and 
enhance protein solubility13,127-129. By binding to proteins through hydrogen and cation-π 
bonds, arginine collects on the surface to prevent protein aggregation129,191,201,229. Despite 
the positive effects on proteins, arginine has been shown to slightly fracture proteins 
through NOx production at high temperatures (≥40°C)166. However, NOx production by 
arginine is too insignificant at or below room temperature to denature a protein166. This 
would rule out denaturation as the cause for inactivation on ice or at 4°C (Figure 3-2, 
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Figure 3-4, Figure 3-5, Figure 3-7) Overall, it is unlikely that the synergistic effects of 
arginine denature proteins. 
 Though it is unlikely that arginine denatures proteins, arginine may prevent host 
cell fusion. Binding of arginine to membrane proteins could render the protein 
unrecognizable to the host cell receptor to obstruct cell fusion. Levels of inactivation 
across viruses could be explained by the capacity for arginine-protein binding. 
Glycoproteins with negatively charged species and aromatic residues would enhance 
arginine binding129,191,201,229. Additionally, the synergistic factor could promote conditions 
for arginine-protein binding. For example, a drop in pH can alter the charge of amino 
acid residues on the membrane proteins, allowing arginine to bind to the protein. 
 In addition to protein binding, arginine molecules in solution tend to self-
aggregate into clusters191,192. Arginine-arginine clusters are thought to occur due to like-
charge pairing of guanidinium moieties192,193 or hydrogen bonding from head to tail191. 
These clusters are known to crowd out protein-protein or protein-surface 
interactions167,199,201,231. Correspondingly, arginine clusters would crowd out protein 
interactions with host cell receptors. Crowding may or may not entail protein binding. If 
no protein binding occurred, the effects would be reversible by dilution of arginine, 
though this is not the case. When diluting arginine samples prior to plaque assays, 
inactivation effects for enveloped viruses remained15. For this reason, arginine-protein 
binding would be required to reduce virus infectivity.  
 In support of arginine-protein interactions, inactivation levels vary across viruses 
with different proteins10. For example, arginine at pH 4 highly inactivated influenza virus 
containing CHA proteins while lower inactivation resulted for influenza virus containing 
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UCHA10. UCHA differs from CHA in structure and stability202 UCHA spike proteins 
must undergo proteolytic cleavage to modify into CHA structure prior to cell uptake189. 
Due to the increased stability, UCHA proteins do not undergo the essential 
conformational changes required for cell fusion that CHA endures during the low pH 
endosomal pathway202. The structure and stability of CHA compared to UCHA could 
explain differences in inactivation levels. Arginine may destabilize the CHA proteins to 
prevent host cell binding, while having limited effect on the stable UCHA protein. 
Alternatively, arginine may further stabilize CHA to hinder endosomal low-pH 
conformational changes that are required for host cell infection. For this reason, CHA and 
UCHA influenza virus inactivation data may support either arginine-induced protein 
denaturation or protein stabilization.  
 Similar to UCHA of influenza, NDV and Sendai virus are not highly inactivated 
by the synergistic effects of arginine10,15. Also similar to UCHA, NDV and Sendai both 
require proteolytic cleavage of glycoproteins prior to infection. In contrast to influenza, 
NDV and Sendai proteins do not undergo low pH conformational changes after 
proteolytic cleavage. Accordingly, stabilization of NDV or Sendai virus proteins would 
not inhibit infectivity because conformational changes are not required for infection, 
favoring protein denaturation as the root cause of inactivation. If we disregard protein 
denaturation as the mechanism, arginine may be more likely to bind to the proteins of 
NDV, Sendai, and influenza to inhibit host cell fusion. Overall, it is not easy to explain 
the difference in NDV, Sendai, and influenza virus inactivation by protein denaturation. 
Protein denaturation or inhibition of host cell binding may be fundamental to 
arginine-induced inactivation. However, one of the largest pieces of evidence against 
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hypothesis 1 is that the synergistic activities of arginine do not affect non-enveloped 
viruses10,15. Similar to enveloped viruses, non-enveloped viruses have external proteins 
that induce host cell recognition and uptake225. For hypothesis 1 to have significance, 
arginine would have some effect on non-enveloped virus infectivity.  
3.6.2 Hypothesis 2: Arginine with Synergistic Factor Interacts with Viral Lipids  
According to hypothesis 2, viral inactivation manifests through the interactions of 
arginine and the synergistic factor (Tris, high temp or low pH) with the lipid bilayer to 
induce membrane deformations. Deformations to the lipid bilayer may completely 
destabilize the outer viral membrane to result in viral inactivation. Alternatively, lipid 
bilayer deformations may prompt conformational changes to membrane proteins, 
resulting in a loss of viral infectivity.   
The synergistic activities of arginine exclusively inactivate enveloped viruses 
while non-enveloped viruses remain unharmed10,15, suggesting that mechanisms for viral 
inactivation involve the lipid bilayer. In support of hypothesis 2, arginine does interact 
with the lipid bilayer through binding124-126 and lipid deformations. Specifically, arginine-
rich peptides deform membranes in order to translocate into the cell for drug 
delivery190,191,232-234. At low arginine concentrations, endocytosis has been observed as 
the sole route for arginine peptide translocation235. However, studies show that at high 
arginine concentrations, direct penetration of arginine peptides is favorable over 
endocytosis197,235,236. Although arginine peptides do have a different charge/size ratio in 
comparison to a single arginine molecule, the guanidinium group on arginine is a large 
component of peptide activity237. Membrane deformations result from the guanidinium 
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moiety binding to negative charges on the lipid bilayer, and/or the hydrophilic peptides 
interacting with the hydrophobic lipids190,191,232-234. Arginine side chains also maintain 
their charge when exposed to the hydrophobic membrane environment where no other 
amino acid can, aiding further in membrane deformations237. The transport of arginine 
peptides through lipid bilayers has been extensively studied where single arginine 
molecules have not198. It is useful to use arginine peptides as a model for arginine to 
further expose the mechanism of arginine inactivation.  
Loosening of lipid packing increases peptide uptake, indicating that arginine 
deforms the lipid bilayer for translocation234,238-241. High cholesterol content in lipids 
decreases membrane fluidity and translocation of arginine238 203,206. In the presence of the 
hydrophobic cation pyrenebutyrate, which is suspected to loosen lipid packing and 
increase membrane fluidity, arginine uptake increased in the lipid bilayer234,239-241.  Virus 
size can also affect membrane curvature and lipid packing density. A mild degree of lipid 
curvature exists in viral membranes with a large diameter. Mild curvature leads to loosely 
packed lipids that deform and bend in response to arginine interactions194. In contrast, the 
drastic curvature of small diameter membranes forms tightly packed lipids that are 
difficult to distort194. This is schematically shown in Figure 3-9194,242. Curvature is not 
likely an issue for cells or bacteria due to their large size in comparison to most viruses. 
However, when exploring the interaction of arginine with small macromolecules, like 
viruses, this curvature may play a role in the selective penetration of arginine into the 

















Figure 3-9. Hypothesized interaction of arginine with large and small diameter 
membranes. The open spacing of lipids in a large diameter membrane increases 
susceptibility to arginine deformations. Oppositely, the tightly packed lipids of a small 
diameter membrane are difficult for arginine to manipulate. 
 
The synergistic factors of low pH, high temperature, and Tris buffer all disrupt the 
lipid bilayer, favoring hypothesis 2. Low pH151-153 and high temperature148 invoke lipid 
hydrolysis. Tris disorders and disassembles the lipid bilayer213,214. However, Tris buffer 
has also been shown to increase membrane stability215. Considering all inactivation 
factors that disrupt the lipid bilayer, it is likely that the synergistic inactivation 
mechanisms of arginine involves the viral membrane.  
Differences in inactivation levels observed across viruses can be attributed to lipid 
bilayer deformations. When analyzing synergistic arginine inactivation data, viruses that 
endure low inactivation (Sendai, influenza, NDV) all contain the M1 matrix protein10,15. 
The M1 matrix protein integrates the membrane to the viral core, increasing lipid bilayer 
stability188. Increased lipid bilayer stability decreases viral susceptibility to membrane 
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defects to increase viral survival when exposed to arginine. However, this would not 
explain the high inactivation levels of CHA influenza and low inactivation of the UCHA 
influenza virus in response to arginine and low pH10. Arginine combined with low pH 
may deform the membrane to the extent of destabilizing integral membrane proteins. 
UCHA has increased stability in comparison to CHA189. Therefore, UCHA may retain its 
structure in response to membrane defects while CHA is denatured.  Protein structure can 
also alter packing density of lipids at the protein-lipid interface206. The differences in 
structure between UCHA and CHA influence the surrounding lipid packing density to 
affect arginine inactivation.  The fact that arginine peptides and synergistic factors are 
known to affect lipid bilayers, in combination with viral inactivation data, support 
hypothesis 2.  
3.6.3 Hypothesis 3: Arginine Forms Pores in the Lipid Bilayer  
Hypothesis 3 considers arginine-induced pore formation in the lipid bilayer as the 
fundamental component in viral inactivation. Similar to membrane deformations, pore 
formation may destabilize the lipid bilayer to disrupt membrane proteins or overall virus 
integrity. Alternatively, pores in the lipid bilayer may allow the passage of the synergistic 
factor through the lipid bilayer and into the viral core, leading to degradation of viral 
genetic material.  
In several studies, arginine-rich peptides have been shown to cross the lipid 
bilayer through the formation of a water pore124,194,197,198,234,242. Pores are hypothesized to 
form in a similar manner to membrane deformations, through electrostatic or hydrophilic 
interactions190,191,232-234.  For example, preferential binding to negative charges in 
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zwitterionic lipids (common in mammalian membranes) results in lipid sorting and 
membrane tension. Membrane tension can lead to lipid flip flop and membrane 
multilamellarity, eventually forming a pore130. In comparison to direct translocation by 
membrane deformations, translocation through a pore is thought to require less energy, 
and is therefore more advantageous205,242. Multiple arginine molecules can cross through 
a pore at one time, lowering the translocation energy198,242,243. Additionally, passing 
through a pore can lower arginine translocation energy through avoidance of the 
hydrophobic lipid core198,242,243. Similar to membrane deformations, pores in the lipid 
bilayer may destabilize the membrane and associated membrane proteins. This would 
coincide with the data for low inactivation of viruses containing the M1 matrix 
protein10,15, along with the increased stability of UCHA influenza virus at low pH10. 
Arginine-induced pores may additionally allow for the synergistic factor to pass 
through the protective lipid bilayer, causing oxidation or cleavage of virus capsid proteins 
or nucleic acids. The membrane of an enveloped virus protects the capsid and nucleic 
acids against environmental factors244,245. A pore in the membrane may allow hydronium 
ions in a low pH solution245, Tris buffer218, or high temperature246 to disrupt the genetic 
material and inactivate the virus. However, the levels of pH and temperature used during 
arginine synergistic viral inactivation are not known to cause DNA degradation245,246. 
Due to the lower energy requirement for a pore formation in comparison to membrane 
deformations, arginine likely forms a pore to result in viral inactivation.  
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3.6.4 Future Study  
It will take a concerted effort and multiple experiments to shed light on the 
mechanism of arginine in virus inactivation. The first is to determine if the virus structure 
has been compromised after treatment. This simple test has not been reported in the 
literature.  To specifically test hypothesis 1, protein binding experiments can determine if 
a protein is still active after arginine exposure. Heparin is a common cell receptor for 
virus, and changes in heparin binding could be used to explore the changes in cell 
attachment247. However, changes in heparin binding could also support hypothesis 2, 
since lipid instability could cause changes in membrane bound proteins, disrupting 
binding events. 
 To assess hypothesis 2 and 3, nanoindentation can measure changes in virus 
stiffness248. If the virus stiffness decreases after arginine exposure, the lipid bilayer is 
being compromised either by deformation or pore formation. If virus stiffness and 
heparin binding are reduced, then hypothesis 2 is most likely. To discern hypothesis 2 
from hypothesis 3, the integrity of the genetic material in the virus can be assessed. The 
reduction in genetic material for would provide evidence that the integrity of the 
membrane has been compromised, as described in hypothesis 3. While literature supports 
all of the hypothesis, it is possible to better discern the mechanism of arginine 
inactivation if more effort is put into this area. 
3.7 Conclusions  
The process of synergistic arginine enveloped viral inactivation provides greater 
protein stability and increased therapeutic protein yields in comparison to conventional 
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methods8-16, making arginine a desirable pathogen removal step in therapeutic protein 
manufacturing. Although there are multiple studies on the synergistic effects of arginine, 
information has not been compiled to determine the mechanisms and optimal conditions 
for viral inactivation. Through analyzing literature data, optimal solution conditions for 
the synergistic ability of arginine include high concentrations (0.7-1M), a time of 60 
minutes, and a synergistic factor of high temperature (40°C), low pH (pH 4), or Tris 
buffer (5 mM)8-16. However, these optimal solutions conditions do not inactivate all 
enveloped viruses evenly, suggesting that inactivation mechanisms are contingent upon 
certain viral structures. Viral structures that were highlighted to reduce the synergistic 
inactivation of arginine included increased protein stability and the presence of a matrix 
protein that integrates the capsid to the lipid bilayer. Three hypotheses were proposed for 
the mechanisms of synergistic arginine inactivation that explained the lower inactivation 
levels for viruses containing stabilized membrane proteins and lipid bilayers. Hypothesis 
1 describes the viral inactivation by arginine through the inhibition of vital protein 
function. Hypothesis 2 describes viral inactivation by arginine through the destabilization 
of the viral membrane. Hypothesis 3 describes pore formation induced by arginine, 
accompanied by further viral damage from the synergistic factor to inactivate the virus. 
Due to the undisputable fact that arginine solely effects enveloped viruses, it is likely that 
either hypothesis 2 or 3 is correct. However, additional data is required for a definite 
understanding of synergistic arginine inactivation. When the mechanisms are fully 
known, viral inactivation by arginine may be further enhanced by the addition of 
functional groups, charges, or molecules to completely inactivate all enveloped viruses.  
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4 Physiochemical Properties of Enveloped Viruses and 
Arginine Dictate Inactivation  
4.1 Abstract  
Therapeutic protein manufacturing would benefit by having an arsenal of ways to 
inactivate viruses. There have been many publications on the inactivation ability of 
arginine at pH 4.0, but the mechanism of this inactivation has not been elucidated. This 
study explored virus structure, arginine-derivatives, arginine clustering, hydrophobicity, 
and buffer type on enhancing inactivation by arginine. Virus structure considerably 
influenced arginine inactivation. Large diameter viruses (SuHV-1, HSV-1) with loosely 
packed lipids were highly inactivated, whereas small diameter viruses (EAV, BVDV) 
with tightly packed lipids were negligibly inactivated by arginine. SuHV-1 experienced 
the highest inactivation of the viruses tested, with full inactivation at pH 7 and 1 M 
arginine. Membrane cholesterol sensitivity likely explains the inactivation difference 
between SuHV-1 and HSV-1. To increase the inactivation of viruses resistant to arginine, 
arginine-derivatives, and arginine peptides were tested. A greater capacity for clustering 
(butyroyl-arginine and R8 peptide) and added hydrophobicity (butyroyl-arginine and 
CapA6R peptide) enhanced virus inactivation. Pyrenebutyrate, a hydrophobic cation, 
improved the inactivation of EAV by arginine. Dynamic light scattering (DLS) and 
transmission electron microscopy (TEM) detected increases in virus size after arginine 
exposure, supporting lipid expansion or arginine binding as the mechanism for 
inactivation. Conclusively, viruses with a large diameter and high cholesterol sensitivity 
were inactivated by arginine to the greatest extent. For viruses resistant to arginine, 
hydrophobicity and arginine-clustering enhanced inactivation.    
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4.2 Introduction  
Therapeutic proteins are a progressive treatment option for cancers, 
autoimmunity/inflammation, infections, and genetic disorders104. When therapeutic 
proteins are produced from mammalian cells, there is potential for the presence of 
infectious viruses in solution249. Therefore, viral clearance is crucial in the manufacturing 
of therapeutic proteins to ensure infectious viruses do not spread to clinical patients. FDA 
regulations require a minimum of two orthogonal downstream viral clearance processes 
during manufacturing250. Typically, orthogonal processes include a filtration step to 
remove nonenveloped viruses and an inactivation step to remove enveloped viruses249. 
Low pH treatment is commonly used to inactivate enveloped viruses because of its 
simple, effective, and robust nature249. Currently, low pH treatment requires pH values ≤ 
4.0251, with pH values ≤ 3.6 being the most effective249. Unfortunately, acidic pH levels 
below 4 can sometimes damage proteins in therapeutic solutions252. Therefore, there is a 
need for an enveloped virus inactivation process that occurs at less acidic conditions.  
 Arginine can inactivate enveloped viruses at pH ≥ 410,15, increasing protein 
stability and reducing product aggregation propensity in comparison to conventional low 
pH treatment. However, optimal conditions for full inactivation of all enveloped viruses 
by arginine are not known17. Several studies demonstrate the inactivation of enveloped 
viruses by 0.7-1 M arginine after 1 hour at pH 4, with diminishing effects above pH 
410,15. However, not all enveloped viruses are equally inactivated under these conditions. 
For example, after 1 hour at pH 4 with 0.7 M arginine, HSV-1 is fully inactivated while 
influenza is only inactivated to 3.1 LRV. Sendai and Newcastle disease virus (NDV) 
experience insignificant inactivation at those conditions10,15. A stabilized lipid bilayer or 
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stabilized membrane proteins are hypothesized to lessen the inactivation effects of 
arginine17. Lipid bilayer stability can be influenced by lipid packing density or integrated 
proteins. In the case of Influenza, NDV, and Sendai virus, lipid bilayer stability is 
increased through the action of matrix proteins that integrate the lipid bilayer to the viral 
core. These viruses also all contain uncleaved glycoproteins that have increased 
stability169,186,187. Since viruses resistant to arginine contain both stabilized lipid bilayers 
and proteins, it is unclear if arginine is interacting with the lipid bilayer, proteins, or both 
to inactivate enveloped viruses.  
Recently, pseudorabies virus (SuHV-1) and xenotropic murine leukemia virus (X-
MLV) were inactivated at pH 7 in a solution of 1 M arginine and 5 mM Tris after 1 hour 
at 4°C11.  In comparison to conventional low pH processes, inactivation at neutral pH 
maintains the stability of proteins, and therefore, is desired for viral clearance in 
therapeutic protein manufacturing. This is the only example in the literature where 
arginine inactivated a virus at neutral pH and below 35°C16. The main differences 
between this singular study and the numerous studies that demonstrated inactivation by 
arginine at pH 4 were the buffers and viruses tested. Acetate or no buffer was used with 
inactivation studies at pH 410,15, while Tris buffer was used at neutral pH. HSV-1 and 
influenza virus were tested at pH 4 and above10,15, while SuHV-1 and X-MLV were 
tested at neutral pH11. The conflicting results in the literature lead to uncertainty in how 
arginine inactivates viruses at pH 7. Inactivation may be the result of virus structure or 
solution conditions.  
Another key to arginine virus inactivation appears to be related to charge and 
hydrophobicity. Butyroyl-arginine, an arginine-derivative with a net charge of zero 
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between pH 3.73-12.14 and a hydrophobic capped amine, was equally or more effective 
than arginine in inactivating enveloped viruses over all conditions tested10. Because of its 
pure zwitterionic nature, butyroyl-arginine more readily forms self-clusters compared to 
arginine, which has an extra positive charge at physiological pH10. Arginine clusters 
support lipid and protein interactions to strengthen inactivation17. Additionally, the 
increased hydrophobicity of butyroyl-arginine may promote uptake into the lipid 
bilayer239. Improved clustering or hydrophobicity enhances inactivation by arginine, 
supporting the idea that solution conditions can enhance inactivation.  
Arginine fully inactivates some enveloped viruses at pH 410,15 and pH 711. 
However, not all enveloped viruses are highly inactivated by arginine under conditions 
reported in the literature. Viral membrane structures or glycoprotein stability appear to 
affect arginine inactivation. Additionally, the charges or functional groups on arginine or 
the buffer influence inactivation. Overall, it is not clear what factors optimize inactivation 
by arginine. This study goes into depth to explore virus structure, arginine-derivatives, 
arginine clustering, hydrophobicity, and buffer type on the inactivation of enveloped 
viruses by arginine. Pseudorabies virus (SuHV-1), herpes simplex virus (HSV-1), equine 
arteritis virus (EAV), and bovine viral diarrhea virus (BVDV) were tested for inactivation 
under various solution conditions. This study improves our understanding of arginine 
inactivation of enveloped viruses and helps to define the ability of arginine to inactivate 
enveloped viruses while retaining therapeutic protein stability during manufacturing.  
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4.3 Materials and Methods 
4.3.1 Materials  
For cell culture and viral assays, Eagle’s medium essential media (EMEM), 
Dulbecco’s modified eagle medium (DMEM), phosphate buffer saline (PBS, pH 7.2), 
sodium bicarbonate, penicillin/streptomycin (pen/strep, 10,000U/ml), sodium pyruvate 
(100mM) and trypsin/EDTA were purchased from Life Technologies (Carlsbad, CA). 
Fetal bovine serum (FBS, Canada origin) for cell culture was purchased from HyCloneTM 
GE Healthcare (Pittsburg, PA). Horse serum (New Zealand Origin) and glycerol for cell 
culture were purchased from Sigma Aldrich. MTT salts (2-(3,5-diphenyltetrazol-2-ium-2-
yl)-4,5-dimethyl-1,3-thiazole; bromide, 98%) were purchased from Alfa AesarTM 
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased 
from VWR (Radnor, PA) for MTT assays.  
Chemicals used during viral inactivation assays included L-arginine 
monohydrochloride (99%) and agmatine sulfate (97%) purchased from ThermoFisher 
Scientific (Waltham, MA) and 1-pyrenebutyric acid (PYB, 97%) and dimethyl sulfoxide 
(Hybri-MaxTM, sterile filtered, ≥ 99.7%) purchased from MilliporeSigma (St. Louis, 
MO). Peptides were synthesized by Biomatik (Wilmington, Delaware) to mimic 
clustering and hydrophobic conditions. Peptide capA6R contained a six-chain 
hydrophobic alanine tail linked to an arginine, capped with an acetyl group at the N-
terminus and amidated at the C-terminus. It was received as the trifluoroacetic acid 
(TFA) salt at >80% purity. Peptide R8 is a chain of eight arginine molecules, which was 
received as the TFA salt at >95% purity. 
100 
Buffers of MES sodium salt (99% Acros OrganicsTM), sodium acetate anhydrous 
(fused crystals/certified ACS), Tris hydrochloride (molecular biology grade), and 
potassium phosphate (ACS AR Crystal, Macron Fine ChemicalsTM) were purchased from 
ThermoFisher Scientific. Buffers of sodium acetate (≥ 99% bioreagent), acetic acid 
(glacial), and citric acid monohydrate were purchased from MilliporeSigma.  Buffers of 
sodium citrate tribasic dihydrate, glycineamide hydrochloride (≥ 99% AT), Trizma® 
Base (≥ 99% bioperformance certified), glycine (99% for molecular biology), tricine, and 
sodium phosphate dibasic heptahydrate (ACS reagent, 98-102%) were generously 
donated by MilliporeSigma. Solution pH was adjusted with sodium hydroxide (NaOH) 
from MilliporeSigma and hydrochloric acid (HCl) from ThermoFisher Scientific. 
For the cholesterol assay, methyl-β-cyclodextrin (BioReagent, suitable for cell 
culture) was purchased from MilliporeSigma and the Amplex Red Cholesterol Assay Kit 
was purchased from ThermoFisher Scientific. For transmission electron microscopy 
imaging, glutaraldehyde (Grade 1, 70% in H20) was purchased from MilliporeSigma, and 
uranyl acetate was purchased from ThermoFisher Scientific.  
4.3.2 Methods 
4.3.2.1 Cells and Viruses 
Bovine turbinate cells (BT-1, ATCC CRL-1390), rabbit-kidney cells (RK-13, 
ATCC CCL-37), and Vero cells (ATCC CCL-81) were purchased from ATCC. Bovine 
viral diarrhea virus (BVDV) strain NADL was purchased from the United States 
Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS). 
Equine arteritis virus strain Buvyrus (EAV, ATCC VR-796), human herpesvirus 1 strain 
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F (HSV-1, ATCC VR-733), and suid herpesvirus 1 strain Aujeszky (SuHV-1, ATCC VR-
135) were purchased from ATCC. All cells were incubated at 5% CO2 and 100% 
humidity during infectivity assays.  
BT-1 cells were cultured in DMEM media supplemented with 1% v/v pen/strep, 
1% v/v sodium pyruvate, and 10% v/v horse serum at 37°C and 5% CO2. Cells were split 
every 3-4 days (or when 70% confluent) at a 1:3 ratio. BVDV was added at a 
concentration of 105 MTT50/ml to BT-1 cells at 80% confluency in supplemented DMEM 
media for virus propagation in a cell culture flask. Once BVDV was added to the BT-1 
cells, the flask was left on a roto-shaker at low speed for one hour. After shaking, the 
virus suspension was removed from the 75 cm2 flask and 15 mL of fresh media was 
added to the infected cells. The infected flask was incubated at 37°C for 72 hours. After, 
the monolayer was scraped with a cell scraper and the media was collected in a centrifuge 
tube. The tube was spun down at 5500xg for 15 min at 4°C. The supernatant was 
collected as the propagated virus sample and 10% v/v glycerol was added for storage at -
80°C.  
RK-13 cells were cultured in EMEM media supplemented with 1% pen/strep, and 
10% FBS and incubated at 37°C and 5% CO2253. Cells were split every 2-3 days (or when 
70% confluent) at a 1:3 ratio. EAV was added at a concentration of 105 MTT50/ml to RK-
13 cells at 70% confluency in supplemented EMEM media in a cell culture flask. The 
flask was shaken at low speeds on a roto-shaker for 1 hour. After shaking, the virus 
suspension was removed from the flask and fresh media was added. The cells were left to 
incubate at 37°C for 3-5 days or when 100% cytopathic effect (CPE) was observed. 
Flasks were then frozen at -80°C and thawed at room temperature for two freeze-thaw 
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cycles. Glycerol was added at a concentration of 10% to the final virus suspension and 
frozen at -80°C for storage.  
Vero cells were cultured in EMEM media supplemented with 1% pen/strep, and 
10% FBS and incubated at 37°C and 5% CO2. Cells were split every 2-3 days (or when 
cells reached 70% confluency) at a 1:5 ratio. For HSV-1 propagation, the virus was added 
at a concentration of 103.56 MTT50/ml into Vero cells at a confluency of 70% in DMEM 
supplemented with 1% pen/strep, 1% sodium pyruvate and 2% FBS. The HSV-1 infected 
flask was shaken for 1 hour on a roto-shaker. After shaking, the virus suspension was 
removed from the flask and fresh media was added. The flask was incubated at 35°C for 
3-5 days until 100% CPE was observed. Flasks underwent two freeze-thaw cycles at -
80°C and room temperature254. HSV-1 virus suspensions were collected from the flask 
and stored at -80°C with 10% glycerol. For SuHV-1 propagation, 104 MTT50/ml was 
added to 70% confluent Vero cells in EMEM supplemented with 1% pen/strep, and 10% 
FBS. The flask was shaken for 1 hour on a roto-shaker. After shaking, the virus 
suspension was removed from the flask and fresh media was added. The flask was 
incubated at 37°C for 3-5 days until 100% CPE was observed. Flasks were subjected to 
two freeze-thaw cycles at -80°C and room temperature. SuHV-1 virus suspensions were 
collected from the thawed flasks and stored at -80°C with 10% glycerol.  
4.3.2.2 Virus Quantification and Purification  
Virus titer was determined through an MTT colorimetric cell viability assay, as 
described previously255. The MTT assay uses absorbance readings to determine the 
concentration of virus that reduces the cell viability by 50%. Briefly, 96-well plates were 
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seeded at a density of 2 x 105 cells/ml (for BT-1/BVDV), 8 x 104 cells/ml (for RK-
13/EAV), 105 cells/ml (for Vero/HSV-1), or 8 x 104 cells/ml (for Vero/SuHV-1). After 
22-26 hours, cells were infected with their respective virus sample and serially diluted 
across the plate at a 1:5 ratio in virus culture media. Plates were incubated for six days at 
37°C for BT-1 (BVDV), RK-13 (EAV), and Vero (SuHV-1) and 35°C for Vero (HSV-1). 
After incubation, MTT salts were added to the 96-well plate, incubated for four 
additional hours followed by the addition of SDS at a pH of 2. Between 4-12 hours after 
the SDS addition, the absorbance of each well was read with a microplate reader 
(BioTek, Winooski, VT) at a wavelength of 550 nm to determine the 50% infectious 
dose, reported as MTT50/ml255. Final viral concentrations were reported as a log10 




                                                     (Eq. 4-1) 
Purification of viruses was performed using a 3MTM EmphazeTM AEX Series 
Hybrid Purifier BVR1 that contained a pore size of 0.2µm, generously gifted by 3MTM 
(Minneapolis, MN). The filter was prepared by loading 20 mM phosphate buffer at pH 7 
until the buffer exited the air vent. The crude virus was mixed with an equal volume of 20 
mM phosphate buffer at pH 7 and loaded into the filter at a total volume of 40 ml. The 
virus was then eluted with 20 mM phosphate buffer with 0.5 M NaCl at pH 7. Eluate was 
collected in 5 ml fractions and tested for virus recovery. The fraction with the highest 
virus titer was used for succeeding assays. Protein reduction was measured for the HSV-1 
sample by the Bradford assay256.  
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4.3.2.3 Inactivation Assays 
All arginine and/or buffer solutions were prepared less than 24 hours before the 
experiment and stored at 4°C. Solutions were prepared with ultrapure water (resistivity of 
≥ 18 MΩ cm) obtained from a Thermo Fisher Nanopure filtration system and sterilized 
before biological assays with a 0.2 µm syringe filter or a 0.2 µm bottle top filter 
purchased from VWR. Respective acid and base solutions were mixed for each buffer to 
achieve a final concentration of 20 mM and a pH of 4 or 7, calculated by the Henderson-
Hasselbalch equation (Eq.4- 2). Acetate buffer was prepared by mixing sodium acetate 
anhydrous with acetic acid. Tris buffer was prepared by mixing Tris hydrochloride with 
Trizma® Base. Citrate buffer was prepared by mixing sodium citrate tribasic with citric 
acid monohydrate. The final solution pH was adjusted with 1M HCl or 1 M NaOH. For 
all assays, EAV was added at a concentration between 106-107 MTT50/ml. BVDV, HSV-
1, and SuHV-1 were added at concentrations between 107-108 MTT50/ml. Triplicates 
were taken at each time point to obtain accurate representation. 
𝑝𝐻 𝑝𝐾 log                                                                               (Eq. 4-2) 
For inactivation studies of arginine or agmatine, 1M arginine or agmatine at pH 4 
or 7 was prepared with 20 mM Tris, acetate, or no buffer. Viruses were added to the 
appropriate solution at a 1:10 v/v ratio in a 1.5 ml sterile microcentrifuge tube. Solutions 
were vigorously mixed with a vortex after virus addition and before sampling. Solution 
pH did not change after virus addition. Samples were stored at 4°C and assessed for virus 
titer with the MTT assay at various time points.  
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For inactivation by arginine peptides, peptides were dissolved in DMSO less than 
1 hour before experiments to avoid error in measurement. Final solutions contained 10% 
DMSO with 7.6 mM CapA6R, 0.95 mM R8, or 7.6 mM arginine buffered with 20 mM 
Tris. The virus was added to the final solution at a 1:10 v/v ratio in a 1.5 ml sterile 
microcentrifuge tube. Solutions were mixed after virus addition and again before 
sampling with a vortex. Solutions were stored at 4°C and virus inactivation was measured 
after 1 hour.  
For arginine inactivation studies with added PYB, solutions were prepared by 
dissolving PYB into DMSO less than 1 hour prior to experiments to avoid error in 
measurements. Final solutions contained 10% DMSO with 1 M arginine, 10 mM PYB, 
and 20 mM Tris buffer at pH 7 or 20 mM acetate buffer at pH 4. PBS with 10% DMSO 
and 10 mM PYB was tested as a control. Mock solutions were created for comparison 
that contained the same components as the primary solutions without PYB. The virus was 
added to the appropriate solution at a 1:10 v/v ratio in a 1.5 ml sterile microcentrifuge 
tube. Solutions were vigorously mixed with a vortex after virus addition, and again 
before sampling. Solutions were stored at 4°C and virus inactivation was measured after 
1 hour.  
4.3.2.4 Dynamic Light Scattering (DLS) and Transmission Electron Microscopy 
(TEM) 
The size distribution of HSV-1 and SuHV-1 after arginine exposure was 
measured by DLS with a Malvern Zetasizer Nano ZS (Westborough, MA). DLS 
evaluated the hydrodynamic diameter of the virus particles after exposure to arginine 
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samples at 1 and 24 hours. Samples were placed in disposable cuvettes (200 acrylate, 
280-900 nm, 3.5 mL volume) purchased from Spectrocell (Oreland, PA) at a volume of 1 
ml. The Malvern Zetasizer Nano ZS was set to a material refractive index of 1.450 and an 
absorption of 0.00. All dispersants were set to a temperature of 21℃ at a viscosity of 1 
cP. A refractive index of 1.378 was used for arginine samples and a refractive index of 
1.335 was used for PBS samples. The refractive index was measured by a digital 
refractometer from Reichert (NY, catalog # 13940000). 
Purified virus samples or purified virus samples with 1 M arginine were prepared 
for TEM imaging according to university biosafety procedures by crosslinking proteins 
through fixation with 7.4 v/v% glutaraldehyde for 1 hour257. Samples were then placed 
onto a plasma-treated carbon type-B 300 mesh copper TEM grid (Ted Pella catalog 
#01813), and allowed to attach for 2 minutes. Following virus attachment, the grid was 
rinsed with ultrapure water and negatively stained with 2 w/v% uranyl acetate in 
ultrapure water. After a 2-minute staining period, the grid was washed again with 
ultrapure water and dried in a desiccator for at least 24 hours before imaging. An FEI 
200kV Titan Themis scanning transmission electron microscope (S-TEM) operating at 
80kV was used to obtain electron micrographs.  
4.3.2.5 Amplex Red Cholesterol Assay 
Purified HSV-1 and SuHV-1 samples were split into two 1 ml aliquots and treated 
in parallel. To extract cholesterol from the samples, methyl-β-cyclodextrin (MβCD) was 
added at a concentration of 5 mM to the first aliquot in PBS buffer. The second aliquot 
for each virus was left unaltered in PBS buffer. All aliquots were incubated at 37°C for 1 
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hour. After incubation, virus titer and cholesterol levels were quantified. Virus titer was 
quantified through the MTT assay described earlier. Cholesterol was measured in 
duplicates with the Amplex Red Cholesterol Assay following manufacturer’s 
instructions. Triplicates for every sample were measured. Separate mock samples for 
each virus were tested to give a representative level of cholesterol in solution without the 
virus. Mock samples contained a solution of cells that underwent the same propagation 
and purification method as their respective virus.  
4.3.2.6 Statistical Analysis  
Statistical analysis of the data was performed in MATLAB using a two-sample 
Student’s t-test to compare the means of two independent groups. The test assumed equal 
variances between the two samples. A significance level of p < 0.05 was used. All data 
sets were tested in triplicate.  
4.4 Results and Discussion 
4.4.1 Model Viruses 
The inactivation of four enveloped viruses was compared to determine the 
influence of viral physical properties on viral-arginine interactions. The viruses were 
chosen based on genomic properties, size, isoelectric point, and structure, with details 
shown in Table 4-1 and Figure 4-1. SuHV-1 and HSV-1 belong to the Herpesviridae 
family and are similar in size, structure, and function168,258. SuHV-1 causes Aujeszky’s 
disease in pigs21, while HSV-1 produces oral or genital lesions in humans20. Both are 
large enveloped viruses with diameters of 110-200 nm170. Distinctive to herpesviruses, 
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the nucleocapsid contains double-stranded DNA and is encircled in a tegument protein 
matrix that contains over 20 identified proteins168,258. The mature capsid and tegument 
layer is enclosed within a lipid bilayer bearing approximately 11 glycoproteins168,258.  
EAV is a small enveloped virus with a diameter of 50-70 nm belonging to the 
Arteriviridae family259. EAV is infectious in horses with symptoms including fever, 
depression, skin rash and abortion in pregnant mares260.  The virion is composed of a 
positive-sense single-stranded RNA coated in a nucleocapsid protein (N) and enveloped 
by a lipid bilayer259. The envelope is complexed with integral membrane proteins 
including E, ORF5a, GP2, GP3, GP4, GP5, and M260.  
BVDV is a small enveloped virus with a diameter of 40-50 nm belonging to the 
Flaviviridae family261. Dengue virus, yellow fever virus and hepatitis C virus are also part 
of the Flaviviridae family, thereby making BVDV ideal for modeling significant human 
viruses262. The virion contains a positive-sense single-stranded RNA enclosed in a 
nucleocapsid protein. The surrounding lipid bilayer contains two glycoproteins, E1 and 
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Figure 4-1. Structure of SuHV-1, HSV-1, EAV and BVDV. HSV-1 and SuHV-1 are 
large enveloped viruses containing a tegument protein layer. EAV and BVDV are small 




4.4.2 Virus Physiochemical Properties Influence Arginine Interactions  
Viral properties, including a stabilized lipid bilayer or stabilized membrane 
proteins, influence the inactivation efficacy of arginine17. However, it is unknown if 
arginine is interacting with proteins or lipids to induce viral inactivation. Inactivation 
levels of the viruses detailed in Table 1 were compared to elucidate the mechanisms of 
arginine. The inactivation of SuHV-1, HSV-1, BVDV, and EAV was tested at pH 4 and 
pH 7 with various solvents (Fig 4-2). Tabular data can be found in Table A1. SuHV-1 
and HSV-1 are commonly used in arginine inactivation studies, and therefore, were tested 
for comparison to literature10,11,15. Particularly, SuHV-1 was chosen to recreate 
inactivation by arginine at neutral pH11. BVDV and EAV were selected to determine the 
effect of arginine on small enveloped viruses. Acetate and Tris were chosen to determine 
the influence of buffers on inactivation at pH 4 and 710,11,15. Citrate inactivates enveloped 







Figure 4-2. Inactivation of enveloped viruses by arginine (arg). Inactivation occurred at 
either pH 4 (1st column), pH 7 (2nd column) or pH 3.5 (citrate) at 4°C over 24 hours. 
Arginine concentration was 1 M and Tris, acetate (act), and citrate concentrations were 
20 mM. Open circles represent limit of detection. Tris buffer was not tested at pH 4 since 
it would not remain at pH 4. All data points are in triplicate and the error bars represent 
the standard deviation. Tabular data can be found in Table A1. 
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Different viruses had distinct inactivation patterns. As shown in Fig. 4-2, SuHV-1 
was inactivated to its limit of detection by all solutions within 1 hour at pH 4. Complete 
inactivation without arginine reveals that 20 mM acetate alone at pH 4 inactivates SuHV-
1. HSV-1 was inactivated to its limit of detection with all arginine solutions at pH 4 
within 1 hour. Without arginine, acetate buffer inactivated HSV-1 to 3.35 ± 0.37 LRV 
after 24 hours, verifying that arginine is required for complete inactivation of HSV-1 at 
pH 4. At pH 7, SuHV-1 was completely inactivated by all solutions containing arginine 
within 3 hours, replicating the data from McCue et al. and confirming that full 
inactivation was independent of buffer11. Unlike at pH 4, acetate and Tris buffer alone 
produced negligible inactivation of SuHV-1. For HSV-1 at pH 7, inactivation increased 
to 3.46 ±0.96 LRV after 24 hours with arginine buffered in Tris. Buffer solutions without 
arginine at pH 7 produced minimal inactivation of HSV-1. EAV and BVDV were 
inactivated to low levels (below 1 LRV) at pH 4 and pH 7 over all solution conditions 
tested. At pH 3.5, citrate fully inactivated HSV-1 and SuHV-1, but had little effect on 
EAV or BVDV. At pH 3.5, 0.1 M citrate has been shown to fully inactivate HSV-115.  
The clear difference in inactivation capacity between large (HSV-1 and SuHV-1) 
and small (BVDV and EAV) enveloped viruses supports the theory that arginine interacts 
with the lipid bilayer to inactivate viruses. Large diameter membranes have a mild degree 
of curvature that leads to loosely packed lipids, while small diameter membranes have a 
large degree of curvature, creating tightly packed lipids194. Loosely packed lipids are 
hypothesized to bend and deform easily in response to arginine17, supported by the high 
inactivation of the larger viruses. The tightly packed lipids of small membranes restrict 
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deformation by arginine to hinder inactivation. This is supported by the low inactivation 
of EAV and BVDV. Overall, the data support the hypothesis that arginine interacts with 
the lipid bilayer to inactivate viruses.  
Though it is clear that membrane diameter is key in arginine inactivation, what 
creates the difference in inactivation levels between SuHV-1 and HSV-1 at pH 7? 
Interestingly, SuHV-1 is more thermal stable than HSV-1266, which is the opposite of 
what would be expected from their arginine sensitivity. The two viruses have different 
charges at pH 7 (HSV-1 has an isoelectric point of ~4.9264, where SuHV-1 has an 
isoelectric point of ~7.5263), creating distinct electrostatic binding potentials. Though 
SuHV-1 and HSV-1 contain comparable glycoproteins, many are structurally or 
functionally different267. Therefore, arginine may disrupt an essential protein in SuHV-1 
where it does not in HSV-1.  
Differences in lipid bilayer cholesterol may explain the higher inactivation of 
SuHV-1 compared to HSV-1 by arginine. Cholesterol in the lipid bilayer controls 
membrane stability and aids in viral infection268. Cholesterol is singularly contained in 
the lipid bilayer or can interact with sphingolipids to form lipid rafts. Singular cholesterol 
and lipid rafts support many viral functions including membrane stability and protein 
interactions269. SuHV-1 may contain less cholesterol than HSV-1, resulting in a less 
stable membrane. Arginine would deform a less stable membrane to a greater extent to 
result in higher inactivation.  Alternatively, arginine may promote cholesterol loss or 
migration, disrupting the infection process. The bending and deformation of lipids by 
arginine may disrupt cholesterol in the membrane to hinder infection. For example, 
membrane deformations have been shown to cause migration of cholesterol in lipid 
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bilayers270. SuHV-1 may require cholesterol to a greater extent than HSV-1 during 
infection, resulting in higher inactivation by arginine as a result of cholesterol loss or 
migration. Overall, the charge, glycoproteins, or cholesterol content may explain the 
discrepancy in arginine inactivation of SuHV-1 and HSV-1.  
The effect of cholesterol depletion on virus inactivation was studied to explore 
differences between HSV-1 and SuHV-1 resulting in varying levels of arginine 
inactivation. Viral cholesterol may influence inactivation by arginine as a result of 
membrane stability or the requirement of cholesterol in the infection process. To begin 
the cholesterol assay, purified HSV-1, SuHV-1, and mock samples were subjected to 5 
mM methyl-β-cyclodextrin (MβCD) to deplete cholesterol, or no MβCD for 1 hour at 
37°C. MβCD sequesters cholesterol in its hydrophobic pocket to extract it from 
membranes271. Past studies have used MβCD to remove cholesterol from the viral or 
cellular membrane to observe effects on viral infectivity268,272. Cholesterol levels in all 
samples decreased to low levels following MβCD exposure (Fig. 4-3A & B). Tabular 
data can be found in Table A2. Similar cholesterol levels were observed in mock and 
viral samples after purification. Therefore, cholesterol levels do not represent virus 
cholesterol exclusively, but a combination of virus and cell fragment cholesterol 
remaining in solution. Though we cannot deduce exact cholesterol levels in the virus, we 
can confirm that overall solution cholesterol was reduced to low levels after MβCD 





Figure 4-3. Effect of cholesterol depletion on the infectivity of HSV-1 and SuHV-1. 
Purified virus and mock samples of (A) HSV-1 and (B) SuHV-1 were incubated for 1 
hour at 37°C at pH 7with either 5mM methyl-β-cyclodextrin (MβCD) or no MβCD. 
Cholesterol was reduced in all samples containing MβCD to low levels. (C) Infectivity 
changes after MβCD exposure. Mock samples contained Vero cells that underwent 
identical propagation and purification as virus samples. All data points are in triplicate 
and the error bars represent the standard deviation. Tabular data can be found in Table 
A2.  
The reduction of cholesterol in the viral membrane inactivated SuHV-1 to a 
greater extent than HSV-1. HSV-1 infectivity reduced by 1.4 LRV while SuHV-1 
reduced by 4 LRV after MβCD exposure (Fig. 4-3C). Cell toxicity in response to MβCD 
concentration can be found in Fig. A1. Again, the data in Fig. 4-3A & B represent a 
reduction of viral cholesterol and not a quantitative measure of viral cholesterol resulting 
from imperfect purification. This means that the LRVs are not representative of viral 
cholesterol levels but instead a loss of viral cholesterol. The high LRV of SuHV-1 
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suggests that cholesterol, or cholesterol-rich lipid rafts, play a larger role in the infection 
process of SuHV-1 compared to HSV-1. These results are consistent with the inactivation 
results by arginine, where SuHV-1 was inactivated to a greater extent compared to HSV-
1 at pH 7. This consistency supports the hypothesis that arginine deforms the viral 
membrane to remove or disrupt cholesterol. The disruption of viral cholesterol may 
highly affect SuHV-1 because of the requirement for cholesterol in membrane stability or 
protein function. Though there may be other factors in play, the higher susceptibility of 
SuHV-1 to inactivation is likely associated with membrane cholesterol loss by arginine.   
4.4.3 Solution Properties to Enhance Inactivation of Viruses by Arginine 
Not all enveloped viruses are fully inactivated by the synergistic effects of 
arginine10,11,15. The results from Fig. 3-2 show that BVDV and EAV are not inactivated 
by 1M arginine under any conditions. Correspondingly, past studies show that influenza, 
Sendai, and Newcastle disease virus (NDV) are not fully inactivated with 0.7 M arginine 
at pH 4 on ice for 60 min10,15. For this reason, various solution properties were tested to 
determine if viral inactivation by arginine could be enhanced. We explored solution 
properties by altering the charges on arginine, artificially inducing clustering, and adding 
hydrophobic molecules to arginine or the solution. In addition to enhancing inactivation, 
modifying solution conditions may also provide insight into mechanisms of arginine 
inactivation.   
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4.4.3.1 Inactivation with Arginine Derivatives  
The guanidinium moiety on arginine is essential for virus inactivation. 
Guanidinium has an affinity for hydrogen and can form ionic bonds with proteins and 
lipids124. Other properties of arginine, such as charge or hydrophobicity, may also be 
crucial for viral inactivation. Charges on arginine affect electrostatic interactions between 
the virus and arginine itself for cluster formation124,191. Hydrophobicity is suspected to 
loosen lipid packaging to allow arginine to easily bend and deform lipid bilayers239. To 
observe the effect of charge and hydrophobicity on arginine viral inactivation, the 
inactivation of three guanidinium-containing arginine derivatives with separate charge 
patterns were compared. The three derivatives were arginine, agmatine, and butyroyl-
arginine, and their structures are illustrated in Fig. 4-4A. Agmatine is arginine with the 
carboxylic acid removed. Butyroyl-arginine is arginine with the amine capped with a 
hydrophobic butyryl group. At pH 4 and 7, arginine is zwitterionic with a + 1 charge, 












Figure 4-4. Inactivation of enveloped viruses with arginine derivatives. (A) The structure 
of arginine, agmatine, and butyroyl-arginine. All arginine-derivatives contain a 
guanidinium group but each has a different charge pattern. Inactivation of HSV-1, SuHV-
1, and EAV in response to agmatine buffered with acetate at (B) pH 4 and (C) pH 7. Solid 
lines represent agmatine solutions buffered with acetate, dashed lines represent solutions 
without agmatine. Inactivation occurred at 4°C over 24 hours. Agmatine concentration 
was 1 M and acetate concentration was 20 mM. (D) Arginine, agmatine, and butyroyl-
arginine inactivation of HSV-1 after 1 hour at 4°C or on ice. Slashed bar graphs of 0.7 M 
arginine and but-arg adapted from Katsuyama et al. *Limit of detection. All data points 
are in triplicate and the error bars represent the standard deviation. Tabular data can be 
found in Table A3 and A4. 
 
The inactivation of HSV-1, SuHV-1, and EAV with 1 M agmatine was compared 
at pH 4 and 7 in Fig. 4-4B&C. Tabular data can be found in Table A3. At pH 4, 
agmatine produced negligible inactivation of EAV and HSV-1, while 3.55 ± 0.01 LRV 
occurred for SuHV-1 after 24 hours. The inactivation of EAV and SuHV-1 at pH 4 with 
agmatine (solid line) were similar to the control solution (dashed line), indicating that 
agmatine did not inactivate the virus. The inactivation of HSV-1 at pH 4 with agmatine 
was much lower than the control solution, demonstrating the stabilizing effect of 
agmatine on HSV-1. At pH 7, agmatine and the controls inactivated all viruses to around 
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1 LRV, demonstrating no effect of agmatine on virus inactivation. When looking at the 
data as a whole, agmatine fails to inactivate enveloped viruses.  
The inactivation efficacy of arginine, agmatine, and butyroyl-arginine is 
compared in Fig 4-4D. Tabular data can be found in Table A4. The butyroyl-arginine 
data was reformatted from Katsuyama et al.10. Solutions containing 1 M arginine, 0.7 M 
arginine10, and 0.7 M butyroyl-arginine10 fully inactivated HSV-1 at pH 4 after 1 hour, 
while 1 M agmatine produced negligible inactivation. Butyroyl-arginine and arginine 
inactivate HSV-1 to the same levels at pH 4. However, as pH increases to 4.5, butyroyl 
arginine is over 2-LRVs more effective than arginine at inactivating HSV-1 (data not 
shown)10. Butyroyl-arginine is the most effective at inactivating enveloped viruses, 
followed by arginine. Agmatine is the least effective in inactivating the tested viruses.  
The difference in inactivation efficacy between butyroyl-arginine, arginine, and 
agmatine is likely explained by added hydrophobicity and/or clustering. Clustering of 
arginine can strengthen protein127 and lipid interactions197 to support inactivation. The 
zwitterionic charge on butyroyl-arginine and arginine allow for the formation of clusters 
through self-aggregation. However, the two positive charges on agmatine are not optimal 
for clustering, consistent with the lesser inactivation capacity observed. Butyroyl-arginine 
has an ideal charge pattern for clustering as a result of one positive and one negative 
charge on opposite ends of the molecule10. Though arginine can also form clusters, it is 
not as effective as butyroyl-arginine as a consequence of its extra positive charge17. 
Butyroyl-arginine also contains a hydrophobic moiety where arginine and agmatine do 
not15. The increased hydrophobicity of butyroyl-arginine can strengthen interactions with 
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lipids, which may aid in inactivation10,15, demonstrated by increased inactivation by 
butyroyl-arginine.  
The difference between agmatine and arginine is charge based. Inactivation 
differences between agmatine and arginine are likely a result of clustering. Agmatine is 
not zwitterionic, therefore, clusters cannot form by electrostatic interaction. The inability 
of agmatine to form clusters is likely the root cause of low inactivation. However, this 
same lack of clustering and a high positive charge may be the reason for agmatine 
appearing to provide virus stabilization in the presence of low pH (Fig. 4-4B). Acidic pH 
commonly inactivates viruses through lipid hydrolysis153 or protein denaturation154. 
However, with agmatine at pH 4, HSV-1 was demonstrated to be further stabilized (Fig. 
4-4B). The positive charges on agmatine may bind to negative charges on HSV-1 to 
counteract deterioration at acidic pH. Through HSV-1 has a positive net charge at pH 4 
with its pI being ~4.9264, negative charges on the virus still exist. SuHV-1 has a higher 
overall positive charge related to its higher pI, and therefore, may not be stabilized by the 
positive agmatine charges. Arginine derivatives with added hydrophobicity, enhanced 
clustering, or both lead to increased enveloped virus inactivation. Therefore, we decided 
to study each effect independently. 
4.4.3.2 Inactivation Based on Charge and Hydrophobicity 
Hydrophobicity or clustering of arginine derivatives appears to enhance viral 
inactivation. To further evaluate these properties, arginine peptides were synthesized 
specifically for this work with added hydrophobicity or forced arginine clustering. 
Hydrophobicity is suspected to loosen lipid packaging to support membrane deformations 
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by arginine239, while clustering strengthens arginine interactions with lipids and 
proteins127,197. CapA6R and R8 peptides were tested for inactivation, and their structures 
are shown in Fig. 4-5A. CapA6R contains an arginine molecule linked to a six-chain 
hydrophobic alanine tail. The peptide is capped on both ends to expose a single positive 
charge on the guanidinium moiety. The single charged peptide avoids clustering to 
exclusively model added hydrophobicity. CapA6R has been previously studied for its 
antimicrobial activity205. The R8 peptide simulates the clustering of eight arginine 
molecules. This peptide has been studied for drug delivery as a cell-penetrating peptide 
















Figure 4-5.Virus inactivation with arginine peptides. (A) Peptide structure of CapA6R 
and R8. (B) Virus inactivation tested after 1 hour at pH 7 at 4°C in Tris buffered solutions 
with 10% DMSO. Arginine and CapA6R concentrations were 7.6 mM. R8 concentration 
was 0.95 mM which is equivalent to an arginine concentration of 7.6mM. Tris 
concentration was 20 mM. The brackets with ** represent statistically different means 
with a p<0.05 by the Student’s t-test. All data points are in triplicate and the error bars 
represent the standard deviation. Tabular data can be found in Table A5.  
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The inactivation of EAV and HSV-1 by CapA6R, R8, and arginine was compared 
in Fig. 4-5B. Tabular data can be found in Table A5. Enveloped virus inactivation 
increases with arginine concentration15, and therefore, an equivalent arginine 
concentration of 7.6 mM for all species was applied for equal comparison. This low 
concentration of peptide was used to demonstrate a change in the inactivation mechanism 
because of costs restraints, and not to provide a method for high virus inactivation. 
Solutions were buffered with Tris at pH 7 and exposed to arginine or arginine peptides 
for 1 hour. As a result of high hydrophobicity, CapA6R was dissolved in DMSO and 
added to the final solution at a concentration of 10% DMSO. For equal comparison, 10% 
DMSO was added to each solution. CapA6R produced the highest inactivation, followed 
by R8, with arginine producing the lowest inactivation at the concentration tested. By the 
two-sample Student’s t-test, CapA6R inactivated EAV and HSV-1 to greater levels than 
arginine, with p-values of 0.0255 and 0.009, respectively. R8 inactivated EAV a greater 
level than arginine, with a p-value of 0.0075. Inactivation of HSV-1 by R8 was not 
statistically different than the arginine control, with a p-value of 0.145. Interestingly, both 
CapA6R and R8 inactivated EAV to a greater extent than HSV-1. Commonly, HSV-1 is 
highly inactivated, whereas EAV is not inactivated by arginine solutions (Fig. 4-2). The 
data supports that added hydrophobicity and clustering enhance the inactivation of 
enveloped viruses under conditions where conventional arginine inactivation is low.  
The increased hydrophobicity of CapA6R resulted in the highest inactivation 
levels of HSV-1 and EAV as compared to arginine. To determine if hydrophobicity could 
further enhance inactivation, pyrenebutyrate (PYB), a hydrophobic counter-anion, was 
added to arginine solutions. PYB is commonly used to increase the uptake of arginine 
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cell-penetrating peptides across the lipid bilayer by electrostatically binding to 
arginine239. Added hydrophobicity is thought to allow for easier translocation of arginine 
through the hydrophobic core of the lipid bilayer239.   
The inactivation of EAV and HSV-1 with PYB is shown in Fig. 4-6. Tabular data 
can be found in Table A6. Inactivation occurred at 4°C after 1 hour. PYB enhanced the 
inactivation of EAV by 1.58 ± 0.29 LRV compared to the control with arginine and Tris 
buffer at pH 7. However, EAV inactivation was not enhanced by PYB at pH 4, and HSV-
1 inactivation was not enhanced by any PYB solution. The difference in inactivation 
capacity of EAV at pH 4 and 7 is likely explained by the charge on PYB. PYB has a -1 
charge at pH 7 and is neutral at pH 4176. The negative charge at pH 7 may bind to the 
positive charges on arginine or EAV for enhanced inactivation. The greater inactivation 
of EAV over HSV-1 by PYB may also be a result of the virus charge. The isoelectric 
point of HSV-1 is ~4.9264, whereas the isoelectric point of EAV is unknown. If the 
isoelectric point of EAV is higher than HSV-1, the charges on EAV at pH 7 may be more 
positive to allow for the binding of PYB. The difference in inactivation of EAV and 
HSV-1 suggest that PYB is binding to the lipid bilayer to loosen the lipid packing, 
instead of binding to arginine itself to aid in translocation.  
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Figure 4-6. Inactivation of EAV and HSV-1 by arginine and pyrenebutyrate (PYB). Solid 
bars represent samples with PYB and 10% DMSO, dashed bars represent mock samples 
with only 10% DMSO. Inactivation occurred after 1 hour at 4°C. PYB was at 10 mM, 
arginine was at 1 M, and Tris and acetate were at 20 mM concentration. *Limit of 
detection. Note that the limit of detection for HSV-1 in Vero cells was lowered by PYB. 
All data points are in triplicate and the error bars represent the standard deviation. Tabular 
data can be found in Table A6.  
 
Though PYB did increase EAV inactivation at pH 7, complete inactivation was 
not reached. When PYB has been used to enhance the uptake of peptides into the cell, the 
concentrations of PYB were larger than the peptide (15µM for PYB and 1.5 µM for 
peptides)239. Here, PYB was 100X less concentrated than arginine as a consequence of its 
solubility limit. If higher concentrations of hydrophobic cations could be used, arginine 
inactivation can be hypothesized to be enhanced to fully inactivate all viruses.  
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4.4.4 Functional Groups and Charges on Buffers 
Since charge interactions of PYB and arginine derivatives with the virus influence 
inactivation, the effect of buffer functional groups and charge were explored. It has been 
shown previously that 1M arginine with Tris buffer at pH 7 can fully inactivate SuHV-
111. Properties of Tris that may aid in the inactivation of viruses include the amine group, 
charge, or high-fat solubility. Amine groups interact with various compounds218, charges 
dictate electrostatic interactions, and increased fat solubility can increase diffusion into 
lipid bilayers274. However, all arginine solutions fully inactivated SuHV-1 at pH 7 (Fig. 
4-2), suggesting the synergy of Tris is not the mechanism causing high inactivation.   
Various buffers were tested to model Tris and acetate to determine if specific 
properties aid in the inactivation of HSV-1 (Fig. 4-7). Tabular data can be found in Table 
A7. Buffers were chosen for their potential inactivation properties. Structure and pKa 
values of the tested buffers can be found in Table A8176. Glycine mimicked the amine 
group on Tris. Glycineamide mimicked the +1 charge and amine group on Tris. Tricine 
has a similar structure to Tris, but lower-fat solubility275. MES mimicked the charge on 
acetate. Despite the differences, all buffers inactivated viruses to similar levels. Overall, 




Figure 4-7. Inactivation of HSV-1 with buffer mimics. Solid lines represent buffered 
solutions with arginine, dashed lines represented buffered solutions without arginine. 
Buffer mimics showed similar inactivation to Tris and acetate used with arginine. 
Inactivation occurred at either (A) pH 4 or (B) pH 7 at 4°C. Arginine concentration was 1 
M. Glycine, glycineamide, MES, and Tricine concentration were 20 mM. Open circles 
represent the limit of detection. All data points are in triplicate and the error bars 
represent the standard deviation. Tabular data can be found in Figure A7.  
4.4.5 Viral Structural Changes after Arginine Exposure  
The hypotheses for the mechanisms of viral inactivation by arginine all infer viral 
structural changes17. Viral structure is speculated to change by complete disassembly, 
aggregation13, deformation of proteins/lipids13, or simply arginine binding15. DLS 
measurements and TEM images evaluated viral structural changes after arginine exposure 
to elucidate inactivation mechanisms.  
Size differences of HSV-1 and SuHV-1 before and after arginine exposure were 
measured by DLS (Fig 4-8A). This data is also presented in Figure A3 in a different 
form for clarification.  Both viruses increased in size after exposure to arginine. Viruses 
were exposed to arginine at 1 or 24 hours at pH 4 or 7. PBS at pH 7.4 was used as a 
control for no arginine exposure. When HSV-1 was exposed to arginine at pH 4, size 
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increased by 110 ± 25 nm after 1 hour and 243 ± 37 nm after 24 hours. Size changes to 
HSV-1 at pH 4 and 7 over all conditions were comparable. Changes to SuHV-1 were 
similar, with the largest size increase of 123 ± 62 nm with arginine buffered with Tris at 
24 hours. Size changes in control PBS solutions were minimal for both viruses over 24 
hours (Fig. A2). The peak at 1 nm is likely the arginine molecule itself. Similar to DLS 
measurements, TEM images showed increased virus size after arginine exposure (Fig. 4-
8B). HSV-1 was 158 nm and SuHV-1 was 179 nm before arginine exposure. After 
arginine exposure, HSV-1 increased to 526 nm while SuHV-1 increased to 358 nm. TEM 
measurements were obtained by measuring the size of the virus in the images shown. An 
increased viral size could be the result of expanding lipids or viral swelling by lipids 
bilayer deformations. Additionally, the binding of large arginine clusters to viral particles 
could increase the size of the viral particle. However, the data suggest that virus 














4.5 Conclusions  
 
Inactivation of enveloped viruses by arginine maintains the structure and stability 
of therapeutic proteins, making it a desired viral clearance process in protein 
manufacturing10,11,15. Arginine had been found to stabilize therapeutic proteins while 
inactivating enveloped viruses. However, not all enveloped viruses are inactivated by 
arginine to safe levels for clinical use17. This study investigated virus structure, properties 
Figure 4-8. Size changes of HSV-1 and SuHV-1 after arginine exposure. (A) DLS after 1 
and 24 hours and (B) TEM after 1-hour arginine exposure at 4°C at pH 4. Arginine was at 
1 M, Tris was at 20 mM, and PBS was at pH 7.4. Inactivation occurred at 4°C. All data 
points for DLS measurements are in triplicate. 
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of arginine, buffer type, and viral changes to further elucidate the mechanisms by which 
the inactivation of enveloped viruses is enhanced by arginine.   
Viral structure influenced the inactivation capacity of arginine. Large diameter 
viruses (SuHV-1 and HSV-1) were highly inactivated by arginine, while small diameter 
viruses (EAV and BVDV) were negligibly inactivated by arginine. The difference in 
inactivation is hypothesized to be the result of lipid packing density17. Large diameter 
viruses have loosely packed lipids for easy deformation by arginine and small diameter 
viruses have tightly packed lipids that restrict deformation by arginine17. However, virus 
size does not solely explain the inactivation differences between SuHV-1 and HSV-1. 
SuHV-1 was completely inactivated at pH 7 by arginine with all buffer types, similar to 
the results from McCue et al.11, whereas HSV-1 was only partly inactivated (3.7 LRV). 
SuHV-1 and HSV-1 are comparable viruses from the Herpesviridae family168,258, 
therefore, it is difficult to discern differences that influence inactivation by arginine. 
Removal of membrane cholesterol inactivated HSV-1 by 1.4 LRV and SuHV-1 by 4 
LRV. SuHV-1 may have a higher sensitivity to cholesterol reduction as a result of the 
requirement for cholesterol in membrane stability or protein function268,272. Bending and 
deforming the viral membrane likely disrupts lipid rafts and cholesterol. Therefore, 
inactivation by arginine because of lipid bilayer deformations would be enhanced with a 
higher sensitivity to cholesterol reduction. Overall, loosely packed lipids or high 
cholesterol sensitivity of enveloped viruses support inactivation by arginine.  
Various solution properties were tested to enhance the inactivation of viruses that 
are naturally resistant to arginine. Charge and functional groups on arginine-derivatives 
were assessed to determine the influence on inactivation. Butyroyl-arginine was the most 
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effective, followed by arginine, and agmatine was the least effective. The ability to form 
dense clusters and the hydrophobic capped amine of butyroyl-arginine likely aid in 
inactivation. To dig deeper into these effects, arginine peptides were tested to model 
added hydrophobicity (CapA6R) and forced arginine clustering (R8). Both CapA6R and 
R8 enhanced inactivation over arginine itself, with CapA6R being the most effective. 
Since added hydrophobicity continually enhanced inactivation, pyrebutyrate, a 
hydrophobic cation, was added to arginine solutions. PYB improved inactivation of EAV 
but not of HSV-1 when exposed to arginine. This difference was likely the result of virus 
charge. Additionally, the impact of buffers with various functional groups and charges 
were explored during inactivation by arginine. Buffers had no obvious effects on 
inactivation. Collectively, the data indicate hydrophobicity and arginine clustering 
enhance the inactivation of enveloped viruses.  
Viral structural changes after arginine exposure were examined by DLS and 
TEM. Both methods detected increasing virus size after arginine exposure for 1 or 24 
hours. The results demonstrate that virus disassembly or virus aggregation do not explain 
inactivation. The increase in virus size may result from lipid expansion or arginine 
binding. Lipid expansion would result from arginine bending and deforming the viral 
membrane. On the other hand, arginine binding to viral proteins or lipids would also 
display an increased virus size. These insights correlate with earlier results where added 
hydrophobicity and arginine clustering enhanced inactivation. Hydrophobicity loosens 
lipid packaging to support lipid bilayer deformations239 whereas arginine clusters 
strengthen lipid and protein interactions127,197. To narrow down the mechanisms further, 
these findings can be related to the impacts of virus structure on inactivation. Viruses 
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with loosely packed lipids or the requirement for membrane cholesterol are highly 
inactivated by arginine. These viral properties would enhance inactivation through 
bending and deforming the viral membrane. Combining the data as a whole, lipid bilayer 
deformation is the likely mechanism for virus inactivation by arginine though no 
mechanism can be completely ruled out.   
The results from this study support lipid bilayer deformation as the mechanisms 
for viral inactivation by arginine. This mechanism can be enhanced by added 
hydrophobicity or arginine-clustering to inactivate viruses that are resistant to arginine. 
Though optimal conditions for full inactivation of all viruses were outside the scope of 
this work, this study provided insight into increasing inactivation by arginine. Additional 
testing is required to optimize hydrophobicity, arginine-clustering, and charge for full 
inactivation of all enveloped viruses. For example, increasing the concentrations of 
arginine-peptides or added hydrophobic molecules may enhance inactivation. By adding 
new components to arginine solutions, it would also be useful to look into the impact of 
inactivation conditions on the final product quality.  
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5 Influence of Buffer Type and Concentration on Virus 
Inactivation during Low pH Treatment  
5.1 Introduction  
Viral safety is a major concern in biotherapeutic manufacturing. Infectious human 
viruses may be present in solution when mammalian cells are used to produce 
biotherapeutic products249. To ensure viral safety is met and infections do not spread to 
clinical patients, regulations require the use of two orthogonal downstream viral removal 
processes during manufacturing112,250,276,277. A filtration and an inactivation step are 
commonly used to remove nonenveloped and enveloped viruses249. Low or high pH, 
solvent/detergent, heat gamma irradiation, or ultraviolet radiation treatments are 
examples of enveloped viral inactivation processes251. Low pH is simple and effective, 
and therefore, is typically used in manufacturing with treatments of pH ≤ 3.6 being most 
effective249. However, acidic pH levels under 4 can damage essential cells, tissues, or 
proteins in biotherapeutic solutions252. For this reason, there is a demand for a robust 
inactivation process at less acidic conditions.  
Under specific operating parameters, virus inactivation has occurred at pH 4 or 
above where conditions are less detrimental to the stability of essential solution 
components252. Operating parameters influencing virus inactivation at pH 4 include 
temperature, incubation time, and solutions conditions278. It is standard with increasing 
temperature and incubation time that virus inactivation is enhanced278,279. However, 
solution conditions including protein concentration, buffer type, and buffer concentration, 
have a more complicated influence on virus inactivation278. High (30 mg/ml) or low 
protein concentrations (0 mg/ml) increase inactivation of viruses at acidic pH278. 
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Concentration and type of buffer in solution also influence virus inactivation, though the 
effectiveness can depend on several solution properties249,251,252,278-280.  
There are many examples in the literature where the concentration and/or type of 
buffer influence the inactivation capacity of viruses in low pH solutions. Table 5-1 
compares buffer effectiveness during the inactivation of viruses at low pH. It is evident 
from previous work that buffer concentration and type largely influence the inactivation 
of viruses at acidic pH. Buffer concentration can influence buffer effectiveness. For 
example, citrate was most effective at low concentrations (0.15 M) in inactivating 
Influenza A virus while acetate was most effective at high concentrations (0.6M). Virus 
type also influences buffer effectiveness. Pseudorabies virus (SuHV-1) was fully 
inactivated by acetate, citrate and glycine279. Acetate was the most effective buffer in 
inactivating xenotropic murine leukemia virus (XMuLV)279. Citrate was most effective 
buffer in inactivating murine leukemia virus251. Viral inactivation depends not only on 







Table 5-1. Examples of Low pH Inactivation with Buffers. 
 










 pH 5 
 5 min 
 30° C 
Citrate most effective at low 
concentrations (0.15 M) while 
acetate was the most effective 








 pH 3.9 
 30 min 
 20° C 
Acetate fully inactivated X-















 pH 3.7 
 10 min 
 
 
Inactivation increased with 










 50 mM 
buffer  
 pH 3.7 
 17° C 
 
Complete inactivation of PRV 
occurred with all buffers after 
4 min.  
Complete inactivation of X-
MLV occurred with glycine 
and acetate after 2 min, and 













Citrate was the most effective 
and glycine was the least 




In this study the influence of buffer type, buffer concentration and time at pH 4 on 
the inactivation of four viruses is examined. Buffers tested include citrate, acetate, and 
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glycine at concentrations of 20-500 mM. Data collected will provide insight into the 
matrix conditions required for high inactivation of viruses at pH 4 to improve 
biotherapeutic manufacturing.   
5.2 Materials and Methods 
5.2.1 Materials  
Buffers used during inactivation assays included sodium acetate (≥ 99% 
bioreagent), acetic acid (glacial), and citric acid monohydrate purchased from Millipore 
Sigma (St. Louis, MO). Glycine (99% for molecular biology) and sodium citrate tribasic 
were generously donated from Millipore Sigma. Chemicals for cell culture assays 
included Eagle’s medium essential media (EMEM), Dulbecco’s modified eagle medium 
(DMEM), phosphate buffer saline (PBS, pH 7.2), sodium bicarbonate, 
penicillin/streptomycin (pen/strep, 10,000U/ml), sodium pyruvate (100mM) and 
trypsin/EDTA, purchased from life technologies (Carlsbad, CA).  Fetal bovine serum 
(FBS, Canada origin) was purchased from HyCloneTM GE Healthcare (Pittsburg, PA), 
and horse serum (New Zealand Origin) was purchased from Sigma Aldrich. For the virus 
titer determination by MTT assay, MTT salts (2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-
dimethyl-1,3-thiazole; bromide, 98%) were purchased from Alfa AesarTM (Haverhill, 
MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased from VWR 
(Radnor, PA). The pH of buffer solutions was adjusted with sodium hydroxide (NaOH), 




5.2.2.1 Cells and Viruses  
Vero cells (CCL-81), rabbit-kidney cells (RK-13, CCL-37), and porcine kidney 
cells (PK-13, CRL-6489) were purchased from ATCC. Suid herpesvirus 1 (SuHV-1) 
strain Aujeszky (VR-135), human herpesvirus 1 (HSV-1) strain F (VR-733), and equine 
arteritis virus (EAV) strain Buvyrus (VR-796) were purchased from ATCC. Porcine 
parvovirus (PPV) strain NADL-2 was generously gifted by Dr. Ruben Carbonell from 
North Carolina State University in Raleigh, NC. Each cell line was incubated at 5% CO2 
and 100% humidity at 37°C during virus propagation or infectivity assays, except Vero 
cells infected with HSV-1 were incubated at 35°C. EAV was propagated in RK-13 cells, 
HSV-1 was propagated in Vero cells and SuHV-1 was propagated in Vero cells, as 
described previously (Chapter 4). PPV was propagated in PK-13 cells, as described 
previously255. 
5.2.2.2 Virus Quantification  
 The MTT colorimetric cell viability assay was used to calculate virus titer281. 
First, 96-well plates were seeded with 8 x 104 cells/well for the combination of Vero cells 
for SuHV-1 titer, RK-13 cells for EAV titer, and PK-13 cells for PPV titer. A density of 
105 cells/well was required for Vero cells for HSV-1 titer. Plates seeded with cells were 
incubated at 37°C, 5% CO2, and 100% humidity before virus infection. Following 22-26 
hours of incubation, 25 ul of the virus sample was added to the first column of the 96-
well plate and serially diluted at a 1:5 ratio down the plate.  Plates were incubated for six 
days at 37°C for SuHV-1, EAV, and PPV and 35°C for HSV-1. After, MTT salts were 
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added to each well to detect live cells by the production of purple formazan. Plates were 
placed back into the incubator for 4 hours, and then SDS at a pH of 2 was added to each 
well and incubated for an additional 4-12 hours to allow SDS to solubilize the formazan 
crystals. Absorbance was measured in each well at a wavelength of 550 nm by a 
microplate reader (BioTeK, Winooski, VT). Final viral concentrations were calculated as 
the 50% infectious dose (MTT50/ml) and reported as a log10 reduction value (LRV), 




                                                            (Eq. 5-1) 
5.2.2.3 Buffer Inactivation Assays 
 To begin inactivation assays, glycine, acetate, and citrate were prepared at 
concentrations of 20mM, 100mM, 250mM, and 500 mM. Buffer solutions were made 
with ultrapure water (resistivity of ≥ 18 MΩ cm) collected from a Thermo Fisher 
Nanopure filtration system. Acetate buffer was prepared by mixing sodium acetate 
anhydrous with acetic acid to concentrations that yielded the final buffer molarity at pH 
4, calculated by the Henderson-Hasselbalch equation (Eq. 5-2)282. Citrate buffer was 
prepared by mixing sodium citrate tribasic with citric acid monohydrate to concentrations 
that yielded the final molarity at pH 4, calculated by the Eq. 5-2282. Glycine buffer was 
prepared with glycine. 1M NaOH and 1M HCl were used for final adjustments to pH 4. 
Buffers were sterilized before biological assays with a 0.2 µm syringe filter from VWR 
(Radnor, PA). 
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𝑝𝐻 𝑝𝐾 log                                                                              (Eq. 5-2) 
 To begin inactivation assays, 100 µl of model virus and 900 µl of the appropriate 
buffer were mixed in a 1.5 ml sterile ultracentrifuge tube. SuHV-1, HSV-1, and PPV 
were added at concentrations of 107-108 MTT50/ml and EAV was added at a 
concentration of 106-107 MTT50/ml. The addition of the virus did not alter the solution 
pH.  Samples were stored at 4°C, and virus titer was measured at 0.5, 1, 2, 3, and 6 hours 
with the MTT assay.  
5.3 Results and Discussion 
5.3.1 Model Virus and Buffers 
 Pseudorabies virus (SuHV-1), herpes simplex virus 1 (HSV-1), equine arteritis 
virus (EAV), and porcine parvovirus (PPV) were chosen as model viruses. Properties of 
viruses are listed in Table 5-2. SuHV-1 and HSV-1 are both large enveloped viruses with 
diameters of 110-200 nm belonging to the Herpesviridae family168,170,175,258. 
Herpesviridae are double-stranded DNA viruses containing a capsid surrounded by a 
tegument protein matrix and enclosed in a lipid bilayer258,267. EAV is a small enveloped 
virus from the Arteriviridae family with a diameter of 50-79 nm259.  EAV contains a 
positive-sense single-stranded RNA coated in a nucleocapsid protein259 and enveloped by 
a lipid bilayer260. PPV is a small non-enveloped virus with a diameter of 18-26 nm283. 
PPV belongs to the Parvoviridae family and contains single-stranded DNA284.  
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Table 5-2. Properties of Tested Viruses 




















PPV No 18-26283 4.8-5.1283 ssDNA 
 
 Citrate, acetate, and glycine were used as buffers during virus inactivation at pH 
4. All buffers are weak electrolytes that have been used in the literature to inactivate 
viruses at low pH 249,251,252,278,279. Structure, pKa, and charges of the buffers are listed in 
Table 5-3. Glycine is a simple non-essential amino acid containing a hydrogen atom side 
chain285. Acetate is monocarboxylic acid anion formed as a salt from acetic acid and a 
base286. Citrate is commonly used as a buffer in inactivating viruses during low pH 
treatment at pH 3.515. Glycine and acetate have a dominant charge of 0 while citrate has a 







Table 5-3. Properties of Tested Buffers176 
 

















5.3.2 Inactivation Capacity of Buffers at pH 4 
 The inactivation of viruses at pH 4 with glycine, acetate, and citrate buffer at 20 
mM, 100mM, 250 mM, and 500 mM was assessed. Inactivation experiments were co 
conducted at 4°C and the LRV for each virus was measured at 0.5, 1, 2, 3, and 6 hours. 
Both viral and buffer properties influenced inactivation as follows.    
 The inactivation of SuHV-1 by glycine, acetate, and citrate is shown in Fig. 5-1. 
The effectiveness of glycine increased with buffer concentration and time, but never fully 
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inactivated SuHV-1. Glycine at 20 mM produced negligible inactivation, while 
inactivation increased over time at all other concentrations, reaching a maximum of 4.13 
LRV after 6 hours at 500 mM glycine. Acetate fully inactivated SuHV-1 at 
concentrations of 250mM or above after 30 min. Full inactivation, or limit of detection, is 
represented by open shapes. Acetate at 20 mM and 100 mM inactivated SuHV-1 to 
similar levels after 6 hours to 4 LRV and 3.76 LRV, respectively. Inactivation increased 
over time with 20 mM and 100 mM acetate to 3 hours and then leveled off.  Citrate 
concentrations ≥ 100 mM completely inactivated SuHV-1 within 30 min. Citrate at 
20mM reduced SuHV-1 by 3.3 LRV after 6 hours, but similar inactivation of 3.5-log10 
occurred after 1 hour. Citrate was the most effective buffer, followed by acetate, and the 
least effective was glycine in inactivating SuHV-1 at pH 4.  
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Figure 5-1. Inactivation of SuHV-1 by various concentrations of glycine, acetate, and 
citrate at pH 4. Citrate is the most effective, and after 30 min all concentrations of 100 
mM or above fully inactivate SuHV-1.  Acetate is the next effective with concentrations 
of 250 or above fully inactivate SuHV-1. Glycine is the least effective at inactivating 
SuHV-1. The limit of detection is signified by open shapes. Data points were measured in 
triplicates and error bars represent standard deviation.  
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Inactivation of HSV-1 was influenced by buffer concentration and type (Fig. 5-2).  
Inactivation of HSV-1 by 20 mM glycine was negligible but increased at concentrations 
≥ 100 mM to 1.78 LRV after 6 hours. Acetate never fully inactivated HSV-1, up to 4 
LRV, at any concentration, where it did fully inactivate SuHV-1 at concentrations ≥ 
250mM. After 1 hour, inactivation at all acetate concentrations leveled out, whereas 20 
mM produced 3.08 LRV, 100 mM produced 3.6 LRV, 250 mM produced 3.4 LRV, and 
500 mM produced 3.7 LRV. The effectiveness of citrate in inactivating HSV-1 increased 
with concentration. Inactivation by 20 mM citrate increased over time to 3.2 LRV after 6 
hours. Inactivation by 100 mM citrate increased drastically after 1 hour to 4.22 LRV, and 
reached 4.6 LRV after 6 hours. Citrate at 250 mM fully inactivated HSV-1 after 1 hour, 
and 500 mM citrate fully inactivated HSV-1 after 30 min. Conclusively, citrate was the 





Figure 5-2. Inactivation of HSV-1 by various concentrations of glycine, acetate, and 
citrate at pH 4. Citrate is the most effective, and at 1 hour all concentrations of 100 mM 
or above fully inactivate HSV-1.  Acetate is the next effective, and glycine is the least 
effective at inactivating HSV-1. The limit of detection is signified by open shapes. Data 
points were measured in triplicates and error bars represent standard deviation. 
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Inactivation of EAV (Fig. 5-3) and PPV (Fig. 5-4) was negligible at all buffer 
concentrations at pH 4 after 6 hours. Properties of EAV and PPV may hinder inactivation 
by buffers at pH 4. EAV is a small enveloped virus, creating a lipid bilayer that is tightly 
packed for increased membrane stability17. This highly stabilized virus may restrict 
inactivation compared to larger viruses (SuHV-1 and HSV-1) that contain loosely packed 
lipids17.  PPV is a non-enveloped virus, meaning it does not contain a lipid bilayer and 
the protein capsid is directly exposed to the environment225. Lipid bilayers are more 
sensitive to environmental degradation than proteins, and therefore non-enveloped 
viruses tend to be more stable than enveloped viruses225. The stability or absence of the 
lipid bilayer likely protects EAV and PPV from inactivation by buffers at pH 4.  
147 
 
Figure 5-3. Inactivation of EAV by various concentrations of glycine, acetate, and citrate 
at pH 4. All buffers and concentrations did not inactivate EAV. Data points were 




Figure 5-4. Inactivation of PPV by various concentrations of glycine, acetate, and citrate 
at pH 4. All buffers and concentrations did not inactivate PPV. Data points were 
measured in triplicates and error bars represent standard deviation. 
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5.3.3 Variables Influencing Inactivation at pH 4 
Inactivation levels are dependent on the virus type, buffer type, and buffer 
concentration (Fig. 1-4). SuHV-1 was inactivated to the greatest extent, followed by 
HSV-1, and both EAV and PPV were negligibly inactivated under all buffer conditions. 
Negligible inactivation of EAV and PPV is likely explained by the absence or increased 
stability of the lipid bilayer. However, this does not explain the higher inactivation of 
SuHV-1 over HSV-1. For both SuHV-1 and HSV-1, citrate was the most effective and 
glycine was the least effective buffer in inactivation. Increasing buffer concentration 
either enhanced inactivation or had no effect on inactivation, but never decreased 
inactivation. The dependence for inactivation on virus type, buffer type, and buffer 
concentration provides insight into mechanisms of inactivation.  
Inactivation effectiveness correlates to buffer and virus charges (Table 1 & 2). 
Citrate is the most negatively charged buffer at pH 4 with a dominant charge of -1. 
Acetate has a dominant charge of 0, however, partial charges of -1 exist since pH 4 is 
close to the pKa of 4.54. Glycine is the least negative at pH 4 with a dominant charge of 
0. As a whole, higher negative buffer charges result in enhanced inactivation of SuHV-1 
and HSV-1. In regards to virus charge, SuHV-1 has an isoelectric point (pI) of ~7.5263, 
whereas HSV-1 has an isoelectric point of ~4.9264 (Table 1). The higher pI of SuHV-1 
leads to greater positive charges on the virus in comparison to HSV-1 at pH 4. The 
greater positive charge of SuHV-1 likely promotes electrostatic interactions of the 
negative charges of citrate or acetate to result in higher inactivation compared to HSV-1.  
Negative buffer charges and positive virus charges appear to correlate to high 
inactivation, therefore, electrostatic interactions between the buffer and the virus likely 
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influence inactivation. It is reported that charges on buffers may weakly bind to viruses 
through electrostatic interactions to modify surface properties such as 
proteins209,210,252,287. At low or intermediate buffer concentrations (millimolar), binding 
may stabilize viral proteins by reducing unfavorable interactions209,210,288. Oppositely at 
high concentrations, binding appears to promote an increase in repulsive forces that 
destabilize viral proteins287,288. Brorson et al. demonstrated membrane and capsid 
structure changes of X-MLV with transmission electron microscopy images as a result of 
inactivation at pH 3.8 with acetate or citrate buffer289. Overall, buffers likely bind to the 
virus at high concentrations (typically molar levels) to destabilize viral proteins causing 
inactivation.  
5.3.4 Conclusions  
 Low pH treatments are commonly used in biotherapeutic manufacturing to 
inactivate enveloped viruses249. There is a need for an enveloped virus inactivation at pH 
≥ 4 to maintain the stability of biological products in solution. This study investigated the 
influence of time, buffer properties, and virus properties on the inactivation of four model 
viruses at pH 4. 
 Inactivation levels were dependent on time, virus-type, buffer-type, and buffer 
concentration. SuHV-1 reached full inactivation with acetate concentrations of ≥ 250 mM 
and citrate concentrations ≥ 100 mM after 30 min. Of the viruses tested, HSV-1 was 
inactivated to the next greatest extent where full inactivation occurred at citrate 
concentrations ≥ 250 mM after 1 hour. EAV and PPV were negligibly inactivated over all 
solution conditions, consisted with the literature, this is likely a result of the stabilized 
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lipid bilayer of EAV and no lipid bilayer of PPV. The increasing inactivation levels from 
glycine, to acetate, to citrate for SuHV-1 and HSV-1 correspond to the increasing 
negative charges on the buffer. Similarly, the greater inactivation of SuHV-1 over HSV-1 
corresponds to the greater positive virus charge. Electrostatic interactions between the 
negatively charged buffers and positively charged viruses likely destabilize viral proteins 
to result in inactivation209,210,252,287.  
 Inactivation of viruses at pH 4 is a function of virus and buffer properties. Viral 
structures, including a stabilized lipid bilayer, can resist inactivation at pH 4. Resistant 
viruses likely require harsher conditions for full inactivation. For viruses that are not 
resistant to pH 4 inactivation, enhancing electrostatic interactions between the buffer and 
the virus can increase inactivation levels.  
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6 Conclusions and Future Work  
6.1 Conclusions  
Infectious diseases considerably impact worldwide health1. For example, the 2019 
novel coronavirus (SARS-CoV-2) sparked a global pandemic by causing a deadly 
respiratory disease3. The SARS-CoV-2 outbreak reminds us that even though society 
enacts practices to protect the public from infectious diseases4, challenges in treatment 
and prevention remain. For this reason, continual improvements to health measures must 
be made to control infectious diseases. Wastewater treatment and viral clearance during 
pharmaceutical applications are examples of health measures that can be improved to 
prevent the spread of infectious diseases.  
 Chapter 2 investigated a low-cost, low-tech biosolids treatment method to 
improve the sustainability of wastewater treatment operations. Many WWTPs are looking 
to upgrade their biosolids treatment processes to Class A standards to open additional 
avenues for sustainable reuse. However, current options for upgrades to biosolids 
treatment typically require high-cost, high-tech processes that are not feasible for smaller 
WWTPs with limited resources. Therefore, there is a need for a low-cost, low-tech 
process that produces high-quality biosolids. During this study, a low-cost, low-tech 
treatment option for Class A biosolids was investigated through long-term storage in 
northern climates. The effects of freeze/thaw cycles, temperature, moisture, volatile 
solids, ammonia, and pH on pathogen inactivation were evaluated for one year. After one 
year of long-term storage at two northern WWTPs, fecal coliforms decreased to 
regulatory standards but Ascaris ova remained constant. Therefore, more than one year of 
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storage in northern climates is required for Class A biosolids treatment to affect proper 
helminth ova inactivation. Freeze/thaw cycles significantly reduced fecal coliform levels 
in all biosolids tested. Specifically, 16% TS produced the highest inactivation of fecal 
coliforms during freeze/thaw cycles. Ultimately, the results of this study provided 
information on minimum process parameters for low-cost, low-technology biosolids 
treatment.  
 Chapter 3 hypothesized the mechanisms for enveloped virus inactivation by 
arginine. Enveloped virus inactivation by arginine maintains protein stability, and 
therefore, is a desirable process in therapeutic protein manufacturing8-16. However, 
optimal conditions for full inactivation of all enveloped viruses by arginine are not 
known. Viruses containing stabilized membranes or stabilized proteins are not highly 
inactivated by arginine17. For this reason, arginine may be interacting with proteins or 
lipids to inactivate viruses. Three hypotheses were developed to explain the potential 
mechanisms of inactivation by arginine.  Hypothesis 1 described inactivation by arginine 
through inhibition of protein function. Hypothesis 2 described inactivation by arginine as 
a result of viral membrane destabilization. Hypothesis 3 described inactivation by 
arginine through membrane pore formation. To reject a hypothesis, the effect of arginine 
on protein function or membrane stability needs to be determined.  Understanding the 
mechanisms of arginine will provide insight into developing treatment methods that 
enhance 
 virus inactivation.  
 Chapter 4 examined the influence of viral and arginine properties on inactivation. 
Viral membrane structures largely affected inactivation by arginine. Viruses with stable 
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membranes (EAV and BVDV), resulting from small diameter membranes with tightly 
packed lipids, were negligibly inactivated by arginine. Viruses with less stable 
membranes (HSV-1 and SuHV-1), resulting from large diameter membranes with loosely 
packed lipids, were highly inactivated by arginine. Additionally, viruses that were 
sensitive to membrane cholesterol reduction were also inactivated to high levels by 
arginine. Overall, the mechanism of membrane deformation was supported by the 
influence of viral membrane properties on arginine inactivation. In regards to arginine 
structure, hydrophobicity and arginine-clustering increased inactivation of viruses 
resistant to arginine. An increasing virus size after arginine exposure was measured by 
DLS and TEM images, alluding to lipid expansion or arginine binding as the mechanism 
for inactivation. Overall, the data from this study supports lipid bilayer deformation as 
the mechanism of arginine inactivation and added hydrophobicity or arginine-clustering 
to enhance inactivation.   
 Chapter 5 investigated buffer type and concentration on the inactivation of several 
enveloped viruses at pH 4. Similar to arginine, viruses with highly stable membranes 
(EAV) or no membranes (PPV) were negligibly inactivated at pH 4. Full inactivation (~5 
LRV) occurred for viruses with less stable membranes (SuHV-1 and HSV-1) at pH 4 
under various buffer conditions. Citrate produced the highest inactivation, and glycine 
produced the lowest inactivation of SuHV-1 and HSV-1. Increasing electrostatic 
interactions between the virus and buffer enhanced inactivation. Conclusively, this study 
provided insight into the conditions (buffer type and time) for virus inactivation by 
buffers at pH 4 which preserves biopharmaceutical protein activity as opposed to lower 
pH treatments.  
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6.2 Future Work  
Meaningful results for the improvement of pathogen inactivation in biosolids and 
pharmaceutical applications are presented in this dissertation. However, gaps in 
information remain that hinder the further development and widespread use of the 
pathogen inactivation processes studied. Future research into biosolids treatment, virus 
inactivation by arginine, and low pH virus inactivation by buffers are required to create 
well-established processes.  
6.2.1 Biosolids Treatment  
To develop a universal long-term storage Class A biosolids treatment, additional 
freeze-thaw and long-term storage studies are required. To start, studies to predict the 
influence of freeze-thaw conditions on pathogen inactivation are needed. Fecal coliform 
reduction in biosolids at two WWTPs after one freeze-thaw cycle with total solids 
contents varying from 5-28% was studied in Chapter 2. Since conditions can vary 
tremendously across plants, the influence of several variables on pathogen inactivation is 
required for an understanding of freeze-thaw cycles. Variables to adjust and analyze for 
pathogen inactivation would include 1) number of freeze-thaw cycles, 2) temperature 
gradient, and 3) biosolids origin. Furthermore, the effect of freeze/thaw cycles on 
pathogen inactivation for enteric viruses and Ascaris ova is needed for Class A 
requirements. After the data is collected, the impact of freeze-thaw conditions on 
pathogen inactivation could be analyzed through multivariate regression to model site-
specific WWTP pathogen inactivation.   
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 Further long-term storage field- and lab-scale studies are required to develop a 
universal low-cost, low-tech Class A biosolids treatment method. Chapter 2 demonstrated 
the influence of biosolids properties on pathogen inactivation during long-term storage at 
two WWTPs over one year. Key information was collected on the inactivation of fecal 
coliforms during winter storage; however, the data indicate that the specific treatment 
conditions did not minimum Class A treatment requirements. To determine the minimum 
conditions required for long-term storage at individual WWTPs, it is necessary to 
conduct field-scale studies across various climates at longer storage times. During the 
field-scale studies, biosolids properties (VS, TS, ammonia, temperature, VFA, and 
pathogen content) and environmental conditions (precipitation, humidity, temperature, 
UV, and wind) should be monitored to determine minimum storage times required to 
reach Class A standards under different climates and biosolids conditions. The field-scale 
study could be paired with a lab-scale study to strengthen the data. In the lab-scale study, 
variables to be altered and quantified for their influence on pathogen inactivation include 
1) pH, 2) temperature, 3) ammonia content, 4) VS, 5) VFA, and 6) TS. The data could 
then be analyzed under multivariate regression to determine the significance of each 
variable on pathogen inactivation. Additionally, a model could be constructed to predict 
pathogen inactivation at WWTPs with known biosolids conditions.    
6.2.2 Virus Inactivation by Arginine  
Greater information on the mechanisms and optimization of enveloped virus 
inactivation by arginine is needed to create a safe and reliable viral clearance process for 
therapeutic protein manufacturing.  
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6.2.2.1 Arginine Mechanisms  
In Chapter 3, mechanisms for enveloped virus inactivation by arginine were 
hypothesized including 1) inhibition of protein function, 2) deformation of the lipid 
bilayer, and 3) holes in the lipid bilayer. Overall, the data collected in Chapter 4 
supported the mechanisms of lipid bilayer deformation. However, supplementary studies 
are necessary to assess and confirm all hypothesized mechanisms.  
Experiments to assess protein function and structure before and after arginine 
exposure are required to evaluate hypothesis 1. Protein binding experiments with 
enzyme-linked immunosorbent assay (ELIZA), bio-layer interferometry technology 
(BLITz), or immunohistochemistry could elucidate protein changes after arginine 
exposure. ELIZA and BLITz work by immobilizing a specific host cell receptor to 
measure the binding capacity of an associated protein. For example, heparin is commonly 
used as a cell receptor for viruses, and differences in heparin-binding before and after 
arginine exposure could signify a disruption in protein function247. 
Immunohistochemistry uses the process of immunostaining to identify specific proteins 
(antigens) through the binding of antibodies. For example, antibodies that bind to HSV-1 
proteins include polyclonal rabbit anti-HSV-1290 and Monoclonal CHA 437 antibody291.  
Quantifying the protein-antibody binding before and after arginine exposure would 
elucidate protein changes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS PAGE) separates proteins by molecular weight and could illuminate general protein 
differences in the virus before and after arginine exposure. Though all these studies 
evaluate hypothesis 1, changes in protein binding or structure could also support 
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hypothesis 2, since lipid instability may alter the efficacy and function of membrane-
bound proteins. 
Nanoindentation experiments, such as atomic force microscopy (AFM), could 
measure changes in virus stiffness to evaluate hypotheses 2 and 3. If the virus stiffness 
decreases after arginine exposure, the lipid bilayer is being compromised either by lipid 
deformations or pores. If virus stiffness and protein structure or binding are being 
changed, then hypothesis 2 is most likely. To test hypothesis 3, the reduction in genetic 
material after arginine exposure could be measured by polymerase chain reaction (PCR). 
Holes in the lipid bilayer likely expose the inner virus to harsh outer conditions, 
degrading the genetic material. While our data supports hypothesis 2, future studies are 
required to assess all potential hypotheses for the mechanisms of viral inactivation by 
arginine.   
6.2.2.2 Arginine Optimization  
Added hydrophobicity and arginine clustering improved viral inactivation by 
arginine, however, full inactivation of all enveloped viruses was not reached. To 
determine the optimal conditions for full inactivation of all enveloped viruses by 
arginine, additional studies are required.  
The influence of membrane cholesterol on HSV-1 and SuHV-1 infectivity was 
examined in Chapter 4. Cholesterol reduction increases membrane fluidity238 203,206, 
which may aid in the destabilization of lipids by arginine. To evaluate the effects of 
membrane cholesterol reduction on inactivation by arginine, future studies are required. 
To begin the studies, membrane cholesterol would be reduced in several viruses (both 
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resistant and non-resistant to arginine inactivation) by MβCD. After cholesterol 
reduction, viruses would be exposed to arginine.  LRV would be calculated from the titer 
before and after arginine exposure. A higher LRV compared to the arginine LRV without 
cholesterol reduction would signify that an increase in membrane fluidity enhances 
inactivation by arginine. If this is the case, other membrane disrupters could be used in 
combination with arginine to produce high inactivation. The membrane disruptor 
pyrenebutyrate (PYB) was tested at low levels of 10 mM in Chapter 4. PYB loosens lipid 
packing and increases membrane fluidity234,239-241, similar to cholesterol reduction. 
Though PYB did enhance arginine inactivation, it did not fully inactivate viruses due to 
low solubility limits. Other hydrophobic molecules (isoleucine, valine, or leucine) or 
membrane disruptors (detergents) with higher solubility limits could be tested to enhance 
inactivation by arginine.  
Testing higher concentrations or different conformations of arginine peptides may 
uncover conditions for full virus inactivation. Chapter 4 studied the effect of CapA6R 
(added hydrophobicity) and R8 (added arginine clustering) peptides at 7.6 mM equivalent 
arginine concentration on the inactivation of viruses. Though these peptides inactivated 
viruses to higher levels than 7.6 mM arginine, the low concentrations were unable to fully 
inactivate any viruses. Higher concentrations of peptides likely improve inactivation 
levels. Additionally, different conformations of peptides could be tested. For example, a 
more hydrophobic amino acid (isoleucine, valine, or leucine) could be replaced for 
alanine in the tail of CapA6R. Also, larger and smaller arginine peptides could be tested 
and compared to R8. Literature shows there may be an ideal number of arginine 
molecules required to disrupt the lipid membrane197.  While our results provided insight 
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into the mechanisms and optimization of inactivation by arginine, additional studies are 
required to more effectively use arginine.  
6.2.3 Low pH Virus Inactivation by Buffers  
Additional information is required to determine the effects of buffers on the 
inactivation of viruses at low pH. Chapter 5 established that viruses with stable 
membranes or no membrane were resistant to inactivation at pH 4. To determine 
minimum conditions to inactivate resistant viruses, lower pH values must be tested. For 
example, testing the inactivation of PPV and EAV with acetate, glycine, and citrate at 
500 mM with decreasing pH values below 4 would determine minimum conditions for 
inactivation. For viruses with less stable membranes, enhancing the electrostatic 
interactions between the virus and the buffer improved inactivation, however, this was 
only studied with two viruses. For a greater statistical significance, additional viruses 
should be tested for inactivation at pH 4 by buffers with several charges. Viruses tested 
must be large enveloped viruses that are not resistant to inactivation at pH 4 such as 
Influenza or xenotropic murine leukemia virus. Largely, supplemental tests are required 
to decipher the minimum conditions for full inactivation of viruses with buffers at low 
pH.  
 This dissertation improved public health by determining mechanisms and optimal 
conditions for pathogen inactivation in wastewater treatment and pharmaceutical 
applications. While key insights into pathogen inactivation were found, continual 
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A Viral Inactivation Data: Chapter 4 
Table A1: Log10 reduction values for Figure 4-2. Inactivation of enveloped viruses by 
arginine. Inactivation at 4°C over 24 hours. Arginine concentration at 1 M. Tris, acetate, 
and citrate concentration at 20 mM 
 
Virus Solvents pH 
Time (hours) 
1 3 6 







4 3.76 0.24 3.62 0.21 3.70 0.25 
7 0.39 0.61 1.16 0.75 1.41 0.51 
Arg + 
Tris 
4 3.51 0.31 3.72 0.10 3.66 0.37 
7 0.10 0.21 1.36 1.00 1.24 0.49 
Arg + Act 
4 3.82 0.37 3.66 0.06 3.76 0.44 
7 0.27 0.46 1.14 0.49 1.22 0.10 
Tris  7 0.11 0.17 0.52 0.73 0.12 0.27 
Act 
4 2.56 0.12 2.75 0.54 2.77 0.41 
7 -0.30 0.18 0.26 1.15 0.61 1.24 








4 4.05 0.39 4.06 0.40 4.00 0.46 
7 3.39 0.89 4.10 0.41 4.01 0.45 
Arg + 
Tris 
4 3.82 0.13 3.87 0.21 3.85 0.11 
7 3.27 0.90 4.05 0.32 3.97 0.37 
Arg + Act 
4 3.99 0.45 4.15 0.46 4.10 0.37 
7 3.16 0.45 4.00 0.33 4.07 0.40 
Tris  7 0.08 0.28 0.29 0.27 0.44 0.32 
Act 
4 3.67 0.63 4.00 0.40 3.82 0.49 
7 0.07 0.34 0.35 0.35 0.23 0.25 






4 0.21 0.45 1.04 1.20 0.24 0.23 
7 0.13 0.20 0.14 0.23 0.24 0.29 
Arg + 
Tris 
4 -0.07 0.36 0.04 0.14 0.48 0.09 
7 0.12 0.32 -0.04 0.22 0.23 0.64 
Arg + Act 
4 0.08 0.81 -0.03 0.43 0.70 0.20 
7 0.17 0.17 0.26 0.21 0.03 0.49 
Tris  7 0.24 0.24 0.18 0.27 0.09 0.44 
Act 
4 0.04 0.44 0.48 0.40 0.74 0.20 
7 0.23 0.52 0.24 0.23 0.07 0.27 







4 0.08 0.43 0.28 0.19 0.42 0.47 
7 0.12 0.15 0.14 0.28 0.14 0.33 
Arg + 
Tris 
4 0.44 0.17 0.56 0.47 0.38 0.37 
7 0.25 0.38 -0.05 0.10 0.33 0.47 
Arg + Act 
4 0.33 0.24 0.29 0.29 0.38 0.37 
7 0.28 0.36 0.36 0.60 0.11 0.18 
Tris  7 0.41 0.36 0.44 0.40 0.53 0.39 
Act 
4 0.52 0.14 0.46 0.22 0.63 0.15 
7 0.14 0.39 0.33 0.19 0.37 0.55 




Table A1 Continued 
 
Virus Solvents pH 
Time (hours) 
12 24 







4 3.71 0.17 3.70 0.25 
7 2.13 0.35 2.67 0.93 
Arg + Tris 
4 3.71 0.25 3.42 0.55 
7 1.81 0.78 3.46 0.96 
Arg + Act 
4 3.77 0.21 3.71 0.15 
7 2.00 0.58 2.62 0.61 
Tris  7 0.59 0.28 0.07 1.20 
Act 
4 3.16 0.21 3.35 0.37 
7 0.87 0.77 0.96 0.47 








4 4.07 0.37 3.97 0.40 
7 4.03 0.40 4.03 0.37 
Arg + Tris 
4 3.90 0.25 3.79 0.08 
7 3.91 0.40 3.98 0.38 
Arg + Act 
4 4.04 0.37 4.03 0.38 
7 4.09 0.36 3.97 0.42 
Tris  7 0.44 0.30 0.75 0.22 
Act 
4 3.86 0.46 3.89 0.42 
7 0.45 0.42 0.82 0.56 






4 -0.11 0.39 0.12 0.17 
7 0.17 0.29 -0.21 0.13 
Arg + Tris 
4 0.15 0.39 0.10 0.04 
7 0.54 0.77 -0.07 0.03 
Arg + Act 
4 0.37 0.48 0.33 0.18 
7 0.22 0.52 0.14 0.30 
Tris  7 -0.04 0.16 0.00 0.19 
Act 
4 0.47 0.60 0.50 0.35 
7 0.23 0.55 0.09 0.23 







4 0.73 0.12 0.99 0.36 
7 0.36 0.27 0.49 0.37 
Arg + Tris 
4 0.69 0.37 0.76 0.35 
7 0.35 0.59 0.56 0.16 
Arg + Act 
4 0.59 0.44 1.17 0.61 
7 0.39 0.17 0.71 0.53 
Tris  7 0.87 0.55 0.90 0.50 
Act 
4 0.87 0.19 1.06 0.43 
7 0.65 0.20 0.97 0.48 





Table A2: Cholesterol and titer values for Figure 4-3A& B. Effect of cholesterol 
depletion on the infectivity of HSV-1 and SuHV-1 after 5mM methyl-β-cyclodextrin 
(MβCD) exposure. 
  No MβCD MβCD 














HSV-1 7.74 0.3 1.07 0.09 
SuHV-1 1.03 0.15 0.36 0.04 
HSV-1 
Cells 
10.65 2.29 1.13 0.07 
SuHV-1 
Cells 












HSV-1 6.8 0.13 5.4 0.15 














Figure A1: Toxicity measurements for Vero cells seeded with HSV-1 and SuHV-1 Mock 
samples based on MβCD concentration. Mock samples for each virus were tested to give 
a representative level of cholesterol in solution without added virus. Mock samples were 


























Table A3: Log10 reduction values for Figure 4-4B&C. Inactivation of enveloped viruses 
by agmatine. Inactivation occurred at 4°C over 24 hours. Agmatine concentration at 1 M 
and acetate concentration at 20 mM. 
   Time (hours) 
Virus Solvents pH 
1 3 6 





 Agm + Act 
4 -0.35 0.24 -0.14 0.29 -0.24 0.24 
7 -0.39 0.31 -0.46 0.10 -0.75 0.49 
Act 4 
2.56 0.12 2.75 0.54 2.77 0.41 





 Agm + Act 
4 3.03 0.10 3.45 0.00 3.53 0.04 
7 -0.15 0.22 -0.04 0.34 0.04 0.01 
Act 
4 3.70 0.60 4.00 0.40 3.80 0.50 




 Agm + Act 
4 0.03 0.29 0.02 0.18 0.00 0.33 
7 0.04 0.32 -0.08 0.26 0.37 0.16 
Act 
4 0.04 0.44 0.48 0.40 0.74 0.20 
7 0.23 0.52 0.24 0.23 0.07 0.27 
   Time (hours)   
Virus Solvents pH 
12 24   





 Agm + Act 
4 0.49 0.22 1.89 0.10 
7 0.11 0.20 1.83 0.24   
Act 
4 3.16 0.21 3.35 0.37   





 Agm + Act 
4 3.37 0.11 3.55 0.01   
7 0.24 0.27 0.69 0.14   
Act 
4 3.90 0.50 3.90 0.40   




 Agm + Act 
4 0.03 0.05 0.51 0.04   
7 0.02 0.15 0.27 0.11   
Act 
4 0.47 0.60 0.50 0.35   






Table A4: Log10 reduction values for Figure 4-4D. Comparison of arginine, agmatine, 
and butyroyl-arginine in the inactivation of HSV-1 after 1 hour at 4°C or on ice. 0.7 M 
arginine and but-arg represent data reformatted from Katsuyama et al.10 
Solvent LRV  STDEV 
1M Agm 3.80 0.37 
1M Agm -0.35 0.29 
0.7 M Arg 5.00 N/A 




Table A5: Log10 reduction values for Figure 4-5. Virus inactivation by arginine peptides. 
Inactivation occurred after 1 hour at pH 7 in Tris buffered solutions with 10% DMSO. 
Arginine and CapA6R concentration at 7.6 mM. R8 concentration at 0.95 mM which is 
equivalent to an arginine concentration of 7.6mM. Tris concentration at 20 mM. 






CapA6R+ 10% DMSO 1.29 0.35 
R8 + 10% DMSO 0.23 0.07 
10% DMSO 0.19 0.15 
Arg + 10% DMSO 0.06 0.11 





CapA6R+ 10% DMSO 1.65 0.63 
R8 + 10% DMSO 0.56 0.07 
10% DMSO 0.27 0.31 
Arg + 10% DMSO 0.05 0.12 
Arg 0.50 0.20 
 
Table A6: Log10 reduction values for Figure 4-6. Inactivation of EAV and HSV-1 by 
arginine with added Pyrenebutyric acid (PYB). Inactivation occurred after 1 hour at 4°C. 
PYB at 10 mM, arginine at 1 M, and Tris and acetate buffer at 20 mM. 
Virus Solvents pH 
PYB DMSO 





 Arg + Tris 7 -0.32 0.22 -0.32 0.22 
Arg + Act 4 3.22 0.13 4.55 0.03 




 Arg + Tris 7 1.38 0.38 -0.20 0.32 
Arg + Act 4 0.01 0.47 0.06 0.17 
PBS 7.2 0.37 0.31 0.24 0.26 
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Table A7: Log10 reduction values for Figure 4-7. Inactivation of HSV-1 with Buffer 
Mimics. Inactivation occurred at 4°C over 24 hours. Arginine concentration at 1 M. 
Glycine, Glycineamide, MES, and Tricine concentration at 20 mM. 
   Time (hours) 
Virus Solvents pH 
1 3 6 






Arg + Glycine 
4 4.49 0.29 4.54 0.19 4.63 0.23 
7 0.04 0.37 0.44 0.48 0.84 0.51 
Arg + 
Glycineamide 
4 4.45 0.17 4.46 0.43 4.60 0.21 
7 0.07 0.37 0.57 0.72 0.74 0.58 
Arg + MES 
4 4.56 0.21 4.53 0.19 4.50 0.17 
7 -0.07 0.22 0.44 0.84 1.31 0.69 
Arg+ Tricine 
4 4.37 0.08 4.52 0.17 4.57 0.15 
7 0.05 0.30 0.22 0.81 0.90 0.15 
Glycine 
4 0.33 0.56 0.04 0.79 0.72 0.78 
7 -0.12 0.37 0.18 0.35 0.21 0.82 
Glycineamide 
4 -0.07 0.29 -0.02 0.60 -0.22 0.53 
7 -0.12 0.21 -0.09 0.67 -0.01 0.77 
MES 
4 0.27 0.78 0.61 0.51 0.72 0.68 
7 -0.19 0.45 -0.18 0.56 0.21 0.66 
Tricine 
4 0.26 0.42 -0.16 0.04 0.32 0.43 
7 -0.09 0.25 -0.10 0.26 0.01 0.43 
   Time (hours)   
Virus Solvents pH 
12 24 






Arg + Glycine 
4 4.48 0.17 4.48 0.21   
7 1.39 0.62 2.01 0.67   
Arg + 
Glycineamide 
4 4.43 0.19 4.26 0.09   
7 1.62 0.49 2.41 0.41   
Arg + MES 
4 4.42 0.18 4.46 0.14   
7 1.73 0.44 2.41 0.56   
Arg+ Tricine 
4 4.54 0.16 4.56 0.24   
7 1.69 0.66 2.15 0.44   
Glycine 
4 1.03 0.89 1.51 0.86   
7 0.57 0.37 0.80 0.81   
Glycineamide 
4 0.68 0.43 0.09 0.61   
7 0.71 0.62 0.11 0.93   
MES 
4 1.23 0.54 1.20 0.60   
7 0.39 0.42 0.32 0.50   
Tricine 
4 0.40 0.60 0.78 1.01   




Table A8: Structure at pH 7 and pKa values of the buffer mimics tested in Figure 4-7176. 
Buffer mimics showed similar inactivation to Tris and acetate when used with 1 M 
arginine at pH 4 and 7. 


































Figure A2: Size changes of control HSV-1 and SuHV-1 in PBS at pH 7.4 measured by 




Figure A3. DLS size changes of HSV-1 and SuHV-1 after 1 (solid) and 24 (hashed) hours 
in comparison to a PBS control. Arginine was at 1 M, Tris was at 20 mM, and PBS was at 
pH 7.4. Inactivation occurred at 4°C. All DLS measurements showed increasing virus 
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